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Sepsis complicated by coagulopathy is associated with a higher mortality rate.  The cell 
surface expression of tissue factor (TF) may be important in its development.  There at least 
three subsets of monocytes – classical, intermediate and non-classical – that vary in 
proportion during sepsis.  This project used three approaches to investigate how the monocyte 
subsets and their endothelial interaction could contribute to sepsis-associated coagulopathy: 
the in vitro stimulation of healthy monocytes with lipopolysaccharide (LPS) and endothelial 
co-culture; the use of a human model of endotoxaemia; and the collection of blood samples 
from individuals with sepsis. 
 
LPS stimulation of healthy monocytes demonstrated that the monocyte subsets express cell 
surface TF to different extents.  Classical and intermediate monocytes express the highest 
proportion of TF in response to LPS.  An in vitro monocyte-endothelial co-culture model 
demonstrated that monocytes could promote coagulation through the increased cell surface 
expression of TF, independent of LPS, and influence the endothelial fibrinolytic response. 
 
Blood samples were taken at a range of time-points following an injection of LPS into a 
healthy volunteer.  An increase in cell surface TF occurred within 90 minutes of exposure to 
LPS and was associated with an increase in markers of coagulation.  Individuals varied in 
their response to LPS, with two groups identified: high and low responders.  The response of 
individuals was consistent between the subsets. 
 
Samples from individuals with sepsis expressed a higher level of cell surface TF compared to 
individuals who were critically ill but did not have sepsis.  The surface expression of TF 
increased further when measured following recovery from sepsis. 
 
This work demonstrates that the cell surface expression of TF varies between the monocyte 
subsets, that individuals may increase monocyte TF expression to different levels, and that 
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Sepsis is defined as life-threatening organ dysfunction caused by a disordered immune 
response to infection (Singer et al., 2016).  Despite significant advances in critical care 
medicine, it has an unacceptably high mortality rate (Angus et al., 2001; Fleischmann et al., 
2016; Meyer et al., 2018).  Frequently, sepsis occurs concomitantly with a coagulopathy that 
further reduces an individual’s chances of recovery.  Multiple interventional studies have 
failed to find any therapies that can improve these outcomes (Warren et al., 2001; Ranieri et 
al., 2012; Vincent et al., 2013).  There is an urgent need to better understand the 
pathophysiology and to identify new therapeutic targets.   
 
The role of intravascular tissue factor (TF), expressed on monocytes, and subsequent 
activation of the coagulation system is believed to be an important trigger for coagulopathy 
(Gando et al., 2016).   Monocytes can be divided into at least three functionally different 
subsets; however, there is a paucity of data regarding TF expression between these subsets 
(Stojkovic et al., 2017).  This work investigates the role of monocyte subsets and their TF 
expression during health, endotoxaemia and sepsis. 
 
Monocytes are divided into subsets using the cell surface markers cluster of differentiation 
(CD)14, a co-receptor for LPS, and CD16, a weak Fc gamma receptor.  The subsets are 
identified as ‘classical’ (CD14++CD16-), ‘non-classical’ (CD14+CD16++) and ‘intermediate’ 
(CD14++CD16+) (Ziegler-Heitbrock et al., 2010a).  Classical monocytes are mainly 
associated with bacterial killing, producing the most reactive oxygen species and being the 
most phagocytic; non-classical are believed to ‘patrol’ the endothelium and have a role in 
tissue repair; and intermediate monocytes have been associated with viral killing (Wong et 
al., 2011). 
 
During sepsis, there is an increase in circulating non-classical monocytes and a proportionate 
decrease in circulating classical monocytes (Fingerle et al., 1993). This project investigates 
whether this change in circulating monocyte subsets may contribute to the coagulopathy of 
sepsis.  Improved understanding of how TF expression varies between the monocytic subsets 
may allow for the identification of new therapeutic targets in the management of sepsis-
associated coagulopathy. 
  
This chapter will discuss the following in further detail: the poorer outcomes from sepsis-
associated coagulopathy; possible causes of the coagulopathy; the role and function of TF; a 
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comparison of the monocyte subsets; and how best to model the immune response to 
inflammation to better understand the pathophysiology.  Current literature will be reviewed, 




This section discusses the incidence and mortality rates of sepsis over the last few decades 
and clarifies the changes in definition that have occurred. 
 
1.2.2 The incidence and outcomes of sepsis 
Sepsis is increasing in incidence.  A review of over 750 million hospital admissions in the 
United States showed an increase in cases of sepsis, between 1979 and 2000, from 82.7 cases 
to 240.4 per 100,000 population (zieglerMartin et al., 2003).   The associated in-hospital 
mortality rate, however, has decreased over the last 30 to 40 years, from approximately 30 % 
to nearer 20 % (Angus et al., 2001; Martin et al., 2003; Brun-Buisson et al., 2004; 
Fleischmann et al., 2016; Meyer et al., 2018).  Most likely this reflects an improvement in 
critical care and evidence-based guidelines such as the Surviving Sepsis Campaign (Levy et 
al., 2014).  Despite this decrease, a significant proportion do not survive, and combined with 
the rising incidence there has been a three-fold increase in the total number of deaths (Martin 
et al., 2003).   
 
Most sepsis trials measure mortality at 28 days or over the ‘in-hospital’ period; the two rates 
have been shown to be similar (Stevenson et al., 2014).  Failure to consider the longer-term 
mortality rates, however, will likely underestimate the true mortality rate of sepsis.   Several 
studies have demonstrated an increasing mortality rate in survivors of sepsis up to 5 years 
following the episode (Quartin et al., 1997; Brun-Buisson et al., 2004; Laupland et al., 2005). 
 
A significant proportion, approximately 20 %, of sepsis survivors are re-admitted to hospital 
within 30 days.  This is higher than for other acute medical admissions (Jones et al., 2015; 
Prescott et al., 2015).  Recent work has shown that although this percentage may be starting 
to drop, to some degree this has been offset by the number of attendances to the emergency 
department where patients received treatment but were not admitted.  Due to the rising 
incidence, this has resulted in a three-fold increase in re-admissions (Meyer et al., 2018).  The 
most common reasons for re-admission are sepsis, congestive cardiac failure and pneumonia 
(Prescott et al., 2015; Sun et al., 2016). 
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Long-term morbidities associated with sepsis should also not be forgotten.  Survivors develop 
more recurrent infections and are at higher risk for thromboembolic disease for at least 12 
months following the episode of sepsis (Mejer et al., 2015; Arens et al., 2016; Ou et al., 
2016).  The cause for these longer-term complications remains unclear.  There is a trend 
towards higher inflammatory markers in survivors, whilst stimulation of ex-vivo blood 
samples of survivors showed a lower level of pro-inflammatory cytokine release (Arens et al., 
2016).  To determine the longer-term impact on survivors of sepsis, further work is needed to 
understand the causes of these morbidities and increased mortality (Shankar-Hari and 
Rubenfeld, 2016). 
 
1.2.3 Defining sepsis 
In 1991, the American College of Chest Physicians (ACCP) and Society of Critical Care 
Medicine (SCCM) reached a consensus for defining sepsis that included the need for 
confirmation of infection and evidence of a host inflammatory response, i.e. the systemic 
inflammatory response syndrome (SIRS) (Bone et al., 1992). 
 
This was reviewed in 2001, when it was recognised that clinicians were unclear as to the 
definitions of sepsis and there was concern that SIRS criteria (extremes of core temperature, 
tachycardia, high respiratory rate, hypoxia, high or low white count or more than 10 % 
immature white cells in the peripheral blood) were not specific enough.  Definitions were 
revisited at the 2001 International Sepsis Definitions Conference, which included the ACCP, 
SCCM, American Thoracic Society (ATS), European Society of Intensive Care Medicine 
(ESICM) and Surgical Infection Society (SIS).  The diagnostic criteria for sepsis were 
expanded to include other physical and laboratory signs of SIRS that may occur due to 
infection (Levy et al., 2003). 
 
The poor specificity of the SIRS criteria remained.  A large cohort study reviewed individuals 
with signs of infection and organ failure from 172 ICUs across Australia and New Zealand 
between 2000 and 2013.  Approximately 10 % did not meet the conventional criteria for 
severe sepsis due to having ≤ 2 SIRS criteria; however, they had a similar mortality rate to 
those with > 2 (Kaukonen et al., 2015). 
 
As the pathophysiology of sepsis has become increasingly understood, the ESICM and SCCM 
again met throughout 2014 and into early 2015 to review the definitions.  Sepsis was defined 
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as “life-threatening organ dysfunction caused by a dysregulated host response to infection” 
and septic shock was taken to refer to a subset of individuals who have “profound circulatory, 
cellular and metabolic abnormalities” (see Table 1.1).  The new definitions do not include 
‘severe sepsis’ and remove the need for SIRS criteria. They are based on the development of 
organ dysfunction, measured with the Sequential (Sepsis-related) Organ Failure Assessment 
(SOFA, see) score, and emphasise the need for close monitoring of all septic individuals 








This table shows the 2015 definitions of sepsis and septic shock from “Sepsis-3: The Third 
International Consensus Definitions for Sepsis and Septic Shock”, adapted from Singer et al. 
2016 (Seymour et al., 2016; Singer et al., 2016). 
  
Concept Definitions 
Sepsis Life-threatening organ dysfunction caused by a dysregulated host 
response to infection 
Organ dysfunction Acute change of 2 or more points in the Sequential (Sepsis-related) 
Organ Failure Assessment (SOFA) score 
Septic shock Severely affected subset of sepsis, when circulatory, metabolic or 
cellular abnormalities are profound enough to increase mortality. 
Requires sepsis diagnosis with one of the below criteria. 
Criteria for shock Vasopressors needed to maintain mean arterial blood pressure at 
greater than 65mmHg  
Lactate greater than 2mmol/L despite fluid resuscitation 








Table 1.2 The Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score 
This table shows the Sequential (Sepsis-related) Organ Failure Assessment (SOFA) adapted 
from Jones et al. (Jones et al., 2009). Glasgow coma scale from Teasdale and Jennett 
(Teasdale and Jennett, 1974). Dopamine, noradrenaline and dobutamine to be administered 
for at least 1 hour, units - µg/kg/min.  
(abbreviations: dL – decilitre, kg – kilogram, mg- milligram, min – minute, mL – millilitre, 
mm – millimetres, mmHg – millimetres of mercury).  
SOFA score 1 2 3 4 
Respiratory criteria         
PaO2/FiO2 (mmHg) <400 <300 <220 <100 
SaO2/FiO2 221-301 142-220 67-141 <67 
Cardiovascular 
criteria 















        
Glasgow coma 
score 
13-14 10-12 6-9 <6 
Renal criteria         
Creatinine (mg/dL) 1.2-1.9 2.0-3.4 3.5-4.9 >5.0 
Urine output 
(mL/day) 
- - <500 <200 
Haematological 
criteria 
        
Platelets 
(x103/mm3) 
<150 <100 <50 <20 
Hepatic criteria         
Bilirubin (mg/dL) 1.2-1.9 2.0-5.9 6.0-11.9 >12.0 
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1.2.4 Summary 
Overall, there has been a rise in the incidence of sepsis, and it is associated with both a 
significant mortality rate and long-term morbidity.  There is a need to better understand the 
underlying pathophysiology to help guide future studies. A continuing challenge to research is 
the difficulty in establishing a concise definition that is useful both clinically and in 
performing research studies.  When reviewing literature regarding sepsis, it is important to 
bear in mind the recent changes in definition.  A recent study prospectively scored cases of 
sepsis by the Sepsis-3 and earlier definitions, demonstrating that Sepsis-3 identified fewer 
cases but of a more severe phenotype than earlier definitions (Driessen et al., 2018).  This 
obviously has implications when considering studies of sepsis prior to the adoption of Sepsis-
3. 
 
1.3 Sepsis-associated coagulopathy 
1.3.1 Overview 
The association between coagulopathy and sepsis has been recognised for many decades, 
initially discussed in multiple case reports.  Corrigan first systematically documented the 
effects of sepsis on coagulation in a series of 26 individuals.  The cases were divided into two 
groups, normotensive and hypotensive, with the latter group displaying a more severe 
coagulopathy.  The correlation between severity of disease and coagulopathy was highlighted 
(Corrigan et al., 1968).  This section will briefly outline the physiological processes of 
coagulation and fibrinolysis before discussing the causes and effects of sepsis-associated 
coagulopathy. 
 
1.3.2 The coagulation system 
The coagulation system was first described in the early 1960s, originally considered a cascade 
of reactions with three pathways, intrinsic, extrinsic and common (Davie and Ratnoff, 1964; 
Macfarlane, 1964).  These pathways are composed of a series of reactions; inactive pro-
enzymes of serine proteases are activated and then catalyse the next pro-enzyme in the 
cascade.  This description of coagulation was based upon laboratory assays and was not a true 
reflection of the in vivo situation.  The extrinsic pathway function is reflected by the 
prothrombin time (PT) measurement and the intrinsic pathway by the activated partial 
thromboplastin time (APTT). 
 
Venous haemostasis is achieved by the formation of a stable clot composed of platelets and 
fibrin; however, the pro-thrombotic factors required to create this must also be contained and 
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localised to the site of injury.  The cell-based model by Hoffman et al. proposed in the 1990s 
is a more accurate representation and involves three stages: initiation, propagation and 
amplification (Hoffman, 2003).  During initiation, TF expressed on a cell surface binds and 
activates the pro-enzyme factor VII into the activated FVIIa (FVIIa); this complex then 
creates a small amount of activated factors X (FXa) and XI (FXIa) on the cell surface.  This 
FXa remains on the cell surface and activates factor V (FVa).  FXa and FVa then bind to form 
the prothrombinase complex (FXa:FVa), capable of cleaving prothrombin into thrombin.  
Although small amounts of thrombin are subsequently formed, this action is quickly inhibited 
by anti-thrombin (AT) and tissue factor pathway inhibitor (TFPI).   
 
For a thrombus to form there must be an amplification step and this requires the proximity of 
an activated platelet.   The small amounts of thrombin already formed serve to activate 
platelets, which release more Va.  Factor VIII bound to its carrier protein von Willebrand 
factor (vWF) in the plasma then binds to the activated platelet.  Thrombin cleaves the vWF 
and activated VIII (FVIIIa).  By the completion of amplification, FVa and FVIIIa are bound 
to the activated platelet surface.   
 
Both the prothrombinase and now the tenase (FIXa:FVIIIa) complexes form on the platelet 
surface, and propagation begins.  The tenase complex greatly increases the formation of FXa, 
leading in turn to a much higher concentration of the prothrombinase complex and a greater 
production of thrombin.  The cell-based model is further explained in Figure 1.1.  Thrombin 
not only serves to cleave fibrinogen into fibrin but is also a potent aggregator of platelets.    
 
Fibrin monomers polymerise to an insoluble fibrin network.  This polymerisation is initially 
reversible but is stabilised by FXIII, activated by thrombin, that covalently crosslinks the 
fibrin strands (Weisel and Litvinov, 2017). 
 
In vitro experiments have also given rise to the idea of a ‘contact pathway’.  This is composed 
of three proteins: factor XII (FXII), prekallikrein (PK) and high molecular weight kininogen 
(HK) that all become activated when on a negatively charged surface and can shorten in vitro 
clotting times.  The in vivo activator has not been identified.  FXII is known to auto-activate 
on negatively charged surfaces; it then activates PK to plasma kallikrein.  Kallikrein itself can 
activate FXII.  HK binds to the negatively charged surface and acts as a cofactor for both the 
activation of FXII and the production of kallikrein.  The cleavage of HK by PK leads to the 
release of bradykinin, a proinflammatory mediator.  C1NH is the main inhibitor of both FXIIa 
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and PK.  The physiological role of this pathway in coagulation is yet to be elucidated and 
remains controversial.  It is worth noting that deficiency in one of these three plasma proteins 
does predispose an individual to an increased risk of bleeding, as is seen with other 
coagulation factors (Schmaier, 2014; Wu, 2015; Maas and Renné, 2018). 
 
Control of coagulation involves three anticoagulant pathways: the protein C system, TFPI and 
antithrombin. Thrombin binds to endothelially bound thrombomodulin and thereby activates 
protein C; this, along with its co-factor protein S, works to degrade FVIIIa and FVa, thereby 
inhibiting both the prothrombinase and the tenase complexes.  TFPI is the main inhibitor of 
TF and works by binding to TF that is complexed to FVIIa.  Antithrombin binds and forms a 
complex with both thrombin and FXa (Gando et al., 2016).   Alpha 1 antitrypsin (A1AT), a 
serine protease inhibitor, has been shown to bind strongly to a fibrin clot and may also play a 







Figure 1.1 demonstrates the cell-based model of coagulation that comprises initiation, amplification 
and propagation as described below. 
1. Initiation  
1.1. TF on cells binds small amounts of factor VIIa in circulation and creates more VIIa from VII. 
1.2. TF bound to VIIa activates factor X and IX to Xa and IXa respectively. 
1.3. Factor Xa activates factor V (slowly) to Va. 
1.4. Factors Xa and Va bind on the cell surface to create the prothrombinase complex that 
cleaves prothrombin into thrombin. 
1.5. Thrombin can only be created in small quantities on the cell surface of the TF-expressing cell 
and is quickly mopped up away from the cell surface by circulating tissue factor pathway 
inhibitor (TFPI) and anti-thrombin (AT). 
 
 
Figure 1.1 Cell-based model of the coagulation system. 
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2. Amplification 
2.1. Occurs when the TF-expressing cell comes into contact with an activated platelet. 
2.2. Factor IXa and small amounts of thrombin produced on the TF-expressing cell reach the 
activated platelet. 
2.3. Factors VIII, IX and V are activated on the surface of the platelet to VIIIa, IXa and Va. 
2.4. Factor VIII is thereby released from von Willebrand Factor (vWF), its carrier protein. The 
released vWF promotes platelet aggregation. 
 
3. Propagation 
3.1. Factors VIIIa and IXa bind together on the platelet surface to form the tenase complex that 
activates factor X into Xa. 
3.2. Factors Xa and Va then bind on the platelet surface and form the prothrombinase complex. 
3.3. The tenase complex on the platelet allows for the creation of thrombin from prothrombin on 
the cell surface. 
3.4. Thrombin itself can then activate further platelets. 
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1.3.3 Overview of fibrinolysis 
Fibrinolysis is the process of resolving a clot.  Endothelial cells under normal conditions 
release tissue plasminogen activator (tPA) to maintain blood flow and prevent thrombus 
formation.  tPA works to cleave plasminogen into plasmin, which is capable of degrading 
fibrin into fibrin degradation products (FDPs) (such as D-dimers).  Monocytes also produce a 
plasminogen activator, urokinase plasminogen activator (uPA).  Both activators have an 
inhibitor: plasminogen activator inhibitor (PAI) -1 and PAI-2 respectively.  Monocytes can 
produce PAI-1 and PAI-2.  Endothelial cells produce PAI-1 and tPA simultaneously, and it is 






Figure 1.2 A summary of fibrinolysis. 
Fibrinolysis is the breakdown of fibrin and is therefore essential for the resolution of thrombus.  It is 
the process of activating plasmin to cleave fibrin into fibrin degradation products (FDPs). Step 1: 
tissue plasminogen activator (tPA) is released from the endothelium.  tPA can be inhibited by 
plasminogen activator inhibitor (PAI-1).  PAI-1 is primarily released by endothelium and a small 
amount of PAI-1 is released from monocytes.  Step 2: tPA cleaves plasminogen into plasmin.  Step 3: 
plasmin cleaves fibrin into fibrin degradation products.  α2-antiplasmin works to inhibit plasmin.  





Innate immunity and coagulation are not separate systems that work in isolation: increasingly, 
there is evidence of complex interaction between the two (Engelmann and Massberg, 2013).  
Invertebrates such as insects and crustaceans have not evolved two separate processes, but use 
a single system called haemolymph coagulation (Muta and Iwanaga, 1996; Dushay, 2009).  
Haemolymph of the horseshoe crab (Limulus polyphemus) contains haemocytes that are very 
sensitive to LPS; this is an endotoxin that forms part of the cell wall of Gram-negative 
bacteria and is a potent stimulus for inflammation.  Once stimulated, haemocytes release their 
granular contents and trigger coagulation.  Intravascular pathogens become trapped within the 
forming thrombus whilst anti-microbial substances also released from haemocytes destroy 
them (Muta and Iwanaga, 1996).  How coagulation and immunity cooperate in humans is still 
to be elucidated. 
 
Considering coagulation initially, thrombin, fibrinogen and fibrin have all been shown to 
recruit and activate innate immune cells.  Thrombin induces the endothelial release of pro-
inflammatory cytokines, including tumour necrosis factor (TNF)α, IL-1α and IL-6;  this has 
been shown with in vitro and animal models to increase neutrophil migration (Drake et al., 
1992).  Thrombin is also able to directly activate complement and can cleave both C3 and C5 
(Huber-Lang et al., 2006; Krisinger et al., 2012). 
 
Fibrinogen and fibrin have been shown repeatedly to have anti-microbial effects.  Evidence 
from animal models suggests that fibrinogen and fibrin may limit the spread of pathogens 
intravascularly.  Group A Streptococcus secretes the enzyme streptokinase, which is highly 
specific for human plasminogen. A transgenic murine model expressing human plasminogen 
has a higher mortality rate following subcutaneous group A streptococcal infection when 
compared to wild-type.  This difference in mortality was not evident with intravenous 
infection.  The authors hypothesise that fibrinogen works to prevent spread of pathogens 
through the vasculature and that streptokinase is a way for bacteria to circumvent this 
defence.  The transgenic mice were shown to have a more widespread distribution of bacterial 
colonies when compared to wild-type following subcutaneous infection (Sun et al., 2004).  
Fibrinogen and plasminogen also play a role in Yersinia petis infection.  Either the creation of 
a plasminogen deficient murine model or the removal of the Yersinia plasminogen activator 




Fibrinogen is able to directly activate innate immune cells.  Through direct binding to 
complement receptor macrophage (MAC)-1 on neutrophils, fibrinogen induced degranulation, 
an increase in phagocytosis and delayed apoptosis (Rubel et al., 2001).  Stimulation of both 
murine and human monocytic cell lines with fibrinogen lead to an increase in monocyte 
chemokine secretion.  This effect was not blocked by hirudin, a thrombin inhibitor, suggesting 
that it was fibrinogen rather than fibrin that was responsible (Smiley et al., 2001). 
 
It is challenging to identify the distinct anti-microbial roles of fibrinogen and fibrin.  A 
fibrinogen resistant to cleavage by thrombin was added to a murine fibrinogen knockout 
model.  Plasma from the model was unable to produce fibrin in response to thrombin, 
although the fibrinogen was still able to induce platelet aggregation.  As with fibrinogen 
deficient mice, there was impaired clearance of Streptococcus following an intra-peritoneal 
injection.  Model mice, however, had a lower early mortality rate when compared to the 
fibrinogen-deficient mice.  This work suggests a role for both fibrinogen and fibrin.  
Potentially, fibrin may limit the spread of infection, but fibrinogen itself also exerts anti-
microbial effects (Prasad et al., 2015).  
 
Platelets also appear to have an immune function.  For many years it has been known that 
platelets will aggregate and become activated by the presence of LPS and bacteria (Clawson 
and White, 1971a; Clawson and White, 1971b; Clawson, 1973; Clawson et al., 1975; Zhang 
et al., 2009).  They are also known to express the toll-like receptor (TLR)-2, TLR-4 and TLR-
9 (Cognasse et al., 2005).  These receptors are important in the detection of pathogen-
associated molecular patterns (PAMPs). 
 
Platelets also have the potential to activate polymorphonuclear cells.  Triggering receptor 
expressed on myeloid cells (TREM)-1 is expressed on neutrophils and monocytes.  Following 
infection, TREM-1 is upregulated and promotes functions such as phagocytosis and IL-8 
release (Bouchon et al., 2000).  Platelets have been shown to express a ligand for TREM-1.  
Whilst binding of TREM-1 did not induction platelet activation or aggregation, there was an 
enhancement in the neutrophil reactive oxygen species production following LPS incubation; 
this effect was blocked by the presence of either a TREM-1 specific Ab or excess of 
recombinant soluble TREM-1 (Haselmayer et al., 2007).   
 
Innate immune cells have also been shown to promote coagulation.  Several innate immune 
cells have been shown capable of expressing TF on their cell surface (Giesen et al., 1999; 
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Darbousset et al., 2012).  The role of TF on the monocyte surface will be discussed in more 
detail later (see section 1.4.4, page 28).   
 
Intra-vital imaging during a mouse model of venous thrombus, induced by restriction of blood 
flow, demonstrated endothelial adhesion of neutrophils and monocytes prior to the formation 
of a thrombus.  This was not seen in control mice that underwent a sham procedure.  
Repeating the experiment using P-selectin knockout models prevented not only the 
accumulation of the leucocytes but also the formation of thrombus.  The development of 
thrombus in this model was TF-dependent.  Repeating the experiment using a mouse that 
received a bone marrow transplant from a TF knockout donor prevented thrombus formation, 
suggesting it was the TF expressed on blood cells rather than the endothelium that initiated 
coagulation.  Intra-vital microscopy also identified the presence of extracellular DNA 3 hrs 
following the flow restriction; the DNA was in close proximity to neutrophils.  The authors 
propose that this may be due to release of neutrophil extracellular traps (NETs) and that they 
may also contribute to thrombus formation (Fuchs et al., 2010; von Bruhl et al., 2012).  A 
knockout mouse deficient in the neutrophil serine proteases elastase and cathespin G shows 
reduced thrombus formation following carotid artery injury.  Compared to wild-type mice, 
thrombi were smaller, more fragile and with a prolonged time to vessel occlusion (Massberg 
et al., 2010). 
 
Cooperation between the coagulation and innate immune systems appears to be necessary to 
fight infection.  Potentially, a failure of thromboinflammation may predispose to both the 
coagulopathy and the immune dysregulation that occurs during sepsis. 
 
1.3.5 Sepsis-associated coagulopathy and disseminated intravascular coagulation 
Most cases of sepsis involve a degree of coagulopathy; it occurs in a spectrum from the very 
mild, detectable only by the most sensitive of laboratory assays, to the clinically evident, 
presenting with thrombosis and/or bleeding (Levi and van der Poll, 2017).  Initially, a 
systemic activation of the coagulation process leads to the deposition of fibrin, particularly in 
vessels smaller than 1µm in diameter (micro-vessels).  Later, a consumption of coagulation 
proteins and a reduction in platelet number can lead to haemorrhagic complications.  The 
fibrinolytic system is also more active in sepsis, with an increase in fibrin degradation 
products such as d-dimer levels and a decrease in the circulating levels of tPA and uPA (Levi 
et al., 1993).   
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Approximately 50-70 % of sepsis cases have associated coagulopathy, a third of which meet 
the criteria for disseminated intravascular coagulation (DIC), a syndrome where the activation 
of intravascular coagulation occurs in small and medium-sized vessels and is not localised to 
a specific site of injury.  The widespread activation of coagulation occurs simultaneously with 
both an inhibition of fibrinolysis and a depletion in physiological anticoagulants, leading to 
intravascular thrombus which contributes to the organ dysfunction associated with sepsis 
(Gando et al., 2016).  Post-mortem studies have shown micro-thrombi to be a frequent 
presentation of DIC, with the kidney as the most commonly affected organ.  Haemorrhage 
was present in only a minority of cases (Robboy et al., 1972). 
 
There is no specific therapy for DIC, other than to treat the underlying cause.  As with sepsis, 
there had been a difficulty in defining DIC, with multiple definitions and guidelines available.  
In 2013, a scientific subcommittee of the International Society of Thrombosis and 
Haemostasis (ISTH) met to combine three guidelines from the British Committee for 
Standards in Haematology (BCSH), the Japanese Society of Thrombosis and Hemostasis 
(JSTH), and the Italian Society for Thrombosis and Hemostasis (SISET).  Recommendations 
included the use of a DIC scoring system.  Currently three scores are available: the ISTH 
overt score, which is most diagnostically specific; the Japanese Ministry of Health, Labor and 
Welfare (JMHLW) score; and the Japanese Association of Acute Medicine (JAAM) score, 
which is most diagnostically sensitive.  All three scores can predict poorer outcomes 





Table 1.3 A comparison of three DIC scores 
This table shows the three ISTH-recommended DIC scores; ISTH (Toh and Hoots, 2007), 
JAAM (Gando et al., 2013) and JMHLW (Wada et al., 2015). (SF – soluble fibrin, ULN – 




ISTH JAAM JMHLW 
Risk factors 
Underlying disease 
capable of causing DIC 0 (essential) 0 (essential) 1 
Clinical symptoms 0 1 if SIRS score ≥3 
1 for bleeding;                
1 for organ 
failure 
Platelet count (x109/L) 1 for 50-100;                     2 for <50 
1 for 80-120 or >30% 
reduction;                        
3 for <80 or >50% 
reduction 
1 for 80-120;                     
2 for 50-80;                       
3 for <50 
Fibrin-related marker 
 D-dimer, FDP or SF.     
2 > ULN but <5X 
ULN;                                 
3 > 5X ULN 
FDP (µg/mL).                   
1 for 10-25;                       
3 for >25 
FDP (µg/mL).                   
1 for 10-20;                       
2 for 20-40;                       
3 for >40 




normal).                        
1 for 3-6;                            
2 for ≥6 
PT ratio.                             
1 for >1.2 
PT ratio.                               
1 for 1.25-1.67;                
2 for >1.67 
Score needed for 
diagnosis of DIC ≥ 5 ≥ 4 ≥ 7 
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1.3.6 Causes of coagulopathy 
As mentioned above, thrombocytopenia is the most common manifestation of sepsis-
associated coagulopathy.  Causes include decreased production, consumption, splenic 
sequestration and possibly an increase in haemophagocytosis by mononuclear cells due to the 
increase in macrophage colony-stimulating factor (MCSF).  In a study of fifty patients with 
sepsis and concurrent thrombocytopenia, haemophagocytosis was found in a bone marrow 
aspirate of 64 %. Although all individuals had high levels of MCSF, cases with 
haemophagocytosis had the highest levels (Francois et al., 1997).  Other co-existing 
conditions such as heparin-induced or drug-induced thrombocytopenia may also contribute to 
low platelet counts (Warkentin et al., 2003; Levi and van der Poll, 2017). 
 
TF is the most important activator of coagulation during sepsis.  It is usually expressed only 
on extra-vascular tissues, but during sepsis it is upregulated on circulating monocytes (see 
section 1.4, page 27).  There are various stimuli that increase the monocytic expression of TF, 
including TNFα , interleukin (IL)-1β and LPS (Rivers et al., 1975; Conkling et al., 1988; 
Schwager and Jungi, 1994).  The upregulation of TF, and subsequent increase in intravascular 
thrombin, is believed to be an important cause of DIC.  Human and animal models of 
endotoxaemia, where a low level of endotoxin is infused and then blood samples taken at 
intervals, demonstrate an initial increase in TNF, followed by a peak in IL-6 and IL-1 levels.  
These models demonstrate an upregulation of TF expression on the monocyte cell surface, a 
125-fold increase in TF mRNA and an increase in thrombin production (van Deventer et al., 
1990; van der Poll et al., 1994; Franco et al., 2000; Gando et al., 2016).  Use of an antibody 
to inhibit TF during a primate model of endotoxaemia prevented both the development of 
coagulopathy and death (Taylor et al., 1991; Levi et al., 1994).  The use of such models will 
be discussed in more detail in section 1.6.  The ex vivo examination of monocytes from cases 
of meningococcal infection showed an increase in TF expression in approximately half, two-
thirds of which had levels 60-300-fold higher than the rest of the cohort.  All individuals with 
the highest levels died (Osterud and Flaegstad, 1983). 
 
Sepsis-associated coagulopathy also involves an activation followed by an inhibition of 
fibrinolysis.  Human models of endotoxaemia first demonstrated these biphasic changes, a 
rise in plasminogen activators (tPA and uPA) followed by a more sustained increase in 
plasminogen activator inhibitor (PAI)-1 (Suffredini et al., 1989; van Deventer et al., 1990).  
Pre-treatment with blocking antibodies to TNF and IL-6 in a chimpanzee endotoxaemia 
model greatly attenuated the increase in both plasminogen activators and PAI-1.  The 
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sustained release of PAI-1 ultimately leads to an inhibition of fibrinolysis during DIC 
(Biemond et al., 1995; Gando et al., 2016).  More recent work has also measured increased 
PAI-1 levels during cases of sepsis (Madoiwa et al., 2006).  
 
The dysregulation is compounded by disruption of the physiological anticoagulant pathways.  
Deficiencies in proteins C and S and antithrombin all occur during sepsis, due to either a 
decrease in production or loss from increased vascular permeability.    
 
Antithrombin activity is potentiated up to a thousand-fold by the binding of heparin.  The 
glycocalyx that covers the surface of the endothelium contains multiple heparin-like cofactors 
that behave in a similar way.  During sepsis the production of endothelial glycosaminoglycans 
is reduced.  Use of labelled sulphate molecules during the in vitro culture of porcine aortic 
endothelial cells showed that IL-1β or TNFα was able to reduce the production of heparin 
sulphate (Kobayashi et al., 1990).   
 
The anticoagulant protein C is activated by binding to endothelial-bound thrombomodulin.  
Skin biopsies from individuals with dermal purpura secondary to meningococcal sepsis 
showed a downregulation of both endothelial-bound thrombomodulin and the endothelial 
protein C receptor when compared to healthy controls (Faust et al., 2001).  This 
downregulation would limit the activity of protein C.    
 
There is no consistent evidence to suggest that TFPI is expressed at a lower level during 
sepsis, but a baboon endotoxaemia model demonstrates a decrease in mortality by the addition 
of TFPI (Novotny et al., 1991; Creasey et al., 1993; Gando et al., 2016). 
 
1.3.7 Predicting outcomes from sepsis-associated coagulopathy 
The development of coagulopathy is associated with a poorer outcome from sepsis (Fourrier 
et al., 1992).  Analysis of 840 individuals diagnosed with severe sepsis showed a correlation 
between 28-day mortality, higher SOFA scores and coagulopathy (Dhainaut et al., 2005).  
Thrombocytopenia at diagnosis of sepsis has also been correlated with organ dysfunction as 
demonstrated with SIRS and SOFA scores, whilst lower anti-thrombin levels have also been 
correlated with a higher mortality rate (Fourrier et al., 1992; Ogura et al., 2007). 
 
PAI-1 works to inhibit the breakdown of thrombus.  Raised PAI-1 levels (>90ng/mL) at the 
diagnosis of DIC (using JMHLW scores) have been associated with a higher 28-day mortality 
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rate and correlated with increasing SOFA scores.  Most non-septic cases in this study had an 
underlying malignancy, two-thirds of which were haematological. This suggests that a failure 
of the regulation of fibrinolysis plays a potential role in septic DIC (Madoiwa et al., 2006).  A 
recent meta-analysis of 19 studies confirmed this finding.  PAI-1 levels appear to be useful in 
predicting disease severity and mortality in cases of sepsis (Tipoe et al., 2018). 
 
DIC associated with sepsis undoubtedly increases the mortality rate; however, there does 
appear to be an improvement in survival over the last few decades.  Data from Japan recorded 
in 2010 and 2012 shows an increase in the incidence of DIC associated with sepsis (39.5 % vs 
43.3 %) but a decrease in sepsis-associated DIC mortality at 14 days (20.4 % vs 17.9 %) and 
28 days (31.1 % vs 27.7 %) (Murata et al., 2014).  This likely reflects a general improvement 
in the care of the critically ill patient (as discussed in section 1.2.2).   As with sepsis as a 
whole, a significant rate of mortality remains.  
 
1.3.8 Efforts to treat sepsis-associated coagulopathy 
With regard to DIC management, the mainstay of treatment is to treat the underlying cause, 
i.e. the sepsis. There is little to no evidence to support replacing deficient coagulation factors 
or platelets with transfusion, unless there are bleeding complications or platelet counts are 
lower than 10-20x109/L (Wada et al., 2013; Levi, 2016).  
 
Multiple interventional studies, which will now be discussed, have been performed with the 
aim of improving the outcomes of individuals with sepsis-associated coagulopathy; 
unfortunately, there has been limited success.  Heparin has been investigated not just as a 
potential anticoagulant but also for its possible role as an anti-inflammatory (Cornet et al., 
2007).  Initial work using a baboon model of DIC, during which animals were given an 
infusion of thrombin, showed that pre-treatment with heparin improved both survival and 
coagulopathy.  Treatment with heparin, two hours after the infusion of thrombin, did not 
correct coagulopathy but did reduce mortality rates to a lesser extent than pre-treatment (du 
Toit et al., 1991).  This model of DIC is significantly limited by the lack of fibrinolytic 
inhibition, reduction in physiological anticoagulants and possibility of increased bleeding due 
to the consumption of coagulation factors and platelets.  A more recent study used a non-
anticoagulant dose of heparin in a mouse model of sepsis (caecal ligation and puncture model, 
discussed further in section 1.6) and showed an improvement in inflammation and mortality 
(Wildhagen et al., 2014).  Evidence outside of animal models is lacking. A randomised 
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controlled trial of heparin as a treatment of sepsis-associated DIC is needed; however, this is 
always going to be hindered by the possibility of increasing a patient’s risk of haemorrhage. 
 
More work has been performed to investigate the efficacy of supplementing activated protein 
C (APC).  Preclinical studies showed that recombinant APC prevented coagulopathy 
(measured by prevention of hypofibrinogenaemia) and reduced mortality in a baboon model 
of lethal Escherichia coli sepsis (Taylor et al., 1987).  A later phase 2 study of drotrecogin 
alfa activated (DrotAA), a recombinant form of APC, showed a dose-dependent reduction in 
d-dimer and IL-6 levels, suggesting it improved coagulopathy and inflammation (Hartman et 
al., 1998).  A phase 3 double-blinded placebo-controlled trial (PROWESS) followed and was 
stopped early due to a perceived benefit.  It demonstrated a small reduction in any-cause 
mortality at 28 days (30.8 % vs. 24.7 %) but also an increased risk of bleeding (3.5 % vs. 2.0 
%) during the infusion period.  Those with the highest Acute Physiology and Chronic Health 
Evaluation (APACHE) II scores, i.e. the more severe disease, received the most benefit.  As 
with the previous studies, D-dimer levels were significantly lower in the treated group 
compared to placebo (Bernard et al., 2001).  A retrospective review of the phase 3 data was 
performed using a modified ISTH DIC score.  Participants with overt DIC derived a greater 
benefit from DrotAA (43 % untreated vs. 27 % treated 28-day mortality).  Rates of serious 
bleeding (defined as intracranial bleeding, a need for more than three red cell transfusions or 
life-threatening bleeding), however, were worse in those with overt DIC (0.9 % untreated vs. 
3.0 % treated) (Dhainaut et al., 2004).  As the original study was stopped early, some doubt 
remained regarding the benefit of DrotAA in treating certain populations, such as those with a 
lower severity of disease (Levi, 2008).  A few subsequent studies also cast doubt on the 
benefit of DrotAA. Abraham et al. showed no benefit compared to placebo when it was used 
in those with less severe disease (APACHE II score <25 or single organ failure) (Abraham et 
al., 2005).  A further randomised placebo-controlled trial was performed (PROWESS-
SHOCK); unfortunately, it failed to replicate the earlier results and no improvement was 
demonstrated in mortality rates at either 28 days or 90 days, but an increased risk of bleeding 
was shown (Ranieri et al., 2012).  Following these results, the use of activated protein C in 
sepsis in DIC was removed from the guidelines (Thachil et al., 2012).  DrotAA is no longer 
available as a therapeutic. 
 
Another possible therapy is antithrombin (AT) concentrate.  Multiple pre-clinical animal 
models have shown that AT can improve outcomes and coagulopathy, such as a rabbit 
endotoxaemia model that demonstrated less intravascular fibrin deposition with AT treatment 
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(Giebler et al., 1999; Opal, 2000).  Initially, a small phase 2 study of 35 cases of sepsis-
associated DIC demonstrated that AT concentrate shortened the duration of coagulopathy and 
suggested that there might be a survival benefit from the treatment (Fourrier et al., 1993).  A 
much larger randomised placebo-controlled trial of over 2000 participants with sepsis 
compared three groups, placebo, AT and AT with heparin.  No significant reduction in 28-day 
mortality was demonstrated in either treatment group, but an increase in bleeding was 
observed in those participants who received heparin and AT (Warren et al., 2001).  As with 
DrotAA, a retrospective analysis of the data showed a mortality benefit in the subset of 
participants with a diagnosis of DIC (again using a modified ISTH score) who received AT 
without concomitant heparin (Kinasewitz et al., 2005).  Later meta-analyses suggest a benefit 
for AT in DIC, but these results must be prospectively investigated before it can be 
considered as therapy (Wiedermann, 2018).  In Japan, however, AT concentrate is 
recommended for the treatment of sepsis-associated DIC (Nishida et al., 2018). 
 
Despite no consistent evidence that TFPI is lowered during sepsis, there is some limited data 
to support the use of recombinant TFPI (rTFPI).  A phase 2 study of 210 cases, comparing 
two doses of rTFPI, showed no significant reduction in mortality but suggested that the 
activation of coagulation was inhibited with a significant reduction in thrombin-antithrombin 
complexes.  As with the previous interventions, there was a trend towards an increase in rates 
of bleeding, but in this case it was not significant (9 % in treated vs. 6 % untreated, p=0.39) 
(Abraham et al., 2001).  A larger phase 3 study showed no reduction in all-cause mortality at 
28 days; however, there was improved survival in participants with an international 
normalised ratio (INR) of less than 1.2 (12.0 % in treated vs. 22.9 % in untreated).  The use of 
rTFPI increased the risk of bleeding for all groups.  Once again, the use of rTFPI did show 
lower levels of thrombin-antithrombin complex and prothrombin fragments 1+2, suggesting it 
did inhibit coagulation; this result was seen regardless of the baseline INR (Abraham et al., 
2003). 
 
Thrombomodulin, which binds to active thrombin and acts as an important cofactor for APC 
when bound to endothelium, has also been investigated.  A phase 3 double-blind trial 
compared the use of thrombomodulin to low-dose heparin in cases of DIC associated with 
either sepsis or haematological malignancy.  Further analysis of the studies investigating 
APC, AT and TFPI suggests a possible improvement in mortality for those in the placebo 
group who received prophylactic dose heparin (Warren et al., 2001; Abraham et al., 2003).  
The use of soluble thrombomodulin, when compared to low dose heparin, reduced both the 
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duration of DIC and the risk of bleeding complications.  In the small cohort of sepsis-
associated DIC (99 cases), there appeared to be a trend towards reduced mortality with 
thrombomodulin (28.0 % vs. 34.6 %).  In the group that received thrombomodulin, almost all 
markers of DIC were normalised, including thrombin:antithrombin, D-dimer and PAI-1 (Saito 
et al., 2007).  A further, placebo-controlled, phase 2 trial was performed to investigate the 
effects of thrombomodulin in cases of sepsis that met the ISTH criteria for DIC.  Although 
thrombomodulin improved markers of DIC as before, there was no reduction in mortality or 
differences in either thrombosis or bleeding between the two groups.  A sub-group analysis, 
however, did suggest a reduction in 28-day all-cause mortality in cases treated with 
thrombomodulin who had either cardiac or respiratory dysfunction, an INR higher than 1.4 
and a platelet count between 30-150 x109/L (26.3 % in treated vs. 38.2 % untreated) (Vincent 
et al., 2013).  As with AT concentrate, thrombomodulin is used in Japan.  A meta-analysis of 
all randomised trials and observational studies suggested a trend towards a decrease in 
mortality but, importantly, no significant increase in bleeding complications (Yamakawa et 
al., 2019).  Further phase 3 studies are needed. 
 
A different approach has been to block the cytokines that are believed to contribute to both 
the inflammation and coagulopathy of sepsis.  A phase 2 placebo-controlled study of a 
humanised monoclonal antibody against TNFα showed no difference in 28-day all-cause 
mortality.  A serum-sickness like reaction was seen in 4 % of those treated.  There was no 
analysis of coagulopathy specifically although a third of all cases met the criteria for DIC and 
were spread evenly between treatment and placebo groups (Abraham et al., 1995).  An earlier 
study of the chimpanzee endotoxaemia model showed that infusing a monoclonal antibody of 
IL-6 had no effect on the induced inflammation but did attenuate the activation of the 
coagulation system (lower thrombin:antithrombin, plasmin:antiplasmin and prothrombin 1+2 
complexes) (van der Poll et al., 1994).  A later study of individuals with renal cancer showed 
that an infusion of recombinant IL-6 led to an activation of coagulation (Stouthard et al., 
1996).  Infusion of an IL-1 antagonist, anakinra, has also been shown to reduce the markers of 
coagulopathy in cases of sepsis.  Whereas IL-6 and TNFα peak within two hours of 
endotoxaemia, as shown by various models, IL-1β has appeared unchanged in some models 
of endotoxaemia and peaked at four hours in others (Andreasen et al., 2008).  This calls into 
question the role of IL-1β in the development of sepsis-associated coagulopathy (van 
Deventer et al., 1990; Boermeester et al., 1995). 
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Collectively, these trials suggest that perhaps a more targeted approach is needed.  It is 
certainly ambitious to improve all-cause mortality in all degrees of sepsis-associated 
coagulopathy, but perhaps investigating specific groups, such as those at lower bleeding risk, 
or aiming to intervene prior to the full diagnosis of DIC, would be more fruitful.  Recently, a 
retrospective analysis of over 400 cases of sepsis-associated DIC was published.  Individuals 
with a baseline INR ≥1.57 and a SOFA score ≥13 were identified as at high risk of an early 
death; 83 % died within 3 days (Iba et al., 2018).  In the future using such a score may allow 
particular populations to be targeted.  
 
1.3.9 Summary 
There is an urgent need to understand the pathology of sepsis-associated coagulopathy in 
more detail, to diagnose it promptly and accurately, and to tailor therapies to improve the 
outcome for affected patients. 
 
1.4 Tissue Factor 
1.4.1 Overview 
As already highlighted, TF plays an important role in activating the coagulation system and 
potentially the coagulopathy associated with sepsis.  This section will discuss the roles of TF 
further. 
 
1.4.2 The discovery of tissue factor 
In the early 1900s, Morawitz proposed the ‘classical theory of blood coagulation’, describing 
how prothrombin, thrombin, calcium and fibrinogen are necessary for the formation of a 
blood clot.  It was in 1905, however, that he published his seminal work Die Chemie der 
Blutgerinnung (The Chemistry of Blood Coagulation); for the first time, a substance in tissue 
was identified that activated clotting. Morawitz named it ‘thrombokinase’, but this would later 
be known as TF (Morawitz, 1905; Morawitz, 1958; Boulton, 2006).  It would take almost 
another eighty years until TF was purified, initially from bovine and then from human tissue 
(Bach et al., 1981; Broze et al., 1985). This was swiftly followed by full sequencing of the TF 
gene, localisation to chromosome 1 and identification of the protein structure by several 
groups (Morrissey et al., 1987; Scarpati et al., 1987; Spicer et al., 1987; Mackman et al., 
1989).  TF has three domains: extracellular, transmembrane and intracellular.  The 
extracellular domain, (the NH2-terminal, residues 1–219) appears to fold in a similar way to 
the cytokine receptor superfamily, with seven β strands arranged as two β sheets; the primary 
protein sequence and structure appear similar to receptors for growth hormone or 
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erythropoietin.  The transmembrane domain (residues 220–242) serves to anchor TF to the 
cell membrane, whereas the intracellular domain (the COOH-terminal, residues 243–263) has 
a role in cell signalling (Ruf and Edgington, 1994; Butenas, 2012). 
 
1.4.3 Tissue factor: an activator of the coagulation system 
TF is a 47kDa trans-membrane glycoprotein expressed predominantly by extra-vascular cells 
such as fibroblasts, creating what is frequently termed ‘the haemostatic envelope’ around the 
vasculature (Drake et al., 1989).  By binding to factor FVIIa on a cell surface, it serves to 
initiate coagulation where there is a vessel wall injury (ten Cate et al., 1993).  No other TF 
ligands, other than FVII and FVIIa, have been identified. TF, once bound to FVIIa, has been 
shown to activate factors X (FXa), FIX (FIXa) and FXI (FXIa) (Mackman, 2004).  A full 
description of the cell-based coagulation model is given in Figure 1.1, but, briefly, the 
prothrombinase complex (a complex of activated factors V and X) works to cleave 
prothrombin to thrombin.  This thrombin is quickly inhibited by antithrombin; to overcome 
this, more FXa is created by the tenase complex (activated factors IX and VIII).  TF is 
therefore able to contribute to both the prothrombinase and tenase complexes and in doing so 
is integral to the activation of coagulation. 
 
TF is inhibited primarily by TFPI, which serves to inhibit the binding of FVIIa to TF and the 
formation of the prothrombinase complex (see section 1.3.2, page 8). Two isoforms have been 
identified: TFPIα and TFPIβ.  Both can inhibit the binding of TF to FVIIa, but only TFPIα 
also inhibits the prothrombinase complex (Wood et al., 2013; Maroney and Mast, 2015).  
TFPIβ is predominantly expressed on the endothelial cell surface, whilst TFPIα is secreted 
from platelets (Maroney et al., 2013). Platelets contain TFPIα and it is released when they are 
activated, such as by thrombin.  The TFPIα in platelets appears to be important in controlling 
the formation of intravascular thrombus; TFPIα knockout mice showed an increase in 
thrombus volume following vascular injury when compared to wild-type mice (Maroney et 
al., 2011). 
 
1.4.4 Tissue factor expression on circulating monocytes and ‘encryption’   
Aside from contributing to the haemostatic envelope, it is now accepted that TF can be 
expressed on the surface of circulating monocytes; however, unless it is induced, this is at 
very low level (Osterud, 2012).  The role of monocytic TF expression is poorly understood, 
but it may have a role in thromboinflammation (see section 1.3.4, page 16).  The induction of 
TF expression on the monocyte surface has been shown with multiple agents including LPS, 
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C-reactive protein and P-selectin (Rivers et al., 1975; Cermak et al., 1993; Celi et al., 1994).  
There is, however, great variability in TF expression between individuals, and so-termed 
‘hyper-responders’, who express higher levels, have been associated with diseases that 
include a higher risk of thrombosis (Egorina et al., 2005). 
 
Maynard et al. first demonstrated that TF was present on cells within the circulation and 
appeared to be associated with the cell surface; however, they also noted the need to cause 
disruption of the membrane to increase activity (Maynard et al., 1975).  It is now accepted 
that the majority of cell-bound TF is supressed through the post-translational mechanism of 
‘encryption’ within the cell membrane.  Whilst encrypted TF is still bound to factor VIIa, and 
thereby demonstrates some procoagulant activity, this is much lower compared to ‘decrypted’ 
TF (Bach, 2006; Kothari et al., 2013).  The process of encryption is yet to be elucidated, but 
for many decades it has been recognised that phospholipids in the cell membrane affect the 
activity of TF and the initiation of coagulation (Studer, 1946; Nemerson, 1968; Jones et al., 
1985; Mann et al., 1990). There are several theories to explain the possible role of lipids in 
encryption.  The most widely accepted theory is that of phosphatidylserine (PS) asymmetry: 
usually this lipid remains in the inner cell membrane, but when it is externalised to the outer 
membrane it has been shown to increase the activity of TF.  The organisation of TF within the 
cell membrane is likely also to be important.  Other more recent work suggests a suppressive 
role for sphingomyelin in the cell membrane and the reduction/oxidation of a cysteine 
disulphide bond with the TF extracellular domain.  All of these will now be discussed.  
 
Phosphatidylserine (PS) is maintained by ATP transport on the inner cell membrane.  In vitro 
work has shown that when PS becomes extracellular there is an increase in cell-bound TF 
activity (Forman and Nemerson, 1986).  PS can be moved to the outer membrane in several 
ways in vitro, including by freezing and by increasing intracellular calcium.  Several in vivo 
mechanisms have also been discovered, including the activation of platelets by thrombin 
leading to an increase in cytosolic calcium and possibly therefore to decryption (Bach and 
Moldow, 1997).  There are three enzymes that are known to transport phospholipids in the 
cell membrane: flippase (which moves them inward), floppase (which moves them outward) 
and scramblase (which can rapidly break down the usual membrane asymmetry).  Scramblase 
has been shown to increase the binding of Annexin V to the outer surface of activated 
platelets in a calcium-dependent manner (Bevers et al., 1983; Zwaal et al., 2005). Another 
mechanism, in vivo, can be seen in apoptotic cells, which are known to increase PS on the cell 
surface (Bach, 2006).  Exactly how PS may decrypt TF is unclear, but a possibility is that PS 
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interrupts the ‘self-association’ of TF – the formation of homodimers in the presence of a 
ligand (Roy et al., 1991; Aras et al., 2004; Bach, 2006).  Alternatively, perhaps, an increase in 
PS on the outer surface increases the binding of Xa (Rao et al., 2012).  Multiple diseases that 
have a thrombotic component have been associated with an increase in outer cell PS, 
including the red blood cells and platelets in diabetes mellitus and the ‘sickled’ red blood cells 
of sickle cell disease (Zwaal et al., 2005).   
 
Lipid rafts, cholesterol-rich microdomains within the outer cell membrane, have also been 
identified as potentially important in maintaining TF encryption. These rafts are composed 
primarily of sphingolipids and cholesterol in the outer cell membrane that connect with 
phospholipids and cholesterol within the inner membrane.  They are organised structures that 
can move around the membrane, are more densely packed than surrounding regions and can 
cluster together (Simons and Ehehalt, 2002).  Disruption of lipid rafts has been demonstrated 
to increase the activity of TF without a corresponding increase in the proportion of cell-bound 
TF or an increase in cell lysis (Dietzen et al., 2004; Mandal et al., 2005).  Rafts have also 
been implicated in the management of intracellular calcium.  Disruption of rafts by the 
removal of cholesterol has been shown to decrease the release of calcium from intracellular 
stores, increase the externalisation of PS and increase the procoagulant activity of affected 
cells (Kunzelmann-Marche et al., 2002). 
 
A more controversial theory involves the regulatory effect of protein disulphide isomerase 
(PDI) on thiol residues at the TF Cys186-Cys209 disulphide bond.   There are two disulphide 
bonds within the extracellular domain of TF: one of these, Cys186-209, has been shown to be 
necessary for TF to demonstrate procoagulant activity (Rehemtulla et al., 1991).  It is 
hypothesised that unpaired thiol residues at Cys186 and 209 create an encrypted structure, 
whereas the creation of a disulphide bond decrypts the TF and increases activity.  Chen et al. 
demonstrated in vitro that the addition of mercuric chloride, which oxidizes dithiols to 
disulphides, increased the activity of TF, whereas blocking unpaired cysteine thiols led to a 
decrease in TF activity.  They suggest that PDI breaks the disulphide bond and may thereby 
control TF encryption and activate the TF procoagulant activity.  The authors, however, were 
unable to demonstrate an excess of free cysteine thiols, which would be expected as the 
majority of cell-bound TF is believed to be encrypted (Chen et al., 2006).  This is supported 
by a murine model of vascular damage: microparticles expressing TF were injected into the 
damaged area, leading to an increase in fibrin.  The addition of an anti-TF antibody prevented 
fibrin formation, as did the addition of an anti-PDI antibody.  PDI was visualised around 
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activated platelets within the forming thrombus and vascular smooth muscle cells, suggesting 
its release following injury or platelet activation (Reinhart et al., 2013). There is also some 
evidence for this mechanism in monocytes. It has long been recognised that the use of anti-
thymocyte globulin (ATG) to deplete lymphocytes (such as prior to allogenic stem cell 
transplant) leads to activation of coagulation.  ATG was shown to increase the TF activity of 
monocytes in vitro, but not through an increase in cell surface PS. Instead the increase in TF 
activity was prevented by blocking the number of free thiols (Langer et al., 2013). 
 
There are several problems with this theory, however. The addition of an oxidising agent such 
as mercuric chloride may increase the surface expression of anionic phospholipids such as PS; 
this could therefore explain the increase in TF activity without the creation of a disulphide 
bond.  There has also been no conclusive evidence that PDI associates with TF, and human 
endothelial cells transfected with mutant TF that does not contain the Cys186-209 bond have 
a similar ability to activate coagulation in vitro (Pendurthi et al., 2007; Kothari et al., 2013).  
Finally, in vitro work with human endothelial cells demonstrates that inhibition of PDI can be 
procoagulant by increasing the cell surface expression of PS independent of calcium (Popescu 
et al., 2010).  Further work is needed, primarily to identify how PDI may associate with TF, 
but this remains an intriguing possibility. 
 
Recent work has suggested that the presence of sphingomyelin in the outer cell membrane 
may work to ‘dampen down’ or encrypt TF.  Sphingomyelin is a phospholipid comprising up 
to 50 % of the outer cell membrane (Wang et al., 2017).  Wang et al. have shown in 
macrophages that the hydrolysis of sphingomyelin through the action of sphingomyelinase 
increases TF activity.  Through stimulation with adenosine triphosphate, acid-
sphingomyelinase was shown to translocate to the outer cell membrane without an increase in 
the proportion of PS (Wang et al., 2017).  This suggests that perhaps sphingomyelin acts to 
suppress TF activity and maintain it in an encrypted state. 
 
Whilst much remains to be understood in relation to encryption, it certainly appears to be an 
important physiological process that is necessary to control TF activity on circulating blood 
cells. 
 
1.4.5 The role of monocyte surface TF expression in coagulation 
As discussed, TF is expressed on cells other than monocytes including activated endothelium.  
Several pre-clinical studies have investigated the specific contribution of TF expressed on the 
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surface of monocytes.   Lethally irradiated mice were transplanted with haematopoietic cells 
from mice that did not express TF.  They were compared to wild-type mice transplanted with 
normal haematopoietic cells.  Both groups were injected with intra-peritoneal LPS and had 
markers of coagulation measured at 3 hrs.  Although both groups showed an increase in the 
thrombin-antithrombin (TAT) complex, the level was higher in the wild-type group that had 
an also demonstrated an increase in haematopoietic cell TF expression of (Schoenmakers et 
al., 2004).  A floxed mouse model that, with a specific myeloid promotor, deleted the 
expression of TF in myeloid cells also demonstrated a reduction in TAT following 
endotoxaemia.  The group did not detect TF mRNA in the murine platelets (both unstimulated 
and stimulated), but did demonstrate it from blood leucocytes.  Further work using a Tie-2 
promoter created a mouse with a > 95 % reduction in TF on all cell types (including 
endothelial).  By transplanting them with bone marrow from control mice, a model was 
created that did not express endothelial TF but did express haematopoietic TF.  Selective 
deletion of TF expressed on the endothelium did not reduce the TAT levels following 
endotoxaemia. This work demonstrated that the TF expressed on leucocytes, and not the 
endothelium or platelets, that activates coagulation following endotoxaemia (Pawlinski et al., 
2010).  The role of TF on platelets has been debated between groups. Although several groups 
have reportedly detected TF mRNA and protein in human platelets, this is disputed by other 
groups who have failed to replicate these results (Zillmann et al., 2001; Butenas et al., 2005; 
Østerud and Bjørklid, 2006; Pawlinski and Mackman, 2010).   
 
Later work involved using the Berkley murine model of sickle cell disease (BERK), a model 
known to express higher levels of TF on leucocytes compared to controls.  The leucocytes 
found to express TF on their surface were identified morphologically as monocytes.  
Transplanting the Tie-2 flox model with cells from the BERK mouse again created a model 
that expressed TF only on haematopoietic cells.  Coagulation markers were higher in the 
BERK transplanted model and not reduced by removing the non-haematopoietic expression 
of TF (Chantrathammachart et al., 2012).   
 
These pre-clinical data support the idea that TF expressed on the monocytic surface is 
functionally active. 
 
1.4.6 High and low responders to the LPS induction of monocytic TF cell surface expression 
The monocytic cell surface expression of TF, following LPS stimulation, varies considerably 
between individuals.   This phenomenon was first noted by Ossterud in 1995: whole blood 
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samples were taken from 135 healthy volunteers and stimulated ex vivo with 5 ng/mL LPS for 
2 hours prior to the measurement of TF activity.  Two groups of individuals were identified, 
those with a high response and those with a low response; the TF activity was shown to vary 
between individuals by as much as 50-fold (Ossterud, 1995).  Later work by the same 
laboratory used flow cytometry to measure TF cell surface expression on a CD14 positive cell 
population and demonstrated a high and low responder group; once again, high and low 
responder groups were defined by the level of TF activity. 
 
The cause of this difference in response is not fully understood.  The presence of platelets 
seems to increase the LPS induction of TF.  Ossterud et al. (1990) used blood preparations 
that contained 15 % of the original platelet count; adding platelets from a low responder to a 
high responder sample resulted in a lower TF activity when compared to the addition of 
autologous platelets (Osterud et al., 1990).  The same group also demonstrated that the 
monocytic TF activity induced with LPS was reduced by two thirds when the monocytes were 
suspended in platelet-poor plasma compared to platelet-rich plasma.  Other work has 
suggested that granulocyte stimulation may increase monocytic TF activity; this effect was 
reduced by blocking CD15 (a p-selectin ligand).  Potentially, an interaction between 
granulocytes, monocytes and platelets enhances the LPS induction of monocyte surface 
expression of TF (Osterud et al., 1990; Halvorsen et al., 1993; Ossterud, 1995).   
 
More recent work has also demonstrated the ability of red blood cells to increase monocyte 
TF activity following LPS stimulation in a dose-dependent manner.  Comparing the red blood 
cell counts of healthy human volunteers to their monocyte TF activity, however, failed to 
show a clear correlation (r=0.199, p=0.001 using Pearson’s co-efficient).  The group used a 
mouse model of endotoxaemia to investigate the monocytic cell surface expression of TF.  
Mice were given an intraperitoneal injection of LPS and blood was collected from the inferior 
vena cava five hours post injection.  There was an increase in TF surface expression on 
murine monocytes at five hours following injection when compared to controls injected with 
phosphate-buffered saline.  This effect was abolished by the use of Duffy anti-gen receptor 
for chemokines (DARC)-null mice (Østerud et al., 2015).  DARC is a red blood cell receptor 
that varies in expression between populations; it is present in a high proportion of white 
Caucasians but a much smaller proportion of sub-Saharan African (Meny, 2010).  DARC is a 
receptor for a range of pro-inflammatory chemokines including monocyte chemoattractant 
protein (MCP)-1 and IL-8 (Gardner et al., 2004; Meny, 2010). 
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Whether a high versus a low response affects clinical outcomes or predisposes to thrombotic 
disease is not yet known.  A small group of 54 individuals with a family history, but not a 
personal history, of myocardial infarction were investigated.  Only a small proportion of 
individuals with high cholesterol were considered high responders (10 %) whereas those with 
normal cholesterol levels had a much higher proportion of high responders (55 %).  There was 
no control group without a family history of myocardial infarction (Østerud et al., 2002).  
Further work is needed before any conclusions can be drawn. 
 
1.4.7 The pathway of lipopolysaccharide-induced tissue factor expression  
The induction of TF expression on monocytes by LPS has long been recognised (Drake et al., 
1989; Gregory et al., 1989); however, the pathway(s) by which LPS induces TF gene 
expression has not fully been elucidated, and particularly not in relation to monocyte subsets.  
LPS is known to bind to the lipopolysaccharide-binding protein and then to CD14 and TLR-4.  
Nuclear factor (NF)–κB, extracellular signal–regulated kinase (ERK) and c-Jun amino 
terminal kinase (JNK) pathways are all activated by LPS and have all been associated with TF 
transcription (Dokter et al., 1993; Groupp and Donovan-Peluso, 1996; O'Connell et al., 1998; 
Guha et al., 2001; Bode and Mackman, 2014).  Studies in THP-1 cells, a human monocytic 
cell line, have demonstrated that LPS is able to increase TF mRNA and increase the cell 
surface expression of TF (Bode and Mackman, 2014).   
 
Multiple regions within the TF promoter have been identified that are suitable for 
transcription factors to bind (see Figure 1.3).  Proximally there are two Sp-1 sites and three 
overlapping Sp-1/Egr-1 sites that appear important for basal TF expression (Mackman, 1995).  
Egr-1 is also required for maximal TF expression; inhibition of the Egr-1 binding site within 
the TF promoter led to a 72 % reduction in TF expression (Guha et al., 2001).  Distally, a 56-
base pair LPS responsive element (LRE) has been identified through the work of Mackman et 
al., using the THP-1 cell line.  The LRE comprises two AP-1 sites and a NF-κB binding site, 
both of which are needed for full LPS-induced transcription (Mackman et al., 1991; 
Mackman, 1995). The NF-κB site, interestingly, does not match the κB DNA consensus 
sequence and binds a c-Rel/p65 heterodimer.  There is also a suggestion that an interaction 
between this heterodimer and AP-1 is required for TF to be fully transcribed following LPS 
stimulation.  Increasing the distance between the NF-κB and AP-1 binding sites prevented 
LPS-induced TF transcription (Glover and Harrison, 1995; Parry and Mackman, 1995; Oeth 





Figure 1.3 demonstrates the three transcription pathways associated with the lipopolysaccharide 
(LPS) induction of TF on monocytes. The AP-1 and NF-κB binding sites make up the 
lipopolysaccharide-responsive element.  The Egr-1 site appears to be important in the maximal 
expression of TF. 
  
Figure 1.3 LPS-induced TF expression. 
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1.4.8 Innate immune training and TF 
Over the last decade there has been increasing evidence to support the idea of the innate 
immune system having a memory, with the potential for innate cells to be ‘trained’ (Kurtz, 
2004).  Initial evidence came from the study of invertebrates that do not have an adaptive 
immune system.  Recovery from infection in a crustacean was shown to relate to previously 
encountered pathogens.  If there had been previous infection with a microbe with similar 
molecular patterns the crustacean was more likely to recover from the infection (Kurtz and 
Franz, 2003).  Witteveldt and colleagues also demonstrated that oral vaccination against a 
virus was possible in shrimp; a reduction in mortality was demonstrated, although the effect 
was significantly reduced at 21 days (Witteveldt et al., 2004).  The mechanisms underpinning 
this ‘memory’ are still unclear, although it has been hypothesised that it may be due to long-
lasting upregulation of molecules that recognise the pathogen (Kurtz, 2004).  Murine models 
have demonstrated the ability of PAMPs to induce immune training in monocytes.  Mice that 
lacked both B and T lymphocytes were shown to have protection from a lethal dose of 
Candida albicans following prior infection with a sub-lethal dose.  This protection did not 
occur in monocyte deficient mice (Quintin et al., 2012). 
 
Several human studies have also supported the concept of innate training.  Following Bacillus 
Calmette-Guérin (BCG) vaccination in healthy volunteers, isolated monocytes stimulated 
with LPS demonstrated an upregulation in PRRs and an increase in pro-inflammatory 
cytokines for up to 12 months (Kleinnijenhuis et al., 2014).  Epigenetic study of the isolated 
human monocyte that had been ‘trained’ with β-glucan (part of the fungal cell wall) showed 
changes in histone H3 acetylation.  Looking at the transcriptome revealed an upregulation of 
genes associated with macrophages (Saeed et al., 2014).  Later work demonstrated that LPS 
could induce macrophage epigenetic modification of histone H3 via cyclic AMP-dependent 
transcription factor (ATF)-7, which conferred resistance to Staphylococcus aureus infection 
(Yoshida et al., 2015). 
 
Potentially, the monocytic surface expression of TF could be a consequence of innate immune 
training. 
 
1.4.9 TF expression and its role in sepsis 
For several decades, TF has been associated with the development of coagulopathy in sepsis 
(Osterud and Flaegstad, 1983).  Several animal models have demonstrated an association 
between TF and DIC.  The injection of an anti-TF antibody to a rabbit model of 
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endotoxaemia, prior to the injection of LPS and TF, prevented the formation of coagulopathy 
seen in those not given the antibody (via a decrease in fibrinogen and factors V and VIII) 
(Warr et al., 1990).  A similar model in baboons showed a decrease in mortality following 
endotoxaemia in animals given an antibody to block TF (Taylor et al., 1987).  This work was 
then extended by the same group using an injection of TFPI prior to a lethal infusion of 
Escherichia coli in a baboon model; in this case the TFPI prevented death from sepsis in 
comparison to the control group, which did not receive TFPI and had 100% mortality (Taylor 
et al., 1991).  Later work blocking the active site of FVIIa reduced coagulopathy but only 
prevented death in half of the cases.  TFPI prevents the formation of both the TF:FVIIa 
complex and also the prothrombinase complex. This suggests that it is the complex of 
TF:FVIIa that is most important and that it may play a role in not just coagulation but also the 
inflammatory response to sepsis (Taylor et al., 1998).   
 
TFPI has been shown to improve survival in other models, including a rabbit model of Gram-
negative peritonitis in which recombinant TFPI was administered four hours after the 
induction of peritonitis, and several murine models of superantigen-induced shock and 
polymicrobial intra-abdominal sepsis (Camerota et al., 1998; Opal et al., 2001).  As 
previously discussed, however, the use of recombinant TFPI had no effect on mortality when 
trialled in humans (see section 1.3.9, page 25) (Abraham et al., 2003). 
 
As mentioned earlier, there has been very little investigation of the high and low responder 
phenomenon in thrombotic illnesses and none looking particularly at sepsis.  Potentially a 
high response during sepsis could predispose to the development of sepsis-associated 
coagulopathy, allowing for the identification of at-risk individuals and a stratified approach to 
management.  Such a stratification has been used in other aspects of critical illness.  An 
excellent example is that shown by the work of Calfee et al. (2015), who have identified 
biomarkers that can be used to distinguish direct (due to pneumonia or aspiration) and indirect 
(e.g. non-pulmonary sepsis) forms of acute respiratory distress syndrome (ARDS) (Calfee et 
al., 2015).  Each form of ARDS has been associated with varying clinical outcomes and 
mortality rates (Luo et al., 2017).  Future clinical trials can therefore investigate the efficacy 
of new therapies in each subtype.  Hinds et al. have taken a similar approach to sepsis, 
identifying four endotypes using the expression of 140 genes. One of the four endotypes was 




TF undoubtedly plays a role in the development of sepsis-associated coagulopathy and in 
inflammatory responses.  Further work is needed to fully understand its effects with the hope 
that future interventions may improve the outcome of individuals with sepsis. 
 
 
1.5 Monocyte subsets 
1.5.1 Overview 
Over the last few decades, monocytes have been divided into subsets that are believed to be 
functionally different.  The development of subset classification, the role of each subset and 
the implications this has during sepsis will now be discussed.  
 
1.5.2 Classification of the three subsets 
Monocytes vary by morphology and function and there have been many attempts to divide 
them into sub-populations.  Initially this was done by size and shape using elutriation.  Two 
populations were defined: small and large.  They differed in reactive oxygen species 
production, how they responded to stimuli such as LPS, and their degree of antigen 
presentation (Yasaka et al., 1981; Esa et al., 1986; Turpin et al., 1986; Shiotsuki et al., 1987).   
As well as using morphology, adhesion to fibronectin was used to separate monocytes into 
subpopulations (Owen et al., 1992).  These methods were fraught with difficulty: monocytes 
needed to be isolated prior to subset identification, which might alter their function; it was not 
possible to ensure there was no contamination with smaller cell populations such as dendritic 
cells; and these methods varied by the skill of the operator (Ziegler-Heitbrock, 1996b). 
 
An alternative method for dividing monocytes into subsets is the use of cell markers.  Three 
populations were first identified by Passlick et al. using the markers CD14 (an LPS co-
receptor) and CD16 (a low affinity Fc gamma immunoglobulin receptor, FcγRIII) (Passlick et 
al., 1989).  The use of markers reduces the risk of contamination with non-monocytes and 
does not require cell isolation prior to identification (Ziegler-Heitbrock, 1996b; Ziegler-
Heitbrock et al., 2010a).  In 2010, nomenclature for monocyte subsets was internationally 
agreed and approved by the Nomenclature Committee of the International Union of 
Immunological Societies (see Table 1.4).  Three human subsets were identified: classical 
(CD14++, CD16-), the major subset, accounting for approximately 85 % of circulating 
monocytes; intermediate (CD14++, CD16+), accounting for 5 %; and non-classical (CD14+, 
CD16++), accounting for 10 % (see Figure 1.4).  This nomenclature is useful to help compare 
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studies and avoids problematic descriptions such as ‘inflammatory monocytes’ (Ziegler-
Heitbrock et al., 2010a; Wong et al., 2011).  Most of the work performed from this time has 
considered only two monocyte subsets, classical and non-classical; there is great variability 
between authors regarding how the intermediate subset was determined.  It was either ignored 
completely or incorporated within the non-classical population.  For clarity, all further 






Table 1.4 Markers of human and murine monocytes used to identify subsets 
This table lists markers that differ between the subsets, based on the international standard 
and others.  + means this marker is expressed at a level at least 10-fold higher than isotype 
control, whereas ++ means an expression at least 100-fold higher.  (CLEC4D - C-Type 
Lectin Domain Family 4 Member D, CXRCR1 - CX3C chemokine receptor 1, Gr - 
glucocorticoid receptor, HLA – human leukocyte antigen, Ly6C - Lymphocyte antigen 6 
complex locus G6D, Siglec10 - Sialic acid-binding Ig-like lectin 10) 
 
  
 Human subsets Murine subsets 







CD14++             
CD16- 
CD14++       
CD16+ 
CD14+         
CD16++ 
Ly6C++       
CD43+ 
Ly6C++      
CD43++ 




CCR2+          
CXCR1+ 
CXCR2+ 
CLEC4D+      
IL-13Rα1+ 
HLA-ABC+         
HLA-DR+          
CD40+ 
CD115+     
CD294+      
Siglec10+ 
CX3CR1+     
Gr1++  





This figure shows the internationally accepted nomenclature for monocyte subsets as agreed 
in 2010 (Ziegler-Heitbrock et al., 2010a). Non-classical monocytes are morphologically 
smaller than classical.  Non-classical monocytes are known to ‘patrol’ the endothelium 
(Auffray, 2007; Cros et al., 2010).  
Figure 1.4 Human monocyte subsets. 
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Some significant limitations to this classification remain. Firstly, they refer to monocytes in ‘a 
steady state’, whereas CD markers may change during conditions such as inflammation or 
potentially through the method of monocyte isolation (Zhou et al., 2012; Mukherjee et al., 
2015).  Secondly, there is increasing evidence that monocytes can transition between subsets 
(classical to intermediate to non-classical); this can make the distinction between subsets 
challenging, particularly as the gating of flow cytometry is operator-dependent and it is 
challenging to separate the intermediate and non-classical subsets (Yona et al., 2013).  To 
some extent this can be improved through use of analysis software such as t-distributed 
stochastic neighbour embedding (tSNE) where similar cells are clustered together (Maaten 
and Hinton, 2008).   
 
Following the definition of the three subsets, there have been additional markers proposed to 
further define the CD16+ subsets.  This include TIE2 (angiopoietin receptor) and Slan (a 
carbohydrate modification of PSGL-1).  Studies of tissue repair following limb ischaemia 
suggest a majority group of non-classical monocytes that express TIE2 at times of critical 
ischaemia in humans and decrease again following recovery.  The expression of the Slan 
marker has been shown to be decreased on the intermediate subset in conditions such as 
sarcoidosis (Patel, 2013; Hofer et al., 2015). This suggests that these markers may be useful 
to define the subsets more accurately, and they may have clinical implications.  
 
1.5.3 Mouse monocyte subsets 
In 2001, Palframan et al. first discussed the possibility of mouse monocyte subsets, during an 
investigation of monocyte recruitment to lymph nodes (Palframan et al., 2001).  Since then, 
mouse monocyte subsets have been shown to be homologous in some respects to human 
subsets.  The use of murine models has been very helpful for investigating monocyte subsets.  
Nomenclature for mouse monocyte subsets was also suggested in 2010, using the markers 
Ly6C (lymphocyte antigen 6C, a haematopoietic differentiation antigen) and CD43 (cell 
surface sialoglycoprotein, a member of the surface mucin family).  The subsets are defined as 
classical (Ly6C++, CD43+), intermediate (Ly6C++, CD43++) and non-classical (Ly6C+, 
CD43++) (Ziegler-Heitbrock et al., 2010a).  Unlike human monocytes, there are equal numbers of 
all subsets (Geissmann et al., 2003; Sunderkotter et al., 2004).  As with human monocyte 
subsets, mouse classical monocytes are recruited through CCR2 and non-classical through 
CX3CR1 (Nahrendorf et al., 2007). 
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A comparison of human and monocyte subset genetic profiles revealed 269 human and 561 
mouse genes that were differentially expressed with a greater than two-fold difference 
between subsets.  An algorithm to rank genes between species for similarity was used to 
identify genetic conservation between species.  Both classical and non-classical subsets 
showed similar genetic profiles between human and mouse monocytes. Staining for cell 
surface markers appeared to confirm that these similarities were also present at the protein 
level (Ingersoll et al., 2010). 
 
A model commonly used to visualise mouse monocytes uses CX3CR1GFP/+ mice.  The use of 
green fluorescent protein (GFP) associated with CX3CR1 allows the two subsets 
(CX3CR1++/Ly6C+, non-classical and CX3CR1+/Ly6C+, classical) to be visualised using 
intra-vital microscopy.  This method was used during a murine model of skeletal muscle 
injury and showed again that classical monocytes were recruited first to the site of injury but 
several days later non-classical monocytes predominated.  The classical monocytes were 
shown to produce TNF-α & IL-1β when compared to the non-classical, which produced more 
IL-10 and TGF-β1 (Arnold et al., 2007).  A murine model of intra-peritoneal infection using 
Toxoplasma gondii once again demonstrated an influx of classical monocytes; repeat with a 
CCR2-/- knockout mouse model abrogated the recruitment of classical monocytes to the site of 
infection and led to increased mortality (Robben et al., 2005).  These studies suggest that the 
classical subset is important in fighting infection. 
 
In a murine model of myocardial ischaemia, different and complementary functions were 
identified.  Classical monocytes in the peripheral blood were predominant for the first five 
days, following coronary artery ligation, whilst non-classical predominated from day five and 
remained at higher than normal levels until day sixteen.  In the tissue, classical monocytes – 
but not non-classical – showed a high proteinase activity and expressed TNF-α.  Non-classical 
monocytes expressed a high level of vascular endothelial growth factor (VEGF) compared to 
classical.  This strongly suggests different functional roles for each subset.  The authors 
suggest that, potentially, the classical monocytes assist in phagocytosing damaged tissue, 
whereas the non-classical may be needed for tissue repair (Nahrendorf et al., 2007).  There 
may  be a role for classical monocytes in the development of atherosclerosis.  Apolipoprotein 
(apoE)-/- mice fed a high-fat diet, a murine atherosclerotic model, showed a monocytosis with 
a proportionate expansion of classical monocytes that infiltrated developing plaques.  Non-
classical monocytes were also shown to be capable of infiltrating plaques, but, interestingly, 
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without the need for CX3CR1, which was instead used by classical monocytes along with 
CCL2 and CCR5 (Tacke et al., 2007).   
 
More recent work also suggests a role of non-classical monocytes in tissue repair.  Using a 
model of skeletal muscle injury in a CX3CR1GFP/+ mouse, both monocyte subsets were 
recruited to the site of injury, reaching a plateau level at 7 days.  Increasing the proportion of 
non-classical monocytes promoted muscle fibre regeneration and decreased fibrosis (San 
Emeterio et al., 2017). 
 
Auffray et al. investigated the movement of the subsets further.  Using the CX3CR1GFP/high 
mouse, they showed that CX3CR1high/Gr1- monocytes ‘crawled’ along the endothelium.  This 
movement was not dependent on blood flow and these monocytes were confined to a 
particular area, hence the author’s description of this crawling as ‘patrolling’.  This movement 
was abrogated in CX3CR1-deficient mice and in mice where either CD11b or CD18 were 
blocked.  In response to tissue damage, the CX3CR1high/Gr1low subset extravasated rapidly 
and prior to PMNs (Auffray, 2007).   A limitation of this study, and others, is the use of the 
Gr-1 epitope on Ly6C.  This should ideally be avoided when identifying monocyte subsets, as 
it occurs on both Ly6C and Ly6G, but monocytes only express the former (Geissmann et al., 
2003). 
 
Mice injected with Listeria monocytogenes experience a monocytopenia in the peripheral 
blood followed by a monocytosis, primarily formed of classical monocytes, 72 hours later.  
This suggests that murine monocytes are released from the bone marrow as classical and later 
differentiate into other subsets (Sunderkotter et al., 2004).  Murine classical monocytes have 
been shown to enter sites of inflammation rapidly, and over time appear to differentiate into 
non-classical monocytes (Jutila et al., 1988; Geissmann et al., 2003).  In vitro studies have 
shown that murine classical monocytes lose Ly6C expression after several days of culture 
(Jutila et al., 1988).  Dichloromethylene-bisphosphonate-loaded liposomes have been used to 
eliminate monocytes in a murine model; the in vivo monocyte recovery was then investigated.  
The initial monocytes to return to the circulation were classical (Ly6C++), later followed by 
non-classical (Ly6C+) (Sunderkotter et al., 2004).   
 
Later work by Yona et al supports the differentiation of classical to non-classical monocytes.  
Once again, classical monocytes were isolated from CX3CR1GFP/+ mice. The monocytes were 
then adoptively transferred into wild-type mice.  One day following transplant all GFP-
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positive monocytes were classical; however, by day three, GFP-positive non-classical 
monocytes were detectable.  Elimination of classical monocytes reduced the levels of non-
classical and, interestingly, appeared to extend the half-life of the Ly6Clow monocytes that 
were already present (Yona et al., 2013). 
 
1.5.4 Human monocyte subsets 
Human monocyte subsets vary in their cell surface expression of markers other than CD14 
and CD16.  Classical monocytes express the majority of CCR2, CXCR1, CXCR2, CLEC4D 
and IL-13Rα1; intermediate monocytes highly express HLA-ABC, HLA-DR and CD40; non-
classical monocytes can be distinguished by the expression of CD115, CD294 and Siglec10 
(Wong et al., 2011).  As with the murine subsets, the terms classical, intermediate and non-
classical as defined in Table 1.4 will be used; if monocytes were identified in a different way, 
this will be stated.  In studies prior to the agreement on nomenclature, the classical subset was 
defined in the same way, but the non-classical subset may have included intermediate 
monocytes depending on the author’s flow cytometry gating methods. 
 
Although it is challenging to reliably separate the monocyte subsets, as with mice, there is 
evidence that the three subsets have distinct roles.  Examination of the transcriptome of each 
subset has provided further information regarding roles.  A comparison of monocyte 
transcriptomes and proteomes performed in 2009, prior to the agreement on identifying the 
three subsets, compared CD16+ and CD16- monocytes.  Classical monocytes had an 
upregulation of genes associated with anti-microbial actions such as myeloperoxidase and IL-
8.  With regard to phagocytosis, there are conflicting reports, with one group suggesting that 
classical monocytes express most genes associated with phagocytosis, whilst another 
described a different pattern (Mobley et al., 2007; Zhao et al., 2009). 
 
The pattern of cytokine secretion by each subset is controversial and varies by the methods 
used to measure it.  In general, it is accepted that classical monocytes release the widest range 
of cytokines, but there is debate over the specific cytokines released by each subset (Wong et 
al., 2011).  Frankenberger et al. performed initial work in 1996: a Ficoll density isolation was 
used and then peripheral blood mononuclear cells (PBMCs) were sorted into CD14++/CD16- 
and CD14+/CD16+ subsets using FACS. These subsets were then incubated with 1μg/mL of 
LPS for 4 hours. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to 
identify transcripts.  TNF levels were the same in both subsets, whereas IL-10 levels were 
higher in CD14++/CD16- (classical) monocytes (Frankenberger et al., 1996).  More recently, 
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whole blood was stimulated with LPS (1μg/mL for between 1 and 4 hours) for various time-
points, after which brefeldin A was added to prevent secretion and subsets were stained for 
intracellular cytokines.  This showed that classical monocytes produce the most IL-1β and 
TNF-α; contradictory to previous studies, intermediate (and not non-classical) monocytes 
produced the most IL-10 (Mukherjee et al., 2015).  Other groups have isolated monocyte 
subsets using FACS; cells were then cultured in the presence of LPS (0-100ng/mL for up to 
18 hours) and cytokine levels measured from supernatants. These groups found that it was the 
non-classical monocytes that produced the majority of IL-1β and TNF-α, whereas the 
classical subset produced the most IL-10 (Cros et al., 2010; Wong et al., 2011).  This 
variability may be due to the dose, the length of incubation and the changes in subset 
definitions. 
 
Most studies suggest that classical monocytes are effective at fighting bacterial infection.  
They seem to display the most phagocytic activity. Mukherjee et al. used whole blood 
analysis to investigate cell surface marker expression and, in their hands, classical monocytes 
were shown to express the most cell markers associated with phagocytosis (CD36 and 
CD163) and to demonstrate the most phagocytic activity in vitro through the ingestion of 
latex beads and GFP-stained E. coli (Cros et al., 2010; Mukherjee et al., 2015).  Classical 
monocytes have also been shown to release the most reactive oxygen species (ROS) in 
response to LPS (Cros et al., 2010).  Aspergillus fumigatus is a source of life-threatening 
infections in patients following allogeneic stem cell transplantation.  Monocyte subsets were 
isolated from allogeneic stem cell transplant donors who had received granulocyte colony-
stimulating factor (GCSF).  Two subsets were identified, CD14+/CD16- and CD14+/CD16+. 
Their proportions in the sample were similar to those in healthy donors who had not received 
GCSF, and they remained viable following the procedure of leukapheresis.  Both subsets were 
shown to phagocytose Aspergillus spores, but only the classical monocytes were able to 
prevent germination (Serbina et al., 2009). 
 
As mentioned earlier, Auffray et al. demonstrated that Gr1- mouse monocytes patrol the 
endothelium.  Cros et al. investigated the ability of non-classical monocytes to act in a similar 
way.  Human monocyte subsets were isolated using FACS into classical, intermediate and 
non-classical and labelled with fluorescent probes.  Each subset was then injected into a 
murine model and their behaviour visualised using intra-vital microscopy.  Most non-classical 
monocytes were seen to adhere rapidly to the endothelium and crawl for a prolonged period, 
similar to the Gr1- subset in mice (Auffray, 2007; Cros et al., 2010).  Analysis of the non-
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classical transcriptome agrees with this finding: most genes differentially expressed in this 
subset related to migration and trans-endothelial motility, as well as MHC class I functions 
(Hofer et al., 2015).  
 
Non-classical monocytes display less phagocytic activity than the other subsets and express 
very little reactive oxygen species.  They were shown to produce TNF-α and IL-1β in 
response to the measles and herpes simplex virus (HSV)-1.  To a lesser extent, a similar 
response was seen in the intermediate subset (Cros et al., 2010). 
 
Generally, the role of intermediate monocytes is less defined, in part because monocytes were 
identified initially in two subsets (CD16+ and CD16-) but also because of the challenges in 
reliably distinguishing them from the non-classical subset. Genetic profiling and cell surface 
expression suggests they express major histocompatibility (MHC) class II receptor and are 
involved in antigen presentation (Mukherjee et al., 2015).  Zawada et al. focussed on 
transcriptome differences between the intermediate and non-classical subsets.  They identified 
more genes associated with phagocytosis, production of ROS, and MHC class II antigen 
processing and presentation in the intermediate compared to the non-classical subset (Zawada 
et al., 2011).   
 
A higher proportion of intermediate monocytes has been reported in patients with coronary 
artery disease (Schlitt et al., 2004).  An increase in the proportion of circulating intermediate 
monocytes has been associated with a higher rate of cardiovascular events and death in 
patients receiving long-term dialysis (Heine et al., 2008; Rogacev et al., 2011).  This suggests 
a possible role for these cells in cardiovascular disease. 
 
Increasingly, it is accepted that the intermediate monocyte, as well as having an individual 
functional role, is also a transitional cell from classical to non-classical.  Following the 
introduction of the 2010 nomenclature defining the three subsets, Wong et al. examined the 
transcriptome of all monocyte subsets from healthy individuals.  The number of differentially 
expressed genes between classical and non-classical subsets was higher than between either 
intermediate and non-classical, or intermediate and non-classical subsets (1456 compared to 
249 and 942 respectively).  The intermediate subset was shown to express 87 % of genes at a 
level between that of the classical and non-classical subsets; a similar result was found when 
they examined cell surface markers, with intermediate monocytes expressing them at levels 
between those of the other two subsets (Wong et al., 2011).   Ancuta et al., prior to the 
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definition of the three subsets, compared the transcriptome of monocyte subsets from healthy 
volunteers, Comparing CD16+ to CD16- monocytes showed that 13,569 genes were similarly 
expressed, whilst 250 genes were down-regulated and 228 up-regulated with at least a 2-fold 
difference in expression. CD16+ monocytes had upregulation of markers also present in 
dendritic cells and macrophages. CD16- monocytes had high levels of granulocyte and 
myeloid markers (Ancuta et al., 2009). The work of both groups supports the idea of 
monocyte subsets having a common progenitor and transition from the classical subset 
through to intermediate and then on to non-classical. 
 
Several mechanisms have been proposed for differentiation between subsets.  Macrophage 
colony-stimulating factor (MCSF) is released by many cells, including endothelial cells and 
monocytes (Stanley et al., 1978; Vellenga et al., 1988).  Two studies in particular suggest a 
role for MCSF in monocyte subset differentiation.  Firstly, a study of monocyte subsets was 
carried out in patients with cancer, a proportion of whom were given recombinant MCSF.  
Initial results showed that patients with gastrointestinal cancer already had an expansion of 
CD16+ monocytes prior to receiving MCSF.  Following the administration of recombinant 
MCSF there was a significant increase in the number of monocytes but also a 20-fold increase 
in the proportion of circulating CD16+ monocytes.  The authors noted that the majority of 
these CD16+ cells were also low in their CD14 expression, but this work was over a decade 
before the identification of the intermediate subtype (Saleh et al., 1995a).  Later work 
investigated the use of an antibody to MCSF in a patient with rheumatoid arthritis.  A week 
following administration of the antibody there was a complete loss of non-classical 
monocytes, which returned to normal four weeks after the infusion (Korkosz et al., 2012). 
 
Accurate understanding of the distinct functions of monocyte subsets is challenging.  As 
discussed above, there are multiple contradictory reports relating to monocyte subset function, 
cell surface expression and cytokine secretion.  In part this is due to the relatively recent 
agreement on defining the subsets, with work performed prior to 2010 tending to consider 
intermediate and non-classical monocytes together or to ignore the intermediate subset 
completely.  Methods of examining the subsets are also imprecise; flow cytometry gating is 
very operator-dependent and the nomenclature for the subsets applies only in ‘steady state’ 
conditions.  There has also been some work to suggest that the isolation of monocytes from 
whole blood can itself affect the proportion of subsets (Zhou et al., 2012; Mukherjee et al., 
2015). Single cell sequencing of whole blood enriched for HLA DR+ cells identified four 
monocyte subsets.  Using principal component analysis, an unbiased classification was 
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performed.   Four monocyte clusters were identified.  The two largest clusters (Mono1 and 
Mono2) contained the classical and non-classical monocytes respectively.  Intermediate 
monocytes however did not form a homogenous group but were divided between Mono1 and 
Mono2 as well as the two remaining smaller clusters (Mono3 and Mono4) (Villani et al., 
2017). 
 
1.5.5 Monocyte subsets during sepsis 
Expansion of different monocyte subsets has been associated with various disease states; as 
mentioned previously, caution is needed when identifying subsets using methods designed for 
the ‘steady state’ (Ziegler-Heitbrock et al., 2010a).  With regard to sepsis, there is also the 
added complication of a changing definition (see section 1.2.3, page 4).   
 
During sepsis, several studies have demonstrated an increase in CD16+ monocyte numbers 
(Fingerle et al., 1993; Herra et al., 1996; Skrzeczynska et al., 2002; Ziegler-Heitbrock, 2007).  
Most studies suggest that this expansion is in non-classical monocytes, although others report 
an expansion of both intermediate and non-classical or intermediate alone (Skrzeczynska et 
al., 2002; Poehlmann et al., 2009; Mukherjee et al., 2015).  This is likely due to the 
heterogenous population of individuals with sepsis, the rapidly changing status of patients 
with sepsis, the range of treatments for such patients, the variations in classifying monocyte 
subsets and the difficulties in separating intermediate and non-classical subsets using flow 
cytometry. 
 
Serial measurements of monocyte subtypes throughout the course of sepsis reveal a transient 
increase in non-classical monocytes for approximately 3 days.  No increase in total monocyte 
numbers was shown, simply a change in proportion (Fingerle et al., 1993; Fingerle-Rowson et 
al., 1998). 
 
HLA DR is a major histocompatibility complex class II molecule.  Its expression has been 
known to decrease in sepsis and critical illness; this has been associated with the development 
of innate immunosuppression, which can lead to secondary infection in sepsis. A prolonged 
decrease in expression has been associated with worsened outcomes (Conway Morris et al., 
2013).  All subsets have been shown to decrease their expression of HLA DR during sepsis 
(Poehlmann et al., 2009).  Later work has demonstrated that during systemic inflammation 
(post-abdominal aorta surgery) the expression of HLA DR varies between the subsets, with 
expression being lower in CD14++ versus CD14+ subsets (Kim et al., 2010).  Further work is 
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needed to enable a better understanding of the control of HLA DR expression between 
subsets. 
 
As previously discussed, MCSF is believed to be involved in the differentiation of classical to 
non-classical monocytes.  MCSF levels increase during sepsis, and this has been shown to 
occur particularly in individuals who have an associated thrombocytopenia, potentially due to 
haemophagocytosis (Francois et al., 1997; Oren et al., 2001).  Perhaps the changes in MCSF 
levels may explain the variations between monocyte subsets during sepsis. 
 
Although the expression of TF on circulating monocytes has been investigated, very little 
work has considered TF expression between subsets.  The induction of TF following IL-33 
stimulation demonstrated that TF expression can vary between monocyte subsets (Stojkovic 




The current system of classifying monocyte subsets is still arbitrary and may require the 
addition of more markers in future, so that we can adequately separate functionally different 
cells.  Problems remain with the operator-dependent nature of flow gating, although clustering 
algorithms can help.  There do appear to be distinct differences, however, between the current 
classical, intermediate and non-classical subsets.  Future work investigating the mechanisms 
underpinning sepsis should consider monocyte subsets and their individual contributions. 
  
1.6 Modelling the immune response to infection 
1.6.1 Overview 
This section discusses the use of models to investigate the pathology of sepsis, with a focus 
on the human endotoxaemia model. 
 
1.6.2 Why do we need a model?   
To comprehend sepsis and its associated coagulopathy better, we need to understand the 
pathophysiological changes that occur prior to an individual’s presentation to healthcare 
services.  Sepsis itself is heterogeneous; with a range of aetiologies, presentations and 
outcomes, cases are difficult to standardise or to control for.  The use of models is therefore 
an important part of studying sepsis. 
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1.6.3 Difficulties with animal models  
There are three main animal models used in sepsis research: the addition of a toxin or 
virulence factor such as lipopolysaccharide (LPS); the addition of a viable pathogen such as 
bacteria administrated intravenously or intra-peritoneally; and the use of host-barrier 
dysfunction such as caecal ligation and puncture (CLP).  The use of animal models in sepsis 
has led to several possibilities for improving outcomes and coagulopathy that have 
unfortunately, as discussed in section 1.3.7, not been translatable into humans (Warren et al., 
2001; Abraham et al., 2003; Ranieri et al., 2012; Vincent et al., 2013; Fink, 2014).   
 
There are differences between the response to endotoxaemia in animals compared to humans.  
Mice and baboons are much more resistant to LPS than humans; rabbits are more sensitive 
but show a very variable response.  Agents such as D-galactosamine (LPS is metabolised by 
the liver, but this agent is hepatotoxic) have been used in the past to further sensitise animal 
models to LPS (Galanos et al., 1979).  Endotoxaemia models are based on a single insult, 
whereas the development of sepsis is believed to involve multiple insults.  Endotoxaemia 
itself is not a model of sepsis but of inflammation; it is not able to replicate the response seen 
to viable pathogens (Buras et al., 2005).  
 
Animal models have been designed to produce sepsis within hours to days without therapeutic 
intervention. Once sepsis is identified in a patient, they are treated with antimicrobials and 
supportive therapies, but such measures are usually not used in animal models.  This may lead 
to a therapy appearing more effective in the animal model compared to the patient who has 
ongoing care (Buras et al., 2005). 
 
Finally, a major concern is the lack of standardisation between animal models, although there 
have been recent efforts to rectify this.  A group of international experts met at a conference 
held in 2017 to discuss a literature review of the 260 most cited papers on pre-clinical models 
of sepsis and to write guidelines for the standardisation of such models, published as 
“Minimum Quality Threshold in Pre-Clinical Sepsis Studies”. Recommendations include that 
the model accurately reflects the clinical situation (for example by employing appropriate 
supportive and antimicrobial therapies), that clear methodologies are included in publications 
to allow for accurate replication by different research groups, that LPS should not be used as a 




1.6.4 The human endotoxaemia model 
The limitations of animal models can to some extent be addressed using human pre-clinical 
models; the most common and long-standing is the administration of LPS to cause 
endotoxaemia in humans.  LPS can be administered in several ways, for example 
intravenously, intradermally and via the inhaled route.  As mentioned earlier this is not a 
model of sepsis but does lead to activation of coagulation, fibrinolysis and inflammation (van 
Deventer et al., 1990).  The main benefit of the model is that it can allow investigators to 
understand the early physiological changes that occur during systemic inflammation and 
potentially provide new therapeutic targets to be further studied (Andreasen et al., 2008). 
 
LPS is a component of the Gram-negative bacterial outer membrane and has been used as an 
experimental model of inflammation in animals for over 200 years.  In the late 1800s it was 
used as a treatment for cancer patients; probably any effects were due to the increase in TNFα 
(Andreasen et al., 2008).  It was first clearly identified in 1935 by Boivin and Mesrobeanu 
and its biochemistry determined in 1952 by Westphal and Luderitz (Boivin and Mesrobeanu, 
1936; Westphal et al., 1952).  LPS works to form a hydrophobic barrier around the bacterium, 
conferring protection against host defences such as complement and some anti-microbials 
(Donaldson et al., 1974; Nikaido and Nakae, 1980; Taylor, 1983).  Endotoxin strictly refers to 
the complex of LPS, phosphates and proteins when bound to the bacterial cell wall, although 
most literature when discussing models of endotoxaemia refers to the use of purified LPS 
(Andreasen et al., 2008).  LPS binds to TLR-4, with the CD14 receptor acting as a co-
receptor.  The binding leads to the activation of NF-κB transcription factors that lead to 
production of pro-inflammatory cytokines including TNFα and IL-1β (Lu et al., 2008). 
 
Intravenous LPS studies in humans have used a range of doses up to 4ng/kg, but a dose of 
2ng/kg has been shown to stimulate inflammation, coagulation and fibrinolysis (van Deventer 
et al., 1990).  The source of LPS used in these studies is important when choosing dose.  The 
standardised source of E. coli group O 113:H10:K negative, used for models between the 
1970s and 1990s, for example, was depleted and multiple investigators noted it became less 
potent over time (Lowry and Fong, 1996)  Another reference endotoxin was produced, again 
from E. coli 0 113, by the American National Institute of Health Clinical Center.  A 
comparison of the two endotoxin sources demonstrated the dose-responsive nature of LPS and 
confirmed that the former batch had lost potency (Suffredini et al., 1999). 
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Unlike in animal models, human participants show a very stereotypical response.  As 
discussed in section 1.3, infusion of LPS into healthy human participants leads to an initial 
activation of the coagulation system in the first few hours, and there is a 125-fold increase in 
TF mRNA.  The TF peaks at 3 hours post-infusion and is followed by an activation of 
coagulation at 4 hours as demonstrated by an increase in thrombin:antithrombin levels and 
prothrombin fragments 1 and 2 (Franco et al., 2000).  After the activation of coagulation there 
is a biphasic fibrinolytic response, with an initial activation of fibrinolysis for several hours 
followed by a more sustained inhibition with high levels of PAI-1 (Suffredini et al., 1989; van 
Deventer et al., 1990; Franco et al., 2000; Andreasen et al., 2008).  This is comparable to 
what is expected during sepsis (Levi et al., 1993).  Endotoxaemia models were primarily 
responsible for revealing the important role TF plays in causing sepsis-associated 
coagulopathy and DIC.  An important difference with regard to sepsis-associated 
coagulopathy, however, is that the physiological anticoagulants change very little or not at all 
following an infusion of LPS (Krabbe et al., 2006).   
 
A striking feature of the human endotoxaemia model is an early monocytopenia that reaches 
its nadir between 1 and 3 hours and resolves over the following 24 hours.  The monocyte 
count drops to <5% of pre-LPS levels.  Examining the recovery of monocytes following LPS 
shows that classical monocytes recover first at about 8 hours, followed by intermediate and 
then non-classical subsets after 24 hours (Tak et al., 2017).  This provides further support for 
the hypothesis that classical monocytes differentiate through intermediate into non-classical 
(see section 1.5.4, page 45).  The level of activation between subsets also appears to vary.  
Intermediate and non-classical monocytes have been shown to produce the highest levels of 
IL-6 and IL-8 following LPS infusion.  CD11b (important for leucocyte adhesion and 
migration) is a marker of monocyte activation and was expressed most highly by the 
intermediate subset (Thaler et al., 2016).  This suggests that each monocyte subset may have a 
different role in systemic inflammation. 
 
1.6.5 Strengths and limitations 
The human endotoxaemia model has multiple strengths: it is reproducible; it has a strong 
safety record; it allows the ability to measure temporal changes following endotoxaemia; and 
it measures responses in humans prior to clinical trials (Andreasen et al., 2008). 
 
As previously stated, the human endotoxic model is not a model of sepsis.  Obviously, it 
would be unethical to cause organ dysfunction in human participants.  As with animal models, 
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it measures the response to a single insult, unlike sepsis which has multiple causes and can be 
a response to repeated exposures.  LPS itself is only present in the circulation for 
approximately 15 minutes before it is cleared (van Deventer et al., 1990).  Endotoxaemia 
causes a rapid increase in cytokine levels that then quickly return to normal, while individuals 
with sepsis have a much more sustained exposure to endotoxin that can last several days 
(Guidet et al., 1994; Andreasen et al., 2008). 
 
LPS is present on the cell wall of Gram-negative bacteria, but a significant proportion of 
sepsis is caused by Gram-positive, fungal and viral pathogens.  However, most intracellular 
pathways and the induction of inflammation are similar with other causes (Andreasen et al., 
2008).   
 
1.6.6 Summary 
Endotoxaemia, although not a true model of sepsis, is a good way of measuring systemic 
inflammation in a human model.  More work is needed to understand the effects on monocyte 
subsets, particularly in relation to TF expression. 
 
1.7 Overall summary 
Despite a great deal of research, sepsis continues to have a high mortality rate that is highest 
in those with sepsis-associated DIC.  There is an urgent need to develop a better 
understanding of the pathophysiology that predisposes to the development of coagulopathy 
during sepsis, so it can be recognised earlier, and new therapeutic targets identified. 
 
The cell surface expression of TF on monocytes is crucial to the development of coagulopathy 
but there is little to no work comparing the expression between monocyte subsets. This 
project will compare the cell surface expression and activity of TF between the monocyte 
subsets. Monocyte TF will be investigated during health, endotoxaemia and sepsis to 







1.8 Hypotheses  
1. The classical monocyte subset predominates in the circulation during health.  This 
subset expresses a low level of cell surface TF, which shows little activity.   
2. Following infection, there is an increase in the cell surface expression of TF and an 
increase in its activity.   
3. Interaction between monocytes and the endothelium allows a local low-level 
activation of coagulation. 
4. During sepsis, there is a decrease in the proportion of circulating classical monocytes 
and an increase in the proportion of non-classical.  Non-classical monocytes, when 
compared to the other monocyte subsets, express higher levels of TF, leading to a 
more pro-coagulant response and predisposing to sepsis-associated coagulopathy. 
 
1.9 Aims & Objectives 
These hypotheses will be tested in three conditions: health, endotoxaemia and sepsis.   
 
Monocytes will be isolated from healthy volunteers and investigated in culture with 
commercially-sourced human primary microvascular endothelial cells (PMVEC).  These 
experiments will be discussed in chapter three and aim: 
- to investigate the cell surface expression and activity of TF between monocyte subsets 
with and without LPS stimulation 
- to create an in vitro model of monocyte-endothelial interactions during sepsis 
- to understand the pathway through which LPS induces TF expression on the cell 
surface monocyte subsets. 
 
A human model of endotoxaemia will be used to simulate the initiation of sepsis.  This 
involves the injection of LPS (2ng/kg) to a healthy volunteer followed by venepuncture at the 
following time points: pre-injection, 90 minutes, 4, 6, 10, 24 hours and 7 days following the 
injection. These experiments will be discussed in chapter four, and aim: 
- to identify the changes in the proportion of circulating monocyte subsets following 
LPS exposure  
- to investigate the effect of endotoxaemia on the cell surface expression of TF between 
the monocyte subsets 
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Blood samples will be taken from individuals with sepsis on a critical care unit.  Sepsis will 
be defined by the requirement of organ support and the presence of an infection (as shown by 
either a positive blood culture, bronchoalveolar lavage or microbiological evidence of a deep-
seated infection such as peritonitis).  A further blood sample will be retrieved on discharge 
from the critical care unit in those individuals who recover and consent to a second sample.  
These experiments will be discussed in chapter five and aim: 
- to identify changes in the proportion of circulating monocyte subsets during sepsis and 
on recovery 
- to investigate the cell surface expression of TF between monocyte subsets during 
sepsis and on recovery 
- to investigate the monocyte-endothelial interactions during sepsis using the same in 









This chapter will outline all methods used to produce the data discussed later.  All materials, 
reagents and equipment used are listed under the relevant providers.  Details of (a) studies 
used to obtain blood samples from healthy volunteers, (b) the human endotoxaemia model 
and (c) studies in patients with sepsis will be included, with protocols, information sheets and 
consent forms attached as appendices. 
 
2.2 Lists of materials and reagents 
Abcam (Cambridge, UK) 
- Human PAI-1 enzyme-linked immunosorbent assay (ELISA) Kit 
- Human tissue-type plasminogen activator ELISA Kit 
- Tissue Factor Activity Assay Kit (Human, colorimetric). 
 
Agar Scientific (Stanstead, UK) 
- Paraformaldehyde 16 % Solution (methanol-free) - 10x10 mL ampoules 
 
BD Biosciences (Wokingham, UK) 
- Alexa Fluor® 647 anti-human cluster of differentiation (CD) 354 (TREM-1), mouse 
IgG1, (clone 193015) 
- BD™ CompBead anti-mouse Ig, κ/negative control compensation particles set 
- BD FACS™ lysing solution 10x concentrate 
- BD Horizon™ brilliant stain buffer 
- BD Trucount™ Absolute Counting Tubes 
- Brilliant Violet (BV) 421 anti-human TLR4 (CD284), mouse IgG1, κ (clone TF901) 
- Fluorescein isothiocyanate (FITC) anti-human CD45, mouse IgG1, κ (clone HI30)   
- Phycoerythrin (PE) anti-human tissue factor (CD142) mouse IgG1, κ (clone HTF-1) 




Biolegend (London, UK) 
- Allophycocyanin (APC)/Cyanine7 anti-human CD19 antibody, mouse IgG1, κ (clone 
SJ25C1) 
- APC/Cy7 anti-human CD16 antibody, mouse IgG2b, κ (clone 3G8)  
- APC/Cy7 anti-human CD20 antibody, mouse IgG2b, κ (clone 257) 
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- Brilliant Violet 605™ anti-human CD3 antibody, mouse IgG2a, κ (clone OKT3) 
- Brilliant Violet 785™ anti-human HLA-DR antibody, mouse IgG2a, κ (clone L243) 
- PE anti-human CD1c antibody, mouse IgG1, κ (clone L161) 
- PE anti-human CD3 antibody, mouse IgG2a, κ (clone HIT3a) 
- PE anti-human CD7 antibody, mouse IgG2a, κ (clone CD7-6B7) 
- PE anti-human CD19 antibody, mouse IgG1, κ (clone 4G7) 
- PE anti-human CD20 antibody, mouse IgG2b, κ (clone 2H7) 
- PE anti-human CD34 antibody, mouse IgG1, κ (clone 581) 
- PE anti-human CD56 antibody, mouse IgG1, κ (clone HCD56) 
- PE anti-human CD66b antibody, mouse IgM, κ (clone G10F5) 
- PE anti-human CD123 antibody, mouse IgG1, κ (clone 6H6) 
- PE/Dazzle™ 594 anti-human CD14 antibody, mouse IgG1, κ (clone HCD14) 
- Peridinin chlorophyll/Cyanine (PerCP/Cy) 5.5 anti-human CD14 antibody, mouse 
IgG1, κ (clone HCD14) 
- Zombie UV™ Fixable Viability Kit. 
 
Fisher Chemical (Loughborough, UK) 
- Isopropanolol. 
 
Greiner Bio-One (Stonehouse, UK) 
- VACUETTE® TUBE 4.5 mL 9NC Coagulation sodium citrate 3.8 % blue cap-black 
ring 
- VACUETTE® TUBE 5 mL CAT Serum Separator Clot Activator gold cap-gold ring 
- VACUETTE® TUBE 9 mL K3E K3EDTA lavender cap-black ring, non-ridged 
- VACUETTE® TUBE 4 mL K3E K3EDTA lavender cap-black ring, non-ridged. 
 
Lonza (Slough, UK) 
- Iscove’s Modified Dulbecco’s Medium (IMDM) 
- Roswell Park Memorial Institute medium (RPMI) 1640 with glutamine. 
 
Miltenyi Biotec (Surrey, UK) 
- Sterile pre-separation filters, 30 µm. 
 
Promocell (Lutterworth, UK) 
- Endothelial cell growth basal medium MV 2 
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- Endothelial cell growth medium MV 2 supplement mix 
- Human pulmonary microvascular endothelial cells isolated from the lung of a single 
donor (C-12281).  
 
R&D Systems (Abingdon, UK) 
- IT 901, NF-κB c-Rel sub-unit inhibitor 
- SR 11302, activator protein (AP)-1 inhibitor 
- FR180204, selective ERK 1 and ERK 2 inhibitor 
- Human M-CSF DuoSet ELISA 
 
Sarstedt (Leicester, UK) 
- Cell culture flasks with ventilation cap (T25 and T75) 
- Cell culture plates (24- and 96-well) 
- Falcon tubes (15 mL and 50 mL)  
- Pipette tips (10 µL, 20 µL, 200 µL, 1000 µL, 5 mL and 10 mL). 
 
Sigma Aldrich Ltd. (Gillingham, UK) 
- 4ʹ, 6-diamidino-2-phenylindole (DAPI) 
- Bovine serum albumin (BSA) 
- Dimethyl sulphoxide (DMSO) 
- Citrate concentrated solution 4 % 
- Giemsa stain solution 
- Lipopolysaccharide from Escherichia coli 026:B6 
- Nalgene® Mr. Frosty, freezing container 
- Phosphate-buffered saline (PBS) 
- Propidium iodide (PI) 
- Sodium azide 
- Triton 10 % 
- Trypsin 
- Trypan blue solution 0.4 % 
- TWEEN® 20. 
 
STARLAB (Milton Keynes, UK) 




- BD FACS Aria III (BD Biosciences, Wokingham, UK) 
- BD FACS Fusion (BD Biosciences, Wokingham, UK) 
- BD Symphony A5 (BD Biosciences, Wokingham, UK) 
- FLUOstar Omega spectrophotometer microplate reader (Aylesbury, UK) 
- MoFLO Astrios (Beckman Coulter, High Wycombe, UK) 




- Flow cytometry was performed using FACS Diva software (version 8.01) for 
acquisition and FCS Express (version 6.06.002) for analysis. 
- Omega (version 5.10) acquisition and MARS data analysis software (version 3.02) 
were used for the multi-plate reader.  
 
 
2.5 Monocyte isolation and preservation 
2.5.1 Isolation of peripheral blood mononuclear cells from whole blood 
Peripheral blood mononuclear cells (PBMCs) were isolated using a Ficoll-Paque™ density 
gradient separation (density = 1.077 g/mL).  In brief, 30 mL of citrated (final concentration of 
1 % sodium citrate) whole blood was centrifuged at 200 g for 10 min at 21 ⁰C.  The plasma 
layer was removed (see Figure 2.1A).  A proportion of plasma was aliquoted, and serum 
obtained by adding 1M CaCl2 (220 µL per 10 mL of plasma) in a glass tube followed by 
incubation in a water bath at 21 °C until the platelets were aggregated.  The serum was then 
removed and either used in experiments that day or frozen at -80 ⁰C.  The volume of plasma 
removed was replaced with warmed 0.9 % saline solution and the cell pellet re-suspended.  
This was layered over 15 mL of Ficoll-Paque™ and the solution centrifuged at 400 g for 30 
min at 21 ⁰C to create a layer of PBMCs (see Figure 2.1B & C).  The PBMC layer was 
removed and washed twice using Hanks’ Balanced Salt Solution without Ca2+ or Mg2+ ions 
(HBSS-).  A 200 µL aliquot was taken.  Of this, 100 µL was stained with 5 µL 0.4 % Trypan 
blue, which stains positive if the cell membrane is disrupted (thereby identifying dead cells), 
and a cell count of live cells performed using a haemocytometer.  The remaining 100 µL was 
used to perform a cytospin to ensure the purity of the sample.  Cytospin slides were fixed in 
acetone for 10 min and then stained in Giemsa for 10 min.  Only PBMC preparations with > 
95 % purity and viability were used.  Typically, 30 million PBMCs are isolated from 30 mL 
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of whole blood.  The PBMCs are then re-suspended in either Hanks’ Balanced Salt Solution 
with Ca2+ and Mg2+ (HBSS+) or IIMDM with phenol red, depending upon the assay to be 
performed. 
 
2.5.2 Isolation of monocytes using adherence 
PBMCs were isolated as detailed above (see section 2.5.1, page 61) and re-suspended in 37 
°C IMDM with 10 % autologous serum at a concentration of 1 million per mL.  Cells were 
cultured in a 24-well plate for one hour, with 500,000 cells added per well, in an incubator at 
37 °C and 5 % CO2.  Following this, wells were washed twice with HBSS- to remove all non-
adherent cells.  500 µL of medium (IMDM with 10% autologous serum at 37 °C) was added 
to each well.  Light microscopy was used to ensure that > 90 % remaining cells were 
monocytes.     
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Figure 2.1 Isolation of peripheral blood mononuclear cells from whole blood isolation  
This figure depicts the stages of isolating mononuclear cells from whole blood using a Ficoll-
Paque™ density gradient separation. A – The whole blood sample is centrifuged to pellet the 
cells and separate the plasma. B – The cell pellet is re-suspended in warm 0.9 % saline and 
layered over 15 mL of Ficoll-Paque™.  C – The sample is centrifuged at 400 g for 30 min and 




2.5.3 Negative selection of monocytes using fluorescence-activated cell sorting 
PBMCs were isolated as described above (section 2.5.1, page 61).  They were centrifuged at 
300 g for 5 minutes at 4 ⁰C and re-suspended in flow buffer at a concentration of 10 million 
cells per 100 µL.  Flow buffer was prepared using PBS with 0.2 % bovine serum albumin and 
0.1 % sodium azide; it was stored at 4 °C.  The antibody mix detailed in table 2.1 was added; 
samples were vortexed and incubated at 4 °C in the dark for 30 min.  Following incubation, 
cells were washed by the addition of 500 µL flow buffer at 4 °C to each sample, and 
centrifugation at 200 g for 5 min at 4 ⁰C.  The supernatant was removed and the pellet re-
suspended in flow buffer at 4 °C at a concentration of 20 million cells per 1 mL of buffer.  
The sample was filtered using a sterile filter with a pore size of 30 µm. 
 
The Newcastle University Flow Cytometry Core Facility assisted in negatively selecting 
monocytes using fluorescence-activated cell sorting (FACS).  Sorting was performed using a 
70 µm nozzle on a BD FACS Fusion cell sorter.   
 
Mononuclear cells were identified using forward and side scatter.  Of these, the live cells 
were selected and all PE-positive cells discarded (see Figure 2.2).  The sample was 
maintained at 4 °C.  Monocytes were sorted into autologous serum, obtained as described 
earlier (section 2.5.1), and used immediately.  The purity of the monocytes was tested using 
flow cytometry for CD14 and CD16 using the panel detailed in Table 2.2. 
 
Both fluorochrome panels were compensated using BD™ anti-mouse compensation beads.  
Each fluorochrome was incubated, at the same concentration used for experimental samples, 
with mouse beads (positive and negative together) for 30 min at 4 °C in the dark.  The 
samples were then washed with the addition of 500 µL of flow buffer.  They were centrifuged 
at 300 g for 5 min at 4 ⁰C and the supernatant removed.  The sample was re-suspended in flow 
buffer and stored at 4 °C in the dark until used.  The beads were used to identify the positive 





Antigen Primary cells to be identified Fluorochrome Wavelength 
Volume to be 
used 
CD3 T cells 
PE 561 586/15 
5 µL of each 
per 10 million 
cells 
CD7 T cells, NK cells 
CD20 B cells 





cells, Dendritic cells 




CD56 NK cells 
DAPI To test cell viability 
 405 450/50 




Table 2.1 Flow cytometry panel for the negative selection of monocytes from PBMCs 
This table details the volume of each antibody used per 10 million PBMCs as well as the 







This figure shows an example of healthy volunteer negatively-sorted monocytes and a check 
of sample purity post-sort.  
1 – Mononuclear cells are gated using forward and side scatter.  2 – Forward scatter height 
and area are used to select single cells. 3 – Live cells are gated by using DAPI-negative 
events. 4 – Monocytes are selected using the PE-negative population, excluding lymphocytes, 
natural killer (NK) cells, neutrophils, basophils and eosinophils.  
 5 – Mononuclear cells are gated using forward and side scatter variables.  6 – Single cells 
are gated using forward scatter area and height variables.  7 – Live cells are gated using PI 
staining.  8 - Monocyte subsets are sorted using CD14 and CD16 positivity.   
  
Figure 2.2 Gating used to negatively sort monocytes from PBMCs using FACS 
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Antigen Primary cells to be identified Fluorochrome Wavelength 











APC/Cy7 640 780/60 1.25 µL per 2 million cells 
PI To test cell viability   561 610/20 
1.5 µL of 0.5 
mg/mL 
 
Table 2.2 Flow cytometry panel used to assess the purity of the negatively sorted monocytes 
This table details the volume of each antibody used per 2 million negatively sorted monocytes, 
as well as the amount of PI to be used to assess viability. 
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2.5.4 Positive selection of monocyte subsets using fluorescence-activated cell sorting 
PBMCs were isolated and re-suspended in flow buffer at 4 °C as described earlier (section 
2.5.3, page 64).  The antibody mix detailed in table 2.3 was added and the samples incubated 
at 4 °C in the dark for 30 min.  Following incubation, samples were washed with the addition 
of 500 µL of flow buffer per 10 million cells at 4°C and centrifugation at 200 g for 5 min at 4 
⁰C.  The supernatant was discarded and the pellet re-suspended in flow buffer at a 
concentration of 20 million cells per mL of buffer.  Prior to sorting, the sample was filtered 
using a sterile filter with a pore size of 30 microns.   
 
The Newcastle University Flow Cytometry Core Facility assisted in positively selecting 
monocyte subsets using FACS.  Sorting was performed using a 70 µm nozzle on a BD FACS 
Fusion cell sorter.  Mononuclear cells were selected using forward and side scatter variables.  
The live cells were selected and BV421 positive cells excluded.  The monocytes were sorted 
into classical, intermediate and non-classical using CD14 and CD16 positivity. 
 




Antigen Primary cells to be identified Fluorochrome Wavelength 
Volume to 
be used 
CD3 T cells 
BV421 405 450/50 
5 µL of each 
per 10 
million cells 
CD20 B cells 
CD19 B cells 










V500 405 525/50 5 µL per 10 million cells 
DAPI To test cell viability UV 405 450/50 
5 µL per 10 
million cells       
(0.1 µg/mL) 
 
Table 2.3 Flow cytometry panel for the positive selection of monocyte subsets from PBMCs 
This table details the volume of each antibody used per 10 million PBMCs, as well as the 






1 – Mononuclear cells are gated using forward and side scatter.  2 – Forward scatter height 
and area are used to select single cells. 3 – Live cells are gated using DAPI-negative events. 4 
– Monocytes are selected using the BV421 negative population, thereby excluding CD3, 
CD19, CD20 and CD56. 5 – Monocyte subsets are sorted using CD14 and CD16 positivity.   
Figure 2.3 Example of the gating used to positively sort monocytes from a healthy 
volunteer into subsets using FACS 
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2.5.5 Cryopreservation of peripheral blood mononuclear cells 
Freezing medium was prepared using 10 mL foetal bovine serum (FBS), 10 mL of sterile 
RPMI-1640 and 5 mL of DMSO.  PBMCs, isolated as described above (section 2.5.1, page 
61), were re-suspended in complete (c)RPMI medium at a concentration of 20 million per 
mL.  The volume of the cell suspension was then doubled using the freezing medium, creating 
a final concentration of 10 million PBMCs per mL.  PBMCs were stored in aliquots of 1 mL 
in cryovials and placed in a Mr Frosty freezing container filled with 70 % isopropanol.  The 
container was stored at -80°C for 24 hours before the samples were transferred into liquid 
nitrogen. 
 
Samples were thawed on the day they were to be used.  Cryovials were removed from the 
liquid nitrogen and their caps loosened to allow any liquid nitrogen that might have seeped 
into the vial to escape. Samples were then thawed quickly in a water bath.  Once only a small 
amount of ice crystal remained in the sample, the cryovials were quickly cleaned with 1 % 
Distel High Level Laboratory Disinfectant, followed by 70 % ethanol.  The PBMCs were 
diluted in 10 mL of HBSS and then centrifuged for 5 mins at 300 g at 21 ⁰C.  PBMCs were 
then re-suspended in the medium appropriate for the experiment to be performed.  An aliquot 
was taken to perform a viable cell count and cytospin (see section 2.5.1, page 61). 
 
2.6 Flow cytometry to determine monocyte subsets and tissue factor expression 
Flow cytometry was used to identify the monocyte subsets and their TF expression.  Flow 
cytometry was run using the BD Symphony machine with FACS Diva software.  Analysis 
was performed using the FCS express software. 
 
2.6.1 Flow cytometry for whole blood samples 
A panel of antibodies was used to identify monocytes and exclude other cells (see Table 2.4).  
Initially mononuclear cells were gated using CD45 positivity.  Single cells and live cells 
(Zombie UV positive) were then chosen.  B cells were excluded using markers for CD19 and 
CD20.  T cells were excluded with CD3.  Size and HLA-DR were used to distinguish 
monocytes from NK cells.  This left a population of monocytes that was gated into subsets 
using CD14 and CD16 positivity (see Figure 2.4). 
 
To calculate the absolute numbers of monocyte subsets in each whole blood sample, BD 
Trucount™ absolute counting tubes were used.  These tubes contain a known number of 
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beads; flow cytometry was run until 20,000 bead events had been measured.  This was then 
used to identify the absolute number of monocytes using the calculation: 
 
Absolute cell count = number of positive cell events   X  total number of beads 
          number of bead events           volume of blood tested 
 
100 µL of whole blood (anticoagulated with 1 % sodium citrate) was added via reverse 
pipetting to the mix of antibodies listed in table 2.4, within the Trucount™ tubes.  To reduce 
non-specific antibody binding, 50 µL of flow buffer at 4 °C was added to each sample.  Tubes 
were then vortexed to suspend the bead pellet and incubated at 4 °C in the dark for 30 min.  
BD FACS™ lysing solution was used to lyse the red cells and fix the antibody staining. Each 
sample was incubated with 1.5 mL of the solution in the dark at room temperature for 20 min.   
 
2.6.2 Flow cytometry for samples containing isolated monocytes 
For samples using isolated cells (either PBMCs or monocytes) the same antibody mix was 
used (see Table 2.4).  The cells were pelleted by centrifugation at 200 g for 5 min at 4 ⁰C, and 
the supernatant was removed and stored at –80 ⁰C before re-suspension in 100 µL flow buffer 
at 4 ⁰C (see section 2.5.1, page 61).  The mix of antibodies was added and left to incubate for 
30 min at 4 ⁰C in the dark.  Following incubation, a further 500 µL of flow buffer at 4 ⁰C was 
added to wash unbound antibody.  Samples were centrifuged for 5 min at 200 g and the 
supernatant discarded.  The pellet was re-suspended in 300 µL of flow buffer and stored in the 






1 – Mononuclear cells were gated using CD45 positivity and side scatter.  2 – Forward 
scatter height and area were used to select single cells. 3 – Live cells were gated using 
Zombie UV-negative events. 4 – B lymphocytes were removed using the CD19 and CD20 
negative population. 5 – T lymphocytes were removed using the CD3 negative population.  6 
– NK cells were excluded using HLA-DR and side scatter variables. 7 – Beads were gated 
using two fluorochromes.  8 - Monocyte subsets were sorted using CD14 and CD16 positivity.  
(CD – cluster of differentiation, NK – natural killer, UV – ultra-violet).  
Figure 2.4 Example (using blood from a healthy volunteer) of the monocyte gating 
strategy for whole blood samples. 
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Antigen Description Fluorochrome Wavelength 
Volume to be used 
per 100 µL of whole 
blood (µL) 
Zombie 
UV Viability marker UV 355 379/28 5 






405 525/50 5 
CD3 T cell marker BV605 405 610/20 5 
HLA-DR MHC class II cell surface receptor BV785 405 780/60 5 
CD45 Leucocyte marker FITC 488 530/30 20 














640 670/30 5 
CD19 B cell marker APC Cy7 640 780/60 5 
CD20 B cell marker APC Cy7 640 780/60 5 
Table 2.4 Antibody panel for whole blood flow cytometry 
This table details the panel used to identify monocyte subsets from whole blood as well as 
their cell surface expression of TLR4, HLA-DR, TREM1 and TF.   
(HLA-DR - Human Leukocyte Antigen DR isotype, TF – tissue factor, TLR4 – Toll-like 






2.6.3 Optimising the flow cytometry panel 
As previously described, the antibody panel was compensated for use on the BD Symphony 
flow cytometer.  Compensation was performed using beads and cells. All antibodies were 
titrated to ensure that the optimal concentrations were used to detect all positive events.  The 
Zombie UV antibody is affected by the level of protein in samples; for this reason, 5 µL was 
used per 100 µL in whole blood samples and 1 µL per 100,000 isolated cells.  Both conditions 
were titrated. 
 
2.6.4 Flow cytometry controls  
Flow gating was based on fluorescence-minus-one (FMO) controls and non-specific binding 
was identified using isotype controls.   
 
FMOs were performed for: CD14, CD16, CD142 (tissue factor), HLA-DR, TREM1 and 
TLR4.  Gating of classical, intermediate and non-classical monocytes was guided by the use 
of a flow sample minus both CD14 and CD16 (see Figure 2.5).  This was later refined for 
endotoxic and septic samples, where FMOs were used for CD14 and CD16 (see Figure 2.6).  
A more detailed description of these antigens is shown in Table 2.4.  For each, a sample was 
prepared as previously described (see methodology sections 2.6.1, page 72 and 2.6.2, page 
73) but the antibody of interest was omitted.  This allows for accurate identification of 
positive events and accounts for cellular auto-fluorescence. Isotype controls were performed 
for all antibodies to identify non-specific binding.  These controls were prepared in the same 
way as for the usual samples for flow cytometry, with the exception that the antibody of 
interest was replaced with the same concentration of isotype control (see methodology 


























An example of monocyte subset gating, using monocytes sorted using FACS from a healthy 
volunteer sample.  Flow plots are shown for sample using all the whole flow panel (fully 
stained), the second sample without the CD14 and CD16 antibodies (No CD14 or CD16).  





































An example of FMOs using a healthy volunteer sample with the whole blood flow panel.  
Flow plots are shown for sample using all the whole flow panel (fully stained), the second 
sample without the CD14 antibody (FMO CD14) and a third sample without the CD16 
antibody (FMO CD16).  The red dashed lines delineate the negative population of cells that 





Figure 2.6 Using FMO to guide the gating of monocyte subsets with the flow panel for 
whole blood 
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2.7 Endothelial cell culture 
All tissue culture was performed using a Class II biological safety cabinet.  Primary human 
pulmonary microvascular endothelial cells (PMVEC) were grown with endothelial cell basal 
medium MV 2 plus supplement mix (all from Promocell).  The incubator was set at 37°C and 
with 5 % carbon dioxide (CO2). 
 
2.7.1 Culture of primary pulmonary microvascular endothelial cells 
Cells were cryopreserved in liquid nitrogen with 10% DMSO, thawed rapidly using a water 
bath at 37 °C and added into 5 mL of endothelial cell medium at 37 °C.  Cells were then 
washed and centrifuged at 200 g for 10 min at 21 ⁰C.  The supernatant was discarded and the 
pellet re-suspended in endothelial medium at 37 °C. 
Cells were grown in a 75 cm2 flask at a density of 500,000 cells in 10 mL of the prepared 
medium. Once seeded, cells were incubated for 24 hr before the medium was changed.  
Following this initial change, medium was changed every 48 to 72 hr.  The medium was 
warmed for 15 min in a water bath at 37 °C before being added to cells. 
 
Primary PMVEC were used at a passage number between 2 and 8, at a confluence of 
approximately 90 %.  Flow cytometry was used to ensure they expressed the expected 
endothelial cell markers (CD31).   
 
Once confluence was reached, cells were removed from the 75 cm2 flask and split between 
another 75 cm2 ‘stock’ flask and 24-well plates for the co-culture experiments described 
below (see methodology section 2.7.2, page 82).  The cells were washed with PBS and then 
incubated with 2.5 mL of 0.05 % trypsin for 5 min at 21 °C.  Cells were detached by a sharp 
tap on the side of the flask and, if necessary, with the use of a cell scraper.  Trypsin was de-
activated with the addition of 7.5 mL of warmed endothelial medium.  The detached cells 
were centrifuged at 200 g for 5 min at 21 ⁰C, the supernatant discarded, and the pellet re-
suspended in warmed endothelial medium.  Each stock flask was seeded with 500,000 cells in 
10 mL medium whilst each well was seeded with 50,000 cells in 500 µL medium. 
 
2.7.2 Co-culture experiments 
Monocyte-endothelial co-cultures were set up as shown in Figure 2.7.  PMVEC cells were 
grown to 90 % confluence in a 24-well plate in endothelial cell medium.  Monocytes from 
healthy volunteers were sorted by FACS into autologous serum and added to the PMVEC, 
50,000 monocytes were added to each well.   
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To investigate the effects of co-culture on activated endothelium, a proportion of PMVECs 
were stimulated with LPS at a final concentration of 100 ng/mL for 1 hour at 37 °C.  To allow 
the LPS to be functional, autologous serum at a final concentration of 10 % was added to the 
wells.  Following this stimulation, the LPS was thoroughly washed off with two washes using 
warmed endothelial cell medium. 
 
Controls included: PMVEC alone, monocytes alone, PMVEC pre-stimulated with LPS and 
monocytes stimulated by LPS.  Monocytes were stimulated with 10 ng/mL of LPS and the 
LPS was not washed off to avoid losing monocytes through washing. 
 
Co-cultures performed using samples from individuals with sepsis did not use FACS sorted 
monocytes but instead used PBMCs.  Due to the smaller volume of blood obtained from 
individuals with sepsis insufficient monocytes could be sorted for co-culture.  PBMCs were 
isolated using a Ficoll-Paque™ density gradient separation and 100,000 PBMCs were added 
to each well.  As with the healthy volunteer monocytes, the same concentration of LPS was 
used to stimulate the PBMCs, and once again it was not washed off but remained for the 
whole co-culture. 
 
Prepared plates were incubated at 37°C in 5 % CO2 for 24 hr, following which adherent cells 
were scraped from the wells and, with the surrounding medium, were centrifuged at 200 g for 
10 min.  Supernatants were frozen in aliquots of 500 mL at -80°C.  Cell pellets were prepared 




This figure shows the six co-culture conditions used.  The flow chart describes how the co-
culture experiment was assembled.   
Figure 2.7 The co-culture conditions and assembling the co-culture experiment 
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2.7.3 ELISA 
Sandwich ELISA kits were used to measure the MCSF, PAI-1 and tPA in the supernatants 
stored following monocyte-endothelial co-culture experiments.  The ELISAs were performed 
according the manufacturer’s instructions.  Sandwich ELISAs were also performed to 
measure levels of coagulation complexes by our collaborators in Maastricht.  These included: 
TAT, FIXa-AT, FXa-AT, FXIa-AT and FXIa-a1AT. 
 
Briefly, standards were prepared using serial dilution from a stock standard.  Either standards 
or samples were added in triplicate to 96-well plates pre-coated with primary antibody.  Three 
wells served as a ‘blank’ and contained only assay buffer, antibodies and substrate.  Wells 
were coated overnight by the addition of 100 µL of capture antibody prior to washing with 
wash buffer (0.5 % BSA and 0.1 % Tween 20 dissolved in PBS).   In the case of PAI-1 and 
tPA the plates were pre-coated. 
 
The plate was blocked with 200 µL blocking buffer (1 % BSA in PBS) added to each well for 
1 hour at room temperature.  The primary incubation of 100 µL of either sample or standard 
in each well occurred at room temperature on the shaker at 300 rpm.  The plate was then 
washed five times with wash buffer.  Secondary incubation with 100 µL per well of 
biotinylated detection antibody then took place at room temperature on a shaker at 300 rpm.  
This was followed by five washes with wash buffer.  Streptavidin-horseradish peroxidase 
(HRP) was added (100 µL per well) to bind the biotin, for 30 minutes at room temperature on 
the shaker at 300 rpm, followed by a further five washes with wash buffer.   Following this, 
100 µL of a 1:1 mixture of 3,3’,5,5’-Tetramethylbenzidine (TMB) solution and hydrogen 
peroxide (H2O2) was added to each well and left for 30 minutes in the dark.  The reaction was 
stopped with 100 µL of 2 N sulphuric acid.  
 
Absorbance was read at the appropriate wavelength using the FLUOstar Omega 
spectrophotometer microplate reader. Omega analysis software was used to calculate a curve 
using a 4-parameter fit.  Only r2 values higher than 95 % were accepted for the standard curve. 
 
 
2.8 Investigating monocytic TF expression 
2.8.1 LPS stimulation of monocytic TF expression  
PBMCs and sorted monocytes were cultured with 500,000 cells per well in 450 µL of IMDM 
and 50 µL of serum in 24-well plates.  Where available, autologous serum was used (obtained 
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as described in section 2.5.1), otherwise it was substituted with FBS.  PBMCs were incubated 
with a range of LPS concentrations (0, 1, 10, 100, 1000 ng/mL) for 24 hr.  The incubator was 
set at 37 °C and with 5 % CO2.  All work was performed in a Class II biological safety 
cabinet.   
 
Following incubation, the samples were removed from the wells with scraping and 
centrifuged for 5 min at 200 g.  The supernatants were frozen at -80 °C.  Cell pellets were re-
suspended in 100 µL flow buffer (see section 2.5.1, page 6162) and flow cytometry antibodies 
added in quantities detailed in table 2.4.  All panels were compensated and FMOs with CD14 
and CD16 were used to gate the subsets (see sections 2.6.3, page 77 and 2.6.4, page 77).  The 
proportion of each subset was measured using BD Diva software. 
 
2.8.2 Measuring TF activity 
Monocyte subsets were isolated using FACS (see section 2.5.3, page 64) and collected in 
IMDM without serum.  A 96-well plate was used to incubate each subset at 30,000 cells per 
100 µL of IMDM.  LPS was added at a concentration of 1 ng/mL with 1 µL of autologous 
serum to each well, making a final concentration of 1 % serum.  Cells were incubated at 37 
°C with 5 % CO2 for 24 hr.  A well containing 99 µL IMDM and 1 µL of autologous serum 
was used to calculate the amount of TF activity in cell-free serum; this value was then 
subtracted from the values recorded from the subsets. 
 
Following incubation, the cells were lysed with the addition of 0.1 % Triton for 10 min at 
4 °C.  Each well was scraped and mixed. 
 
A TF activity was measured using a human TF activity colorimetric assay kit according to the 
manufacturer’s instructions.  Briefly, eight TF activity standards were reconstituted using 
serial dilutions and one blank.  An assay mix containing 50 µL assay diluent, 10 µL of FX 
and 10 µL of FVII were added to each well, followed by 10 µL of either a standard or sample.  
The plate was incubated at 37 °C for 30 min.  In the presence of TF, FX will become FXa.  
Each well had 20 µL of FXa substrate added; in the presence of FXa a yellow para-
nitroaniline (pNA) chromophore is released. 
 
Absorbance was measured at 405 nm every 5 min for 25 min on a FLUOstar Omega 
spectrophotometer microplate reader.  The Omega analysis software was used to create a 
standard curve using a 4-parameter fit; only curves with r2 values higher than 0.95 were 
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accepted.  Concentrations were measured during the time frame when the TF standards 
recorded a steady level.  The TF activity was calculated and expressed as pM per minute. 
 
2.8.3 Inhibition of LPS induction of TF cell surface expression 
Monocytes were isolated as described earlier (section 2.5.2, page 62).  A total of ten wells in a 
24-well plate were filled with 500,000 PBMCs, with a presumption that approximately 
100,000 monocytes would adhere.   
 
Three inhibitors were used to investigate the role of ERK, cRel and NFκB signalling in the 
LPS induction of TF transcription.  Each inhibitor had been previously shown to be effective 
(Fanjul et al., 1994; Shiohara et al., 1999; Ohori et al., 2005; Perrett et al., 2013; Shono et al., 
2016).  All were titrated to ensure optimum inhibition whilst maintaining cell viability above 
90 % (see section 3.3.3, page 115).   FR180204, an inhibitor of ERK1 and ERK2, was used at 
a concentration of 15 µM.  IT901, an inhibitor of the NFκB subunit cRel, was used at a 
concentration of 1.0 µM.  SR11302, an inhibitor of AP-1 was titrated and used at a 
concentration of 1.0 µM.  All were reconstituted as per the manufacturer’s instructions using 
DMSO; further dilutions were performed using IMDM.   
 
The inhibitors were added at titrated concentrations to monocytes isolated by adherence and 
the cells were left to incubate for 30 min.  Following incubation, LPS was added at a 
concentration of 1 ng/mL and the cells incubated for 24 hr.  Flow cytometry was performed 
on cells as described earlier (see section 2.6.2, page 73). 
 
2.9 Healthy volunteer samples 
2.9.1 Recruitment 
Healthy volunteers were recruited into the study ‘The role of inflammation of human 
immunity’ from the students and staff of Newcastle University (Research Ethics Committee 
number 12/NE/0121).  Participants were screened and excluded if they had a history of 
infection, autoimmune disease or significant illness, or if were taking regular medication 
(excluding the oral contraceptive pill).  All participants received a participant information 
sheet and were given an opportunity to discuss the study with a researcher before providing 
written, informed consent (see appendix A).  Venepuncture was performed with a 21-gauge 
butterfly needle and blood collected into a 50 mL Falcon tube containing a final concentration 
of 1 % sodium citrate. 
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2.9.2 Processing of samples 
Samples were stored at room temperature and processed within 30 minutes of venepuncture.  
PBMCs were isolated using Ficoll-Paque™ as described earlier (see methodology section 
2.5.1, page 61). Once isolated, PBMCs were stored on ice and used within 1 hour. 
 
2.10 Human endotoxic samples 
2.10.1 Recruitment 
Healthy volunteers were recruited through electronic mail advertisement to the study ‘Does 
the DNA of our cells’ batteries influence our response to bacteria?’ (Research Ethics 
Committee number 17/YH/0021).  This study was performed in the integrated critical care 
unit (ICCU) at City Hospitals Sunderland NHS Foundation Trusts (CHSFT), in a dedicated 
research bed space by a Consultant Intensivist.  Interested volunteers were sent a participant 
information sheet and given time to consider the information.   
 
Screening of possible participants occurred in the out-patients department at CHSFT and was 
performed by a Consultant Intensivist.  This involved a short medical history, physical 
examination, a blood sample (for a full blood count, coagulation screen, liver and renal 
function), an electrocardiogram and a pregnancy test in female participants.  Exclusion 
criteria included: age outside the range 18-40 years; known history of respiratory, cardiac or 
infectious diseases; pregnancy; current medication except the oral contraceptive pill in female 
participants; and laboratory blood results outside of the reference range. 
 
Following screening, written informed consent was taken and the participant’s general 
practitioner informed of their involvement.  Female participants were advised to use 
contraception for 48 hr following the study.  Copies of the participant information sheet, 
consent forms and protocol can be found in appendix B. 
 
2.10.2 Protocol  
The study involved three visits.  The initial visit involved a stay of 10 hr on the ICU.  A bolus 
injection of 2 ng/kg of U.S. reference Escherichia coli-derived endotoxin was given to induce 
a state of systemic inflammation.  Vital signs (pulse rate, blood pressure, blood oxygen 
saturations, respiratory rate and temperature) were measured at 30 min intervals throughout 
the ICCU stay.  An intravenous cannula was placed into each arm; one was used to give an 
infusion of Hartmann’s solution and the other to take blood samples at baseline, 90 min, 4 hr, 
6 hr and 10 hr.  Blood was collected into three types of vacutainers, containing either 
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ethylenediaminetetraacetic acid (EDTA), sodium citrate or serum-separating silica (see table 
2.5). 
 
Two further study visits were performed at 24 hr and 7 days following the injection of 
endotoxin.  The participant was reviewed at the out-patient department in CHSFT, where a 









Serum         
separating tube 
Baseline (pre-endotoxin) 84 4.5 10 
90 min 84 4.5 10 
4 hr 4 4.5 10 
6 hr 84 4.5 10 
10 hr 84 4.5 10 
24 hr 4 4.5 10 
7 days 4 4.5 10 
 
Table 2.5 Blood samples taken following endotoxaemia 




2.10.3 Processing of samples 
At each time point, a 1 mL sample of EDTA anti-coagulated blood was processed according 
to the flow cytometry protocol as outlined in section 2.6.1 (page 72). 
 
At baseline, 90min, 6 hr and 10 hr time-points, nine extra 9 mL EDTA samples were taken 
and used to isolate PBMCs that were then frozen as described earlier (see sections 2.5.1, page 
61 and 2.5.3, page 64). 
 
The remaining 6 mL EDTA and citrate samples were centrifuged at 300 g for 10 min 21 ⁰C.  
Sodium heparin tubes were centrifuged at 1500 g for 10 min at 21 ⁰C to separate the serum.  
Plasma and serum were removed and stored in 200-400 µL aliquots at -80 °C. 
 
2.11 Critically ill and septic samples 
2.11.1 Recruitment 
Participants from the intensive care units (ICUs) at Newcastle upon Tyne Hospitals NHS 
Foundation Trust (NuTH) and CHSFT were recruited into the study ‘The effects of critical 
illness on innate immunity’ (Research Ethics Committee number 18/NE/0036).  Samples for 
this work were taken from June 2017 until March 2019.  The study involved taking a 20 mL 
blood sample, and collecting medical data, whilst patients were in ICU.  In those participants 
who recovered, a second blood sample was taken within one working day of discharge from 




Inclusion Criteria Exclusion criteria 
Expected to remain in the ICU for 
longer than 24 hr <16 years of age 
Expected to survive for longer than 24 
hr Pregnancy 
Provision of written consent (or written 
consultee declaration) 
Known infection with human 
immunodeficiency virus 
Requires one or more of the following 
organ supports: inotropes, invasive 
ventilation, non-invasive ventilation, 
haemofiltration or dialysis. 
Use of immunosuppressants or 
corticosteroids at a dosage higher than 
the equivalent of prednisolone 10 
mg/day 
  Haematological malignancy 
 
Table 2.6 Inclusion and exclusion criteria for the study ‘The effects of critical illness on 
innate immunity’ 
This table lists inclusion and exclusion criteria for the study used to obtain samples from 




2.11.2 Consent  
Individuals were identified and assessed for capacity to consent to the study by a Consultant 
Intensivist in charge of their care.  If all eligibility criteria were met and the individual had 
capacity to consent, they were provided with a participant information sheet and given as 
much time as they needed to read and understand the information.  Research nurses and 
myself were available to discuss the study with the individual and their relatives.  If they 
wished to proceed with the study, they were asked to provide written informed consent. 
 
Frequently, individuals staying on ICU did not have the capacity to give informed consent.  In 
this setting, the next of kin was approached to act as a personal consultee and given a copy of 
a personal consultee consent form.  Again, the research team were available to answer any 
questions.  If the personal consultee believed the individual would agree to the study, they 
were asked to sign a personal consultee declaration form.  If there was no next of kin, a 
Consultant Intensivist, who was independent of the research study, was asked to act as a 
professional consultee.  The relevant consultant was given a professional consultee 
information sheet and asked to sign a professional consultee declaration form. 
 
If those participants recruited using a consultee later regained capacity, they were given a 
recovered capacity information sheet and the study was explained.  The participant would 
then be asked to sign a recovered capacity consent form if they wished to remain in the study.  
Individuals who did not wish to remain in the study were asked if samples and data already 
gathered could be kept; if they did not agree, samples were destroyed. 
 
It was clearly explained to all participants, their families and the clinical teams caring for 
them that they could withdraw from the study at any time. 
 
Copies of the study protocol, all participant information sheets and consent and declaration 
forms are included in appendix C. 
 
2.11.3 Processing of samples 
A single sample of 20 mL of whole blood was collected into a 50 mL Falcon tube with a final 
concentration of 1 % sodium citrate on recruitment into the study and then, if appropriate, 
within one working day of discharge from ICU. 
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A 1 mL aliquot of whole blood was taken to perform flow cytometry as described earlier 
(methodology section 2.6.1, page 72). 
 
The whole blood sample was initially centrifuged for 5 minutes at 300 g at 21 ⁰C to separate 
cells from plasma.  The plasma was removed and stored at -80 °C in aliquots of 200 µL. The 
volume removed was then replaced with warmed 0.9 % saline.  This was layered over Ficoll-
Paque™ and PBMCs were isolated as previously described (methodology section 2.5.1, page 
61).   
 
Serum samples were also obtained from plasma as previously described (section 2.5.1, page 
61) using 1 mL of plasma.  Serum was then stored in aliquots of 200 µL at -80 °C. 
 
Recovery samples were processed in the same way. 
 
2.11.4 Data collection 
Clinical data were collected at the time of the first sample.  This included clinical, 
radiological and microbiological evidence of infection; types of organ support used; 
information to calculate the Acute Physiology and Chronic Health Evaluation (APACHE) II 
and Sequential Organ Failure Assessment (SOFA) scores; co-morbidities; concurrent 
medication; and recent full blood count and coagulation screen.  A copy of the data collection 
form is shown in appendix C. 
 
2.12 Statistical analysis 
Statistical analysis was performed using Graphpad Prism (version 7.01). 
 
Data were tested for normality using the D’Agostino & Pearson normality test.  The 
significance level for all analysis was set at p<0.05. 
 
 
Data assuming a normal distribution were analysed using a paired t-test if the data sets were 
dependent, or an unpaired t-test if they were not.  If more than two variables were compared, 
either a one-way or repeated measures ANOVA was used. 
 
Data not assuming a normal distribution were analysed using the Wilcoxon signed-rank test 
when they were dependent or the Mann-Whitney U test if they were not.  Where more than 
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two measurements were compared, significance was analysed using Friedman’s test with 
Dunn’s multiple comparisons test (if repeated measures were compared) or the Kruskal-
Wallis test (when there was no matching between variables). 
 










Monocytes are known to express TF on their cell surface; however, there are very limited data 
comparing this expression between monocyte subsets (Rivers et al., 1975; Stojkovic et al., 
2017).  There is no published work investigating the effects of LPS on TF induction, TF 
activity or transcription of TF between the subsets.    
 
TF is believed to be important in the pathogenesis of disseminated intravascular coagulation 
(DIC), a widespread activation of coagulation that occurs in small blood vessels and increases 
mortality from sepsis (Warr et al., 1990).  Multiple groups report a change in monocyte 
subsets during sepsis, with a decrease in classical and an expansion of either intermediate or 
non-classical monocytes (Fingerle et al., 1993; Herra et al., 1996; Mukherjee et al., 2015).  
Potentially, relative TF expression on these subsets could contribute to the coagulopathy of 
sepsis. 
 
This chapter will focus on the cell surface expression of TF between the monocyte subsets 
and investigate the interactions between monocyte subsets and microvascular endothelium. 
 
3.2 Research aims 
- to investigate the cell surface expression and activity of TF between monocyte subsets 
with and without LPS stimulation 
- to create an in vitro model of monocyte-endothelial interactions during sepsis 
- to understand the pathway through which LPS induces TF expression on the cell 






3.3 Investigating changes in monocyte subsets and TF expression following LPS 
stimulation 
To investigate the expression of monocyte TF, monocytes were cultured with LPS, a 
component of the Gram-negative bacterial cell wall.  Monocytic co-culture PMVECs, with 
and without LPS stimulation, was used to investigate changes in TF cell surface expression in 
the subsets. 
 
PBMCs were isolated from healthy volunteer whole blood using Ficoll-Paque™  
density gradient separation.  FACS was then used to sort monocytes as a whole or each subset 
individually (see methodology section 2.5.3 and 2.5.4, pages 64 to 67).   
  
3.3.1 Effect of LPS stimulation on monocyte subsets 
Monocytes (not sorted into individual subsets) were obtained using FACS and were cultured 
for 24 hours with LPS in IMDM and 10 % autologous serum.  Into each well 50,000 
monocytes were added.  Following this the proportions of monocyte subsets were assessed 
using flow cytometry.  Figure 3.1 shows the percentage of sorted monocytes that were 
recovered following in vitro culture with LPS.  The majority of monocytes were not 
recovered following culture.  Propidium iodide was used to assess cell viability. The LPS 
concentrations used (1 ng/mL to 1000 ng/mL) did not impact cell viability (Figure 3.2).   
 
There was a dose-dependent increase in the proportion of classical monocytes following LPS 
stimulation (Figure 3.3).  This was accompanied by a relative reduction in the intermediate 
and non-classical subsets.  Further analysis of the flow data, using the same samples, showed 
a decrease in the CD16 median fluorescent intensity (MFI), whilst the CD14 MFI was 




























Monocytes, negatively sorted using FACS, were incubated with varying concentrations of 
LPS in IMDM and 10% autologous serum.  Following a 24-hour incubation, flow cytometry 
was performed to measure the proportions of monocyte subsets and TF surface expression. 
This figure shows the percentage of monocytes recovered from each sample following the in 
vitro culture with increasing levels of LPS. The results of 7 independent experiments are 
displayed.   Black dots show the median values whilst error bars show the interquartile range.  
Significance was calculated using the Friedman test with Dunn’s multiple comparisons test.  
There was no statistically significant difference between the time-points. 
 
 






















Figure 3.1 Percentage of sorted monocytes recovered following culture with LPS 
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Monocytes, negatively sorted using FACS, were incubated with varying concentrations of 
LPS in IMDM and 10% autologous serum.  Following a 24-hour incubation, flow cytometry 
was used to measure cell viability using propidium iodide. This figure shows the percentage 
of live cells in each sample with increasing levels of LPS. The results of 7 independent 
experiments are displayed.   Black dots show the median values whilst error bars show the 
interquartile range.  The red dashed line shows 90% cell viability.  Significance was 
calculated using the Friedman test with Dunn’s multiple comparisons test.  There was no 
statistically significant difference between the time-points.  




Monocytes, negatively sorted using FACS, were incubated with increasing concentrations of 
LPS in IMDM and 10% autologous serum.  Following a 24-hour incubation, flow cytometry 
was used to measure the proportions of monocyte subsets. This figure shows the results of 7 
independent experiments.  Error bars represent median values and the interquartile range.   
The classical subset increased in proportion (p=0.006 by Friedman test, ** - p<0.001 
between 1000 ng/mL LPS and no LPS using Dunn’s post hoc test). The intermediate subset 
decreased following incubation with LPS (p=0.006 by Friedman test, *- p<0.05 between 100 
ng/mL LPS and 1000 ng/mL LPS compared to no LPS using Dunn’s post hoc test).  The non-
classical subset decreased in proportion (p=0.06 by Friedman test, * -p<0.05 between 1000 
ng/mL LPS and no LPS using Dunn’s post hoc test). 
 





Monocytes, negatively sorted using FACS, were incubated with increasing concentrations of 
LPS in IMDM and 10 % autologous serum.  Following a 24-hour incubation, flow cytometry 
was used to measure the total monocyte median fluorescence for CD14 and CD16. This figure 
shows the results of 7 independent experiments.  Error bars represent median values and the 
interquartile range.  There was no statistically significant difference in the CD14 MFI 
between the LPS concentrations (p = 0.53 by Friedman test).  The CD16 MFI decreased with 
LPS incubation (p=0.02 by Friedman test, *- p<0.05 when the 10 ng/mL and 100 ng/mL LPS 































Figure 3.4 Incubation with LPS reduces the expression of CD16 
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3.3.2 Changes in TF expression following LPS incubation 
Using the same 7 donors as described in figures 3.3 and 3.4 the cell surface expression of TF 
was measured on monocyte subsets using flow cytometry.  As before, this followed 
incubation in IMDM and 10 % autologous serum with increasing concentrations of LPS.  
Initially, the total monocyte population was examined.  This showed a dose-dependent 
increase in TF in response to LPS stimulation (Figure 3.5).   
 
A comparison between the monocyte subsets demonstrated a variation in TF expression.  All 
monocytes subsets increased TF expression with LPS stimulation.  Classical and intermediate 
monocytes expressed similar amounts, whilst non-classical had both fewer cells expressing 
TF and a lower MFI (Figure 3.6). 
 
To investigate whether the expressed TF was functionally active, the ability of TF to activate 
FX was compared between the subsets.  PBMCs from 5 different healthy volunteers were 
sorted into monocyte subsets using FACS (see methodology section 2.5.4, page 69).  Each 
subset was incubated at a concentration of 10,000 cells per 500 µL, with and without 1 ng/mL 
LPS for 24-hours.  A TF colorimetric assay was used to measure the amount of FXa created 
from FX.  LPS requires LPS-binding protein to be effective; this is found in autologous 
serum, and for this reason 5 % serum was added to each culture.  Autologous serum was used 
for each culture and the level of TF measured in serum alone at the same dilution.  The serum 
value of TF was subtracted from each monocyte sample and the activity expressed as pM per 
10,000 cells. 
 
TF activity varied by subset.  Classical monocytes had the highest level of total activity per 
10,000 cells, whereas intermediate and non-classical monocytes showed similar total activity 
levels.  However, as shown in Figure 3.6, compared to the classical and intermediate subsets, 
fewer non-classical monocytes increase TF cell surface expression in response to LPS.  
Earlier experiments have shown a median of 15 % of both the classical and intermediate 
subsets express TF on the cell surface following incubation with 1 ng/mL LPS.  This is higher 
than the 10 % of non-classical monocytes that express TF on the cell surface at the same LPS 
concentration.  Assuming these percentages are representative of the monocytic TF from the 5 
different healthy volunteers used to investigate TF activity, the classical and non-classical 
monocytes show a similar TF activity (Figure 3.7).   
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Although incubation with LPS increases the cell surface expression of TF, incubation with 
LPS does not increase the activity of TF.  Using the same five donors as the earlier TF 
activity work, a comparison between monocyte subsets cultured alone and those incubated 








Monocytes, negatively sorted using FACS, were incubated with varying concentrations of 
LPS in IMDM and 10 % autologous serum.  Following a 24-hour incubation, flow cytometry 
was used to measure the percentage of monocytes expressing TF.  Error bars in figures B and 
C represent the median values and interquartile range.  The results of 7 independent 
experiments are shown.   Both the 1 and 10 ng/mL concentrations of LPS were statistically 
compared to no LPS.   A demonstrates the TF gating and is a representative example of 
monocytes incubated without LPS, with 1000 ng/mL of LPS and monocytes not stained for 
TF.  The red gate shows the negative population as set by the FMO, whilst the blue line gates 
the TF positive population.  B shows the percentage of monocytes expressing TF, as 
measured by flow cytometry using an FMO control.  The percentage of monocytes expressing 
TF on their surface increases following incubation with LPS (p=0.04 by Friedman’s test, **- 
p<0.01 for both 100 and 1000 ng/mL of LPS using Dunn’s post hoc test).  C shows the 
change in TF MFI.  The TF MFI increases with LPS incubation (p=0.003 by Friedman’s test, 
*- p<0.05 for 10 ng/mL of LPS, **-p<0.01 for 100 and 1000 ng/mL of LPS using Dunn’s post 
hoc test).   
 




Monocytes, negatively sorted using FACS, were incubated with and without 1 ng/mL of LPS 
in IMDM and 10% autologous serum.  Following a 24-hour incubation, flow cytometry was 
used to measure the percentage of monocyte subsets and the monocytic expression TF.  This 
figure shows the results of 7 independent experiments (the intermediate and non-classical 
subset incudes 5 experiments as there were too few of these monocytes to allow accurate 
gating). Error bars represent median values and the interquartile range. Both the 1 and 10 
ng/mL concentrations of LPS were statistically compared to no LPS.   A shows that all 
monocyte subsets increased the cell surface expression of TF following incubation with LPS 
(classical TF %: p=0.04 by Friedman’s test, * - p<0.05 for 10 ng/mL LPS using Dunn’s post 
hoc test;  intermediate TF %: p=0.04 by Friedman’s test, p=0.05 for 10 ng/mL of LPS using 
Dunn’s post hoc test; non-classical TF %: p=0.02 by Friedman’s test, * - p<0.05 for 10 
ng/mL of LPS, p=0.05 for 1 ng/mL using Dunn’s post hoc test).  B shows that the classical 
and non-classical subsets increased TF MFI following incubation with LPS (classical TF 
MFI: p=0.003, *-p<0.05 for 1 ng/mL LPS, **-p<0.01 for 10 ng/mL LPS by Dunn’s post hoc 
test; non-classical TF MFI: p=0.04 by Friedman’s test, p=0.05 for 10 ng/mL LPS by Dunn’s 
post hoc test).  There was no statistically significant difference between the intermediate 










Monocytes were positively sorted into subsets using FACS.  Each subset was incubated at a 
concentration of 50,000 cells per 500 µL with 1 ng/mL of LPS for 24-hours.  Following 
incubation, the TF activity of each subset was measured using a TF colorimetric assay that 
quantified the activated FX.  Both figures show the results of 5 independent experiments.  A 
shows the TF activity measured as pM per 10,000 cells.  The classical subset displays the 
highest TF activity (p=0.03 by Friedman’s test, * - p<0.05 compares the non-classical to the 
classical subsets by Dunn’s post hoc test).  B shows TF activity per TF positive cell.  
Assuming the classical and intermediate subsets have 15 % of cells expressing TF on the cell 
surface, whilst the non-classical subset has 10 % of cells.  This is based on earlier work 
shown in Figure 3.5.  There is no statistical difference between the subsets (p=0.09 by 
Friedman’s test).   
Figure 3.7 Monocyte subset TF activity 
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Monocytes were positively sorted in subsets using FACS.  Each subset was incubated with 
and without 1 ng/mL of LPS for 24 hours.  Following incubation, the TF activity of each 
subset was measured using a TF colorimetric assay that measured the amount of activated 
FX.  Values represent the TF activity per 10,000 cells.  Error bars represent median values 
and the interquartile range.  This figure shows the results of 5 independent experiments. 
There was no statistically significant difference between each subset cultured alone and each 
subset cultured with LPS (classical- p=0.82, intermediate- p=0.63, non-classical- p=0.44 by 

























































Figure 3.8 Incubation with LPS does not seem to increase TF activity 
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3.3.3 Inhibiting the LPS induction of monocytic cell surface expression of TF 
The ERK, NFκB and JNK transcription pathways have all been shown to be important in 
monocytic TF expression (Bode and Mackman, 2014).  To investigate whether the pathways 
were important in all subsets, PBMCs were obtained from 6 different healthy volunteers using 
Ficoll-Paque™ density gradient separation.   Monocytes were isolated using the adherence 
method and were incubated with inhibitors prior to application of LPS at 1 ng/mL in a 24 well 
plate (see Figure 3.9 for the plate set-up).  The LPS remained in the culture for the duration of 
culture.  TF cell surface expression was once again measured using flow cytometry (see 
methodology section 2.6.2, page 73). 
 
Three inhibitors were used to investigate the role of ERK, cRel and NFκB signalling in the 
LPS induction of TF transcription.  All were titrated to ensure optimum inhibition whilst 
maintaining cell viability above 90 % (see Figure 3.10).   FR180204, an inhibitor of ERK1 
and ERK2, was used at a concentration of 15 µM (Ohori et al., 2005; Perrett et al., 2013).  
IT901, an inhibitor of the NFκB subunit cRel, was used at a concentration of 1.0 µM (Shono 
et al., 2016).  SR11302, an inhibitor of AP-1 was titrated and used at a concentration of 1.0 
µM (Fanjul et al., 1994; Shiohara et al., 1999).  All were reconstituted as per the 
manufacturer’s instructions using DMSO; further dilutions were performed using IMDM. 
 
The cell surface expression of TF was lower than in earlier experiments.  No results were 
statistically significant, although there was a trend for TF expression to decrease in response 
to inhibitors in the total monocyte population, without a drop in cell viability (see Figure 
3.11).  A similar trend was seen in the classical and intermediate monocyte subsets but not in 
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Figure 3.9 Set-up of TF cell surface expression inhibitor plate 
This figure demonstrates the set-up of a 24-well plate used to investigate the LPS induction of 
monocytic cell surface TF expression. 
Abbreviation Meaning 
M Monocyte 
L Lipopolysaccharide (LPS) 
ERK ERK inhibitor, FR180204 
cRel cRel inhibitor, IT901 
AP-1 AP-1 inhibitor, SR11302 
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This figure details the change in TF expression on monocytes following incubation with 
various inhibitors. The inhibitors were titrated to identify the concentration associated with a 
clear decrease in TF expression whilst maintaining cell viability above 90 %. 






PBMCs were incubated in IMDM in 24-well plates for 1 hour and then washed to leave only 
adherent monocytes. Monocytes were incubated with and without 1 ng/mL of LPS in IMDM 
and 10% autologous serum.  In some wells, inhibitors to ERK1 & 2 (FR180204, 15 µM), AP-
1 (SR11302, 1 µM) and c-Rel (IT901, 1 µM) were added 30 minutes prior to the LPS.  
Following a 24-hour incubation, flow cytometry was used to measure the percentage of 
monocytes expressing TF. The results of 6 independent experiments are shown.  A shows the 
effects of the inhibitors of the cell surface TF expression of all monocytes.  The blue bar 
represents monocytes alone, dark for orange for monocytes with LPS and light orange when 
an inhibitor is added.   Error bars show the upper quartile and bar height the median values.  
The inhibitors did not significantly decrease the LPS-induced TF expression (p=0.03 by 
Friedman’s test, * - p<0.05 when monocytes incubated with LPS are compared to those 
incubated alone, p=0.06 when monocytes incubated with LPS and FR180204 are compared 
to monocytes incubated with LPS alone using Dunn’s post hoc test).  B shows the cell 
viability for each condition.  Black dots show the median value and the error bars the 
interquartile range. Viability remained above 90 % for all conditions. There were no 
statistically significant differences (p=0.19 by Friedman’s test). 
  







PBMCs were incubated in IMDM in 24-well plates for 1 hour and then washed to leave only 
adherent monocytes. Monocytes were incubated with and without 1 ng/mL of LPS in IMDM 
and 10% autologous serum.  In some wells, inhibitors to ERK1 & 2 (FR180204, 15 µM), AP-
1 (SR11302, 1 µM) and c-Rel (IT901, 1 µM) were added 30 minutes prior to the LPS.  
Following a 24-hour incubation, flow cytometry was used to measure the percentage of 
monocytes expressing TF. The results of 6 independent experiments are shown.  The blue bar 
represents monocytes alone, dark for orange for monocytes with LPS and light orange when 
an inhibitor is added.   Error bars show the upper quartile and bar height the median values.  
The inhibitors had no statistically significant effect on the LPS-induction of cell surface TF 
expression. (Classical: p=0.05 by Friedman’s test, *-p<0.05 for monocytes with LPS 
compared to monocytes alone by Dunn’s post hoc test; intermediate: p=0.17 by Friedman’s 
test; non-classical: p=0.05 by Friedman’s test).  
Figure 3.12 Effects of transcription factors on LPS-induced TF cell surface expression 
across the monocyte subsets 
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3.4 The effects of monocyte-endothelial interactions on TF cell surface expression 
An in vitro model of monocyte-endothelial cell interaction was used to investigate the effects 
on TF and monocyte subsets.  Monocytes were sorted with FACS from PBMCs using 5 
healthy donors.  They were cultured for 24 hours with endothelial cells in PMVEC medium.  
Some PMVEC were pre-treated with LPS (100 ng/mL) for one hour; the LPS was then 
washed off and monocytes were added to the culture.   
 
Some monocytes were stimulated by the addition of LPS (10 ng/mL); this LPS was not 
washed off (see methodology section 2.7.2, page 82). These conditions were set-up in a 24-
well plate as shown in Figure 3.13. 
 
The co-culture of monocytes with unstimulated PMVEC increased in the proportion of the 
classical subset.  Endothelial stimulation with LPS prior to the addition of monocytes does not 
appear to alter this effect (Figure 3.14). 
 
Monocyte-endothelial co-cultures were also used to investigate the effect on TF expression.  
TF expression was shown to increase in both the classical and intermediate subsets.  This 
effect was once again independent of LPS.  There were no statistically significant changes in 
the non-classical subset (Figure 3.15).   
 
To investigate whether contact was needed for the observed monocyte-endothelial cell 
interaction, co-cultures were repeated, using 5 different donors, with transwells to prevent 
cellular contact (see methodology section 2.7.2, page 82).  The yield of monocytes from 
transwells was too poor to accurately identify monocyte subsets; however, considering the 
flow data for all monocytes, contact did not affect monocyte TF expression (Figure 3.16). 
 
As discussed earlier, MCSF has been shown to alter monocyte subsets by promoting the 
differentiation of classical, through intermediate, to non-classical (Saleh et al., 1995b; 
Korkosz et al., 2012).  Measurement of MCSF in the co-culture supernatants showed no 
significant difference in levels between the conditions (Figure 3.17). 
 
The endothelial response to co-culture was measured using the supernatants.  There was no 
significant change in tPA levels.  PAI-1 levels increased following co-culture with monocytes 
and PMVECs pre-treated with LPS (figures 3.18 and 3.19).   
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Figure 3.13 Co-culture plate set-up 
This figure depicts the set-up of a 24-well plate for a co-culture experiment of PMVEC and 
monocytes.  LPS (100 ng/mL) was added to PMVEC, and washed off after 1 hour, prior to the 
addition of monocytes.  LPS (10 ng/mL) was added to monocytes and not removed.  Co-
culture were incubated at 37 ⁰C and 5 % CO2 for 24 hours.  Following this, monocyte were 
harvested, and flow cytometry used to measure the monocytes subset proportions and the 




PM Human pulmonary microvascular endothelial cell (PMVEC) 




Monocytes were negatively sorted using FACS and incubated with and without PMVEC.  A 
proportion of PMVEC were stimulated with 100 ng/mL of LPS for 1 hour, and the LPS was 
washed off prior to the addition of the monocytes.  Some monocytes were cultured alone with 
10 ng/mL LPS; unlike with the PMVEC stimulation, the monocyte LPS was not removed but 
remained there for the duration of culture.  Following a 24-hour incubation, the proportions 
of monocyte subsets were measured using flow cytometry.  This figure shows the results of 5 
independent experiments. Error bars represent median values and the interquartile range.  
The proportion of classical monocytes increased following culture with PMVEC and LPS 
stimulated PMVEC (p=0.01 by Friedman’s test, **-p<0.01 for monocytes cultured with 
unstimulated PMVEC compared to monocytes alone by Dunn’s post hoc test).  The 
intermediate subset decreases in response to PMVEC co-culture (p=0.02 by Friedman’s test, 
*-p<0.05 for monocytes cultured with PMVEC compared to monocytes alone by Dunn’s post 
hoc test).  The non-classical subset decreases in response to PMVEC co-culture (p=0.02 by 
Friedman’s test, *-p<0.05 for monocytes cultured with PMVEC and with LPS-stimulated 
PMVEC when compared to monocytes alone by Dunn’s post hoc test).   
  






Monocytes were negatively sorted using FACS and incubated with and without PMVEC.  A 
proportion of PMVEC were stimulated with 100 ng/mL of LPS for 1 hour, the LPS was 
washed off prior to the addition of the monocytes.  Some monocytes cultured without PMVEC 
were stimulated with 10 ng/mL LPS that was not removed but remained there for the duration 
of culture.  Following a 24-hour incubation, the subset TF expression was measuring using 
flow cytometry.  This figure shows the results of 5 independent experiments. Error bars 
represent median values and the interquartile range.  A shows the percentage of TF-positive 
cells for each subset following co-culture. Classical monocytes increase the cell surface 
expression of TF following PMVEC co-culture (p=0.02 by Friedman’s test, **- p<0.01 for 
monocytes cultured with unstimulated PMVEC compared to monocytes alone by Dunn’s post 
hoc test).  Intermediate (p=0.31 by Friedman’s test) and non-classical monocytes (p=0.88 by 
Friedman’s test) do not increase the percentage of cells expressing cell surface TF.  B shows 
the TF MFI of each subset following co-culture.  Classical monocytes increase TF MFI 
following PMVEC co-culture (p=0.02 by Friedman’s test, **- p<0.01 for monocytes cultured 
with unstimulated PMVEC compared to monocytes alone by Dunn’s post hoc test).  The 
intermediate subset increases TF MFI following co-culture with unstimulated and LPS-
stimulated PMVEC (p=0.001 by Friedman’s test, **- p<0.01 for monocytes cultured with 
LPS-stimulated PMVEC compared to monocytes alone by Dunn’s post hoc test).  There was 
no statistically significant change in the non-classical subset (p=0.80 by Friedman’s test).  




Monocytes were negatively sorted using FACS and incubated with and without PMVEC.  A 
proportion of monocytes were cultured in transwells above PMVEC.  Following a 24-hour 
incubation, the percentage of monocytes expressing TF was measuring using flow cytometry.  
This figure shows the results of 5 independent experiments. Error bars represent median 
values and the interquartile range. ‘No contact’ refers to the use of a transwell to prevent 
cellular contact between monocytes and PMVEC.  Monocyte culture with PMVEC increased 
the cell surface expression of TF; this was not affected by the use of the transwell (p=0.02 by 
Friedman’s test, *- p<0.05 for monocytes and PMVEC cultured with a transwell compared to 
monocytes alone, p=0.05 for monocytes and PMVEC cultured in contact compared to 
monocytes alone using Dunn’s post hoc test).  
  




Figure 3.17 Co-culture of monocytes with PMVECs pre-treated with LPS does not affect 
MCSF levels 
Monocytes were negatively sorted using FACS and incubated with and without PMVEC.  A 
proportion of PMVEC were stimulated with 100 ng/mL of LPS for 1 hour, and the LPS was 
washed off prior to the addition of the monocytes.  Some monocytes cultured without PMVEC 
were stimulated with 10 ng/mL LPS that was not removed but remained there for the duration 
of culture.  This figure shows the quantity of MCSF in supernatants harvested following 24 
hours of culture.  MCSF was measured by ELISA. The figure shows data from 6 independent 
experiments.  Error bars represent median values and the interquartile range.  There was no 




Monocytes were negatively sorted using FACS and incubated with and without PMVEC.  A 
proportion of PMVEC were stimulated with 100 ng/mL of LPS for 1 hour, and the LPS was 
washed off prior to the addition of the monocytes.  Some monocytes cultured without PMVEC 
were stimulated with 10 ng/mL LPS that was not removed but remained there for the duration 
of culture.  This figure shows the concentration of PAI-1 in supernatants harvested following 
24 hours of culture.  PAI-1 was measured using an ELISA. The figure shows data from 6 
independent experiments.  Error bars represent median values and the interquartile range.  
There was an increase in PAI-1 levels when monocytes were cultured with LPS-stimulated 
PMVEC compared to LPS-stimulated PMVEC cultured alone (p=0.07 by Friedman’s test, *- 





Figure 3.18 Co-culture of monocytes with LPS-pre-treated PMVECs 
increases PAI-1 levels 
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Monocytes were negatively sorted using FACS and incubated with and without PMVEC.  A 
proportion of PMVEC were stimulated with 100 ng/mL of LPS for 1 hour, and the LPS was 
washed off prior to the addition of the monocytes.  Some monocytes cultured without PMVEC 
were stimulated with 10 ng/mL LPS that was not removed but remained there for the duration 
of culture.  This figure shows the concentration of tPA in supernatants harvested following 24 
hours of culture.  tPA was measured using an ELISA. The figure shows data from 6 
independent experiments.  Error bars represent median values and the interquartile range.  
There was no significant difference between the conditions involving PMVEC (p=0.027 by 
Friedman’s test, ns – non-significant between the conditions containing PMVEC). 
 
 




3.5.1 Change in monocyte subsets following LPS incubation 
The proportion of classical monocytes was increased by culture with LPS.  This was 
associated with a lower expression of CD16, the marker used to distinguish intermediate and 
non-classical subsets.  Interestingly, contrary to these results, multiple reports have suggested 
that LPS increases the expression of CD14.  Marchant et al. showed an increase in CD14 
expression within 30 minutes and 3 hours of incubation with LPS, an effect that did not 
require protein synthesis (Marchant et al., 1992). Landmann et al. demonstrated that after a 
few hours’ incubation, LPS appeared to decrease CD14 mRNA; this was followed, however, 
by an increase after 2 days.   The authors also demonstrated an increase in the protein surface 
expression, with CD14 MFI on both PBMCs and purified monocytes increasing following 
incubation with LPS at doses higher than 1 ng/mL (Landmann et al., 1996).   
 
The cultures described in this chapter were incubated for 24 hours. It may be that this was too 
early to detect an increase in CD14 and supports a change in CD16 expression as a cause for 
the rise in proportion of the classical subset.  There is some evidence to suggest that LPS 
stimulation of monocytes can result in the internalisation of CD16.  Both the intermediate and 
non-classical subsets have been shown to be capable of internalising their CD16 receptor in 
vivo (Paniagua et al.; Picozza et al., 2013). 
 
It is important to note, however, that a change in monocyte subset does not necessarily 
translate into a change in monocyte function.  As previously mentioned, the nomenclature for 
monocyte subsets applies during health (Ziegler-Heitbrock et al., 2010b).  Further work 
would need to be performed to investigate a change in function following stimulation of 
monocyte subsets with LPS. 
 
Finally, this data is limited by the measurement of proportions.  It is possible that during the 
experiment there was a disproportionate loss of non-classical and intermediate monocytes, 
rather than an increase in classical monocytes.  As demonstrated, only a minority proportion 
of monocytes were recovered following in vitro culture.  There were several parts of the 
protocol during which cells could be lost: these include harvesting monocytes that have 
adhered to the plastic wells, cell washing following antibody staining, and transfer to the flow 
cytometry tubes.  Although there was no significant decrease in yield with increasing levels of 
LPS, it is possible that increasing levels of LPS may increase the adhesiveness of some 
subsets to plastic.  Further work is needed to confirm whether this data represents a genuine 
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increase in the proportion of classical monocytes or in fact a disproportionate loss of the 
intermediate and non-classical subsets. 
 
3.5.2 Expression of TF by monocyte subsets 
All monocyte subsets were shown to increase their TF expression following LPS stimulation.  
The non-classical subset, contrary to my hypothesis, was shown to express the lowest levels 
of TF.  To my knowledge there is no published work comparing the TF expression of 
monocyte subsets following LPS stimulation.  Stojkovic et al. used IL-33 as a stimulus and 
showed an increase in the percentage of TF expressing intermediate monocytes, with a trend 
to increase demonstrated in the non-classical subset and no change noted in the classical 
subset.  TF activity following IL-33 stimulation was not investigated in their study (Stojkovic 
2017).   
 
There is no published work comparing the activity of TF expressed on monocyte subsets.  
Accounting for the lower proportion of non-classical monocytes that express TF, there was no 
significant difference in TF activity across the monocyte subsets.  Whilst LPS consistently 
increases the proportion of TF expressed by all monocytes, there was no evidence that it 
increased TF activity.  The discrepancy between the level of cell surface expression and 
activity may be explained by the process of encryption, a post-translation modification of TF 
on the monocytic cell surface to control its activity (see introduction section 1.4.4, page 28) 
(Bach, 2006).  Previous groups have suggested that the discrepancy between LPS-induced TF 
expression and its activity may be explained by an increase in cell death.  The process of cell 
death leads to an externalisation of phosphatidylserine (PS) and thereby a ‘decryption’ of TF 
expressed by the cell (Henriksson et al., 2007).  The work described in this chapter, however, 
consistently showed a cell viability of greater than 90 % at the levels of LPS stimulation used, 
as measured by propidium iodide, thereby excluding late apoptosis and necrosis (Figure 3.1).  
It is still possible that the cells are entering early apoptosis and future work to identify the 
exposure of PS and signs of apoptosis would be useful.  Potentially, this could involve the use 
of fluorescently-labelled Annexin V to assess the PS on the cell surface and DAPI to search 
for chromatin condensation (Cummings and Schnellmann, 2004).  The low yield of recovered 
monocytes may also mean that many dead cells were lost during the experiment.  This may 
have kept the viability artificially high. 
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3.5.3 Mechanisms involved in LPS-induced TF up-regulation on monocytes 
As discussed earlier, the pathway(s) through which LPS induces transcription of TF are 
unclear.  Three pathways have been implicated, with key roles for NFκB, ERK and JNK 
(Bode and Mackman, 2014).  There is no published work considering the pathways in 
different monocyte subsets. 
 
No statistically significant results were seen during this project, although there appeared to be 
a trend for inhibitors of all pathways to reduce TF surface expression, in total monocytes and 
in the classical and intermediate subset.  No such trend was seen in the non-classical subsets.  
The TF expression during the inhibitor experiments was lower than that measuring during 
earlier experiments.  This may be due to the use of adherence rather than FACS to isolate the 
monocytes.  To fully understand the up-regulation of surface TF expression, future work 
should investigate the monocyte transcriptome and proteome post LPS activation. 
 
3.5.4 The effect of monocyte-endothelial cell interaction on subset proportions and TF 
expression 
Co-culture of monocytes and PMVECs led to an increase in the proportion of classical 
monocytes, which did not appear to be dependent on the presence of LPS.  As discussed 
earlier (see introduction 1.5.5, page 49), MCSF can affect monocyte subset differentiation 
from classical to intermediate to non-classical (Saleh et al., 1995a; Korkosz et al., 2012).  
Measurement of the MCSF levels in supernatants following co-culture, however, showed no 
changes in MCSF levels between endothelial cells alone and those in contact with monocytes. 
 
Another explanation may be the ability of each subset to transmigrate through an endothelial 
monolayer.  Chimen et al. used monocyte and human umbilical vein endothelial cell 
(HUVEC) co-cultures to describe how all the subsets transmigrated from the apical to the 
basal side of an endothelial layer.  Interestingly, the classical subset then underwent a reverse 
transmigration by 90 minutes such that they returned to the apical surface and remained on 
there.  Intermediate and non-classical monocytes remained in a basal polarity (Chimen et al., 
2017).  Human and murine monocyte subsets, as previously described (see introduction 
section 1.5), have been shown to move differently across the endothelium, which may explain 
this behaviour; in both cases, the non-classical subset was shown to adhere more strongly to 
endothelium (Auffray, 2007; Cros et al., 2010).  Future work investigating the transmigration 
and adhesion abilities of human subsets in endothelial co-cultures are needed to better 
understand this.   
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Endothelial co-culture led to an increase in TF expression on classical and intermediate 
monocytes. Again, this effect appeared to be independent of endothelial LPS stimulation.  Lo 
et al. have previously demonstrated that direct contact between monocytes and endothelium 
led to an increase in endothelial TF expression, although monocytic TF expression was not 
investigated (Lo et al., 1995).  The work discussed in this chapter did not demonstrate a need 
for cellular contact between monocytes and endothelium to increase monocyte TF expression.   
 
There are several potential mediators that may explain the induction of monocytic TF without 
the presence of contact or LPS.  The release of homocysteine from endothelium at 
physiological levels has been shown to increase monocytic TF (Khajuria and Houston, 2000).  
P-selectin, bound to the endothelial surface, has also been shown to induce monocytic TF, but 
whether the release of soluble P-selectin could have a similar effect has so far not been 
investigated (Celi et al., 1994; Semenov et al., 1999).  Interestingly, both membrane-bound 
and soluble P-selectin have been shown to increase the proportion of PS in the monocytic 
outer cell membrane.  Potentially, this could support decryption of membrane-bound TF (del 
Conde et al., 2005). 
 
3.5.5 The endothelial response to co-culture 
Sepsis-associated coagulopathy is associated with an inhibition of the endothelial fibrinolytic 
response (Suffredini et al., 1989).  In my experiments co-culture of monocytes and 
endothelial cells resulted in no difference in tPA released, but there was an increase in PAI-1 
concentration when monocytes were co-cultured with PMVEC pre-treated with LPS.  
Monocytes are known to release a small proportion of PAI-1, but the increase in levels is 
higher than the amount of PAI-1 measured from monocytes cultured alone.  Multiple authors 
have also noted an activation of endothelium following co-culture with monocytes (Rainger et 
al., 1996; Tsouknos et al., 2003).  The increase in PAI-1 and unchanged level of tPA, 
following monocyte-endothelial co-culture has been noted previously by Funayama et al.  
They noted the effect occurred by 6 hours and was blocked by antibodies to IL-1β and TNF-α 
(Funayama, 1997).  As previously shown, there appeared to be a trend towards an increase in 
IL-1β and TNF-α following co-culture in this project, however more work is needed to 
investigate a possible mechanism. 
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3.6 Summary of key findings  
TF expression and activity has been shown to vary between monocyte subsets.  Interestingly, 
a discrepancy was noted between the TF expression and activity in the subsets.  This does not 
appear to be explained by cell death and warrants further investigation to consider the 
encryption of TF on each subset.  
 
My initial hypothesis, that the non-classical subset would express the highest level of TF has 
been refuted.  Although there is variation between the monocyte subsets, the classical and 
intermediate monocytes express the highest levels of TF, whilst there was no difference in TF 
activity. 
 
The in vitro model of sepsis using endothelial co-culture has demonstrated an induction of 
monocyte TF that appears independent of LPS, as well as an increase in PAI-1 production.  





4. Chapter 4.  Investigation of Monocyte Subsets following Endotoxaemia 





Chapter 3 looked at the effects of LPS in vitro. To investigate how the TF on monocytes 
responds to LPS in vivo, a model of human endotoxaemia was used.  Although not a model of 
sepsis, this allows for the temporal investigation of LPS activation of both the immune and 
coagulation systems (van Deventer et al., 1990).   
 
This chapter will discuss the impact of endotoxaemia on monocyte subsets and TF cell 
surface expression in healthy volunteers.  Previous work has demonstrated a profound 
monocytopenia within 90 minutes of exposure of LPS.  This is followed by the recovery of 
classical monocytes followed by intermediate and then non-classical subsets (Tak et al., 
2017).  A review of the literature revealed no previous investigation of changes in monocytic 
TF expression. 
 
4.2 Research aims 
- to identify the changes in the proportion of circulating monocyte subsets following 
LPS exposure  
- to investigate the effect of endotoxaemia on the cell surface expression of TF between 
the monocyte subsets 
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4.3 The human endotoxaemia model 
The human endotoxaemia model involves the injection of LPS (2 ng/kg) to a healthy 
volunteer followed by venepuncture at the following time points: pre-injection, 90 minutes, 4, 
6, 10 and 24 hours, and 7 days following the injection.  The participant is monitored 
throughout the first 10 hours in a dedicated research space within a critical care unit.  The 
experiment is performed by a critical care physician.  A small proportion of the blood taken is 
processed by the hospital’s laboratory to obtain full blood cell count and coagulation 
measurements.  The remaining blood is processed by the research team, including whole 
blood flow cytometry. 
 
Thirteen participants were recruited between July 2018 and February 2019.  Their median age 
was 24.5 years (range 18-37 years) and 8 (62%) were male.  
 
Most participants experienced a leucocytosis following the LPS injection.  Peak levels were 
reached at 10 hours and all white blood counts had returned to within the reference range 7 
days following the experiment.  The predominant circulating leucocytes were neutrophils, 
with levels following the trend of the total white blood count.  All participants developed a 





This figure shows the total white blood cell counts at each time-point following an injection of 
2 ng/kg LPS in healthy volunteers (n=13).   Cell counts were measured by flow cytometry in 
the hospital’s laboratory using the Sysmex XN-3000TM analyser (Sysmex, Milton Keynes, 
UK).  Most participants had a white blood count and white cell differential measured at each 
time-point, but two had a single missing sample; the 4 hr and 10 hr timepoints therefore show 
the results of 12 participants.  The red dashed line marks the upper limit of the reference 
range, whilst the blue dashed line marks the lower limit. A – white blood cell count, B – 
monocyte count, C – neutrophil count, D – lymphocyte count.  Significance was calculated 
using the repeated-measures one-way ANOVA test (A, B, C and D: p<0.0001)) with 
Dunnett’s multiple comparisons test to compare each time-point to baseline (* – p<0.05, ** – 
p<0.01, *** – p<0.001, **** – p<0.0001). 
  
Figure 4.1 White cell counts of healthy controls following endotoxaemia 
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4.4 Monocyte subsets following endotoxaemia 
100 µL of whole blood from each time-point was used for flow cytometry in a BD 
Trucount™ tube to allow the calculation of absolute values (see methodology section 2.6.1, 
page 72). 
 
As seen in the full blood count sample, there was a profound monocytopenia.  This occurred 
in all participants and was most pronounced at the 90 min time-point following the LPS 
injection (Figure 4.2). 
 
The recovery begins at 4 hours but is not complete until 24 hours.  Reviewing the subsets 
individually shows a loss of virtually all intermediate and non-classical monocytes at early 
time points, with only a small population of classical remaining.  The classical subset begins 
to recover at 4 hours, but the intermediate and non-classical subsets do not return until 24 





The monocyte count was measured with flow cytometry using 100 µL of whole blood in a BD 
Trucount™ tube for all 13 participants.   A – Endotoxaemia is followed by a profound 
monocytopenia.  The bars represent median values and the error bar the upper quartile.  The 
decrease in monocyte count was statistically significant (p<0.0001 by Friedman’s test, ** – 
p<0.01 comparing 4 hr to baseline and **** – p<0.0001 comparing 90 min to baseline by 
Dunn’s post hoc test).  B – A representative example of one participant’s flow cytometry at 
four time-points. 
 
Figure 4.2 Endotoxaemia induces a profound monocytopenia 
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This figure shows the changes in monocyte subsets, as gated by CD14 and C16 positivity, at 
each time-point following an injection of 2 ng/kg LPS in a single participant.  The classical 
population is gated in the red gate, the intermediate in blue and the non-classical in green.  













This figure shows the absolute monocyte subset counts at each time-point following an 
injection of 2 ng/kg LPS in healthy volunteers (n=13).  Counts were measured with flow 
cytometry using 100 µL of whole blood in a BD Trucount™ tube.  The bars represent median 
values and the error bars the upper quartile.  Classical monocytes decrease at 90 mins and 
recover by 6 hr (p<0.0001 by Friedman’s test, **** – p<0.0001 comparing 90 min to 
baseline and *** – p<0.001 comparing 4 hr to baseline by Dunn’s post hoc test).  
Intermediate monocytes decrease at 90 mins and recover at 24 hr (p<0.0001 by Friedman’s 
test, **** – p<0.0001 comparing 90 min and 4 hr to baseline, ** – p<0.01 comparing 6 hr to 
baseline and * – p<0.05 compares 6 hr to baseline by Dunn’s post hoc test).  Non-classical 
monocytes decrease at 90 mins and recover at 24 hr (p<0.0001 by Friedman’s test, *** – 
p<0.001 comparing 90 min and 6 hr to baseline, ** – p<0.01 comparing 4 hr and 10hr to 





Figure 4.4 The classical subset recovers before the others following endotoxaemia-induced 
monocytopenia 
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4.5 TF expression following endotoxaemia 
As part of the whole blood flow cytometry, the proportion of TF-expressing monocytes was 
measured.  Only a very small proportion of circulating monocytes express TF.  The 
percentage of cells expressing TF was much lower than reported with LPS in vitro stimulation 
as described in chapter 3 (see section 3.3.2, page 105). 
   
The TF cell surface expression of each monocyte subset was investigated.  When considering 
all 13 participants there appeared to be two broad categories of response: in 8 participants the 
proportion of TF-expressing monocytes increased after LPS administration (high responders), 
while in the remaining 5, monocytes expressed a very low level of TF that did not change in 
any subset following LPS (low responders).  Figure 4.5 shows the data for all participants 
together as well as separately for each of these categories.  The level of 0.5 % of cells 
expressing TF was used to distinguish the two populations.  This level was chosen since the 
highest baseline level of TF noted in all participants was 0.48 %. 
 
There appeared to be two peaks in TF expression, at 90 minutes and then at 6 hours. 
When the TF expression on the monocyte subsets from the two categories was investigated, 
the pattern in each subset mirrored the pattern observed for total monocytes (Figure 4.6). The 
intermediate subset had the highest levels of TF expression (Figure 4.6).  This may be 
explained by the smaller number of cells present between 90 min and 6 hr, particularly in the 
intermediate and non-classical subsets (Figure 4.4). 
 
There was no difference between the ages, sex or white blood count of these the high and low 
responders (see table 4.1).  C-reactive protein (CRP) levels were measured, as a marker of 
inflammation, at baseline, 10 hr, 24 hr and 7 days in the hospital’s laboratory using 
chemoluminescence with the cobas® 8000 analyser.  The CRP increased for all participants at 
10 and 24 hr before returning to normal at 7 days.  There was no difference between the high 
and low responder groups.  Although the changes seen in the low responder group were not 
statistically significant, this is likely due to the small number of participants, particularly as 
one participant did not have CRP measured at 10 and 24 hr (see Figure 4.7). 
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This figure shows the percentage of monocytes that express TF at each time-point following 
an injection of 2 ng/kg LPS in healthy volunteers (n=13).  TF expressing cells were measured 
with flow cytometry using FMO to gate the negative the population.  A – This figure includes 
all participant data (n=13).  There was no statistically significant difference in the 
percentage of monocytes expressing TF (p=0.11 by Friedman’s test).  B – compares ‘high 
responders’ (participants who increased the percentage of cells expressing TF on their 
surface above 0.5%, n=8) and ‘low responders’ (participants who did not increase the 
percentage of cells above 0.5%, n=5).  The red dashed line marks 0.5 % of cells expressing 
TF.  There was an increase in the percentage of monocytes expressing TF at 90 min following 
LPS injection in the high-responder group (p=0.0005 by Friedman’s test, * – p<0.05 
comparing 90 min to baseline by Dunn’s post hoc test).  The percentage of monocytes 












This figure shows the percentage of each monocyte subset that expresses TF at each time-
point following an injection of 2 ng/kg LPS in healthy volunteers (n=13).  TF-expressing cells 
were measured with flow cytometry using FMO to gate the negative population.   Frequently 
in the low responder groups and the non-classical subset, there were no cells expressing TF 
on their cell surface.  A – These figures include all participant data (n=13). The percentage 
of monocytes expressing TF did not change (classical: p=0.08, intermediate: p=0.34, non-
classical: p=0.65 by Friedman’s test).  B – includes data for ‘high responders’ (increased TF 
expression to >0.5 % of the total circulating monocyte population, n=8).  The classical 
monocyte subset increased the percentage of cells expressing TF (p=0.02 by Friedman’s test, 
* – p<0.05 comparing 90 min and 6 hr time-points to baseline by Dunn’s post hoc test).  C – 
includes data for ‘low responders’ (did not increase their TF expression to >0.5 % of the 
total circulating monocyte population, n=5).  There were no significant changes in the 
percentage of monocytes expressing TF in the low responders (classical: p=0.49, 
intermediate: p=0.56, non-classical: p=0.10 by Friedman’s test).   
Figure 4.6 All monocyte subsets in the high responder population show an increase TF 




        
    High responders Low responders 
Number of participants 8 5 
Median age (years) 25 (range 18 to 37) 24 (range 22 to 32) 
Male 5 (62%) 3 (60%) 
White blood count Baseline 5.80 5.30 
 90 min 3.73 6.18 
 4 hr 8.07 11.92 
 6 hr 10.05 12.75 
 10 hr 13.70 14.82 
 24 hr 8.21 11.32 
  7 day 5.70 5.56 
 
Table 4.1 Demographic comparison of responders and non-responders 
This table compares the age, sex and white blood cell count of both populations.  There was 
no statistically significant difference found.  Cell counts and age of participants were 
compared using an unpaired t-test; the proportion of male participants in each group was 





This figure shows the level of CRP at baseline, 10 hr, 24 hr and 7 days following an injection 
of 2 ng/kg LPS in healthy volunteers (n=13).   One participant missed two CRP 
measurements at the 10 and 24 hr timepoints; they were in the low responder group.  The red 
dashed line marks the upper limit of the CRP reference range. A – shows the CRP level for all 
participants.  The CRP level increased at 10 and 24 hr (p<0.0001 by Friedman’s test, ** – 
p<0.01 comparing 10 hr to baseline, **** – p<0.0001 comparing 24 hr to baseline using 
Dunn’s post hoc test).  B – The CRP levels for high and low responders are displayed.  Both 
show an increase at 10 and 24 hr, although only the high responder group are statistically 
significant (high responders: p<0.0001 by Friedman’s test, * – p<0.05 comparing 10 hr to 
baseline, **** – p<0.0001 comparing 24 hr to baseline using Dunn’s post hoc test; low 
responders: p=0.0009 by Friedman’s test, p=0.08 comparing 24 hr to baseline using Dunn’s 
post hoc test). 
  
 
Figure 4.7 CRP levels following human endotoxaemia between the responder groups 
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4.6 Markers of coagulation following endotoxaemia 
As discussed earlier, TF, through binding to VIIa, activates the pro-enzyme clotting factors 
and creates FXa, FIXa and FXIa.  This allows the formation of both the tenase and 
prothrombinase complexes, leading to the propagation phase of coagulation and an increased 
production of thrombin.  Each factor has an inhibitor that binds to control coagulation: 
antithrombin (AT) binds to FIXa, FXa, FXIa and thrombin.  FXIa is also inhibited by α-1-
antitrypsin (FXIa-a1AT) (for a more detailed summary see introduction section 1.3.2, page 8).    
 
The down-stream effects of TF were investigated by measuring TAT, FIXa-AT, FXa-AT, 
FXIa-AT and FXIa-a1AT.  To investigate a role for the contact pathway during 
endotoxaemia, levels of FXIIa-C1NH were also measured.  All levels were obtained using 
ELISA by our collaborators at Maastricht University, The Netherlands (see methodology 
2.7.3, page 85). 
 
There was an increase in TAT, FIXa-AT, FXa-AT and FXIa-AT at 4 hr following LPS 
injection.  No change was seen in the FIXa-a1AT levels. At 6 hr there was a decrease in the 
FXIIa-C1NH levels (see Figure 4.8). 
The high and low responder groups were compared but there was no consistent difference 





This figure shows the changes in markers of coagulation at each time-point following an 
injection of 2 ng/kg LPS in healthy volunteers.  Markers of coagulation were measured using 
an ELISA.  This work was performed by our collaborators in Maastricht University, The 
Netherlands.  Markers were measured in 12 participants; the 13th participant was unavailable 
at the time of processing.  Bar height represents median values and error bars the upper 
quartile.  A – TAT levels were increased between 4 and 6 hr (p<0.0001 by Friedman’s test, 
*** – p<0.001 comparing 4, 6 and 10 hr with baseline using Dunn’s post hoc test).  B – 
FIXa-AT levels were increased between 4 and 10 hrs (p<0.0001 by Friedman’s test, **** – 
p<0.0001 comparing 4 hr to baseline, ** – p<0.01 comparing 4 and 6hr to baseline using 
Dunn’s post hoc test). C – FXa-AT levels were increased at 4 and 6 hr (p<0.0001 by 
Friedman’s test, *** – p<0.001 comparing 4 hr to baseline, * – p<0.05 comparing 6 hr to 
baseline using Dunn’s post hoc test).  D – FXIa-AT levels increased between 4 and 10 hr 
(p<0.0001 by Friedman’s test, **** – p<0.0001 comparing 4 and 10hr to baseline, 
** – p<0.01 comparing 6 hr and baseline using Dunn’s post hoc test).  E – FXIa-AT levels 
were unchanged following LPS injection (p=0.44 by Friedman’s test).  F– FXIIa-C1NH 
levels increased at 6hr (p=0.03 by Friedman’s test, * – p<0.05 comparing 6 hr to baseline 
using Dunn’s test).  
  




This figure compares the changes in coagulation markers at each time-point following a 2 
ng/mL injection of LPS between high and low responders.  Markers of coagulation were 
measured using an ELISA.  This work was performed by our collaborators in Maastricht 
University, The Netherlands.  Markers were measured in 12 participants; the 13th participant 
was unavailable at the time of processing.  Bar height represents median values and error 
bars the upper quartile.  There was no consistent difference between the two groups.   A – 
TAT levels were increased between 4 and 6 hr; this change was statistically significant in the 
low responder group  (high responder: p<0.0001 by Friedman’s test, p=0.06 comparing 4 hr 
with baseline using Dunn’s post hoc test; low responder: p=0.0007 by Friedman’s test, 
** – p<0.01 comparing 4 hr to baseline, * – p<0.05 comparing 6 and 10 hr to baseline using 
Dunn’s post hoc test).  B – FIXa-AT levels were increased at 4 hrs in each group and at 10 hr 
in the low responder group (high responder: p<0.0001 by Friedman’s test, ** – p<0.001 
comparing 4 hr to baseline using Dunn’s post hoc test; low responder: p=0.007 by 
Friedman’s test, ** – p<0.01 comparing 4 hr to baseline, * – p<0.05 comparing 10 hr to 
baseline using Dunn’s post hoc test). C – FXa-AT levels were increased at 4 hr; this was 
statistically significant only in the low responder group (high responder: p<0.0001 by 
Friedman’s test, p=0.08 comparing 4 hr to baseline using Dunn’s post hoc test; low 
responder: p=0.008 by Friedman’s test, ** – p<0.01 comparing 4 hr to baseline using 















Figure 4.10 Comparison of FXIa-AT, FXIa-a1AT and FXIIa-C1NH between high and low 
responders 
This figure compares the changes in coagulation markers at each time-point following a 2 
ng/mL injection of LPS between high and low responders.  Markers of coagulation were 
measured using an ELISA.  This work was performed by our collaborators in Maastricht 
University, The Netherlands.  Markers were measured in 12 participants; the 13th participant 
was unavailable at the time of processing.  Bar height represents median values and error 
bars the upper quartile.  There was no consistent difference between the two groups.   D – 
FXIa-AT levels were increased between 4 and 10 hr; this change was statistically significant 
in the low responder group (high responder: p=0.0004 by Friedman’s test, ** – p<0.01 
comparing 4 hr with baseline, * – p<0.05 comparing 10hr to baseline using Dunn’s post hoc 
test; low responder: p=0.002 by Friedman’s test, *** – p <0.001 comparing 4 hr to baseline, 
** – p<0.01 comparing 10 hr to baseline using Dunn’s post hoc test).  E – FXIa-a1AT levels 
were increased at 24 hrs in the low responder group, there was no statistically significant 
difference in the high responder group (high responder: p=0.94 by Friedman’s test; low 
responder: p=0.05 by Friedman’s test, * – p<0.05 comparing 24 hr to baseline using Dunn’s 
post hoc test). F – FXIIa-C1NH levels were decreased between 4 and 6 hr in the high 
responder group (high responder: p<0.002 by Friedman’s test, ** – p<0.01 comparing 6 hr 
to baseline, * – p<0.05 comparing 10 hr to baseline using Dunn’s post hoc test; low 






4.7.1 Changes in blood counts and monocyte subsets 
The human endotoxaemia model leads to a stereotypical response.  All participants 
experienced a neutrophilia, lymphopenia and monocytopenia.  The cause of such a profound 
monocytopenia is not clearly understood. Potentially, the monocytes may be marginating and 
adhering to the endothelium, which may have become activated following the administration 
of LPS.  Several studies have described the ability of monocytes to ‘roll’ or ‘crawl’ along the 
endothelium (Auffray, 2007; Cros et al., 2010).  Blood samples that measure circulating 
monocytes would therefore fail to collect the marginated cells. 
 
As shown by Tak et al., following the monocytopenia, the subsets recover differentially (Tak 
et al., 2017).  Initially the classical monocytes recover at 6 hours, followed by intermediate 
and non-classical at 24 hours.  This group also identified an increase in intermediate 
monocytes at 24 hours. Although no statistically significant difference was seen in this 
project, there did appear to be a trend in that direction (Tak et al., 2017).    
 
It is likely that monocytes are repopulated from the bone marrow.  There is increasing 
evidence that monocytes can transition through the subsets, from classical to intermediate to 
non-classical.  Murine classical monocytes have been shown to differentiate into the 
intermediate subset over several days (Yona et al., 2013).  Single-cell RNA sequencing data 
support the concept of separate classical and non-classical monocyte subsets, but suggest that 
the intermediate subset is not homogeneous and support the idea that it is a transitional 
population (Villani et al., 2017).  Patel et al. injected healthy volunteers with deuterium-
labelled glucose and demonstrated that deuterium-labelled classical monocytes appeared first 
from the bone marrow and intermediate monocytes were seen with a lower level of 
deuterium, while labelled non-classical monocytes did not appear for 7 days.   The group also 
injected deuterium 20 hours prior to performing the human endotoxaemia model. Their 
previous experiments had shown that at this time-point no circulating monocytes would be 
labelled.  Deuterium-labelled classical monocytes were shown to repopulate the circulating 
pool from the bone marrow from 4 hours after LPS administration, whereas the intermediate 
and non-classical subsets did not appear until 24 hours (Patel et al., 2017).  All these 
experiments support the idea of monocytes repopulating the circulation from the bone marrow 
and then differentiating into intermediate and non-classical monocytes.  What is not explained 
is the recovery in non-classical monocytes at 24 hours following LPS injection. Although the 
differentiation of intermediate cells from classical monocytes is feasible over 24 hours, the 
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non-classical population takes longer to appear (Patel et al., 2017).  Potentially, the non-
classical subset is released from the endothelium at 24 hours.  Further work is needed to 
clarify this as well as to investigate the cause of the initial monocytopenia. 
 
4.7.2 Monocytic TF expression 
The percentage of monocytes expressing TF was lower than reported in chapter 3.  The cause 
of this is unclear but may relate to activation of monocytes following isolation (Bennett and 
Breit, 1994).  Potentially the monocytes expressing most TF may not be circulating but be 
marginated.  Sampling the circulating blood may not accurately reflect the TF surface 
expression on monocytes (Auffray, 2007; Cros et al., 2010). 
 
All participants had a low percentage of monocytes that expressed TF prior to injection but an 
increase occurred from 90 minutes and continued until 6 hours.  Considering the percentage 
of TF positive cells, there appear to be two peaks of TF.  TF mRNA has been previously 
shown to increase several hours after LPS injection.  Increased transcription may account for 
the increase in TF expression at 6 hours but does not account for the earlier response at 90 
minutes (Franco et al., 2000). 
 
Egorina et al. stimulated whole blood with LPS and measured the time course of TF 
expression.  They also noted an increase within the first few hours.  Immunostaining for TF 
revealed an intracellular pool near to the membrane.  This is a plausible source of the initial 
peak in TF expression (Egorina et al., 2005). 
 
4.7.3 High and low responders 
This work supports the phenomenon of high and low responders following LPS stimulation 
(Ossterud, 1995).  Although TF transcription has been shown to increase throughout 
endotoxaemia, there has been no previous work comparing high and low responders (Franco 
et al., 2000).  Immunostaining has revealed that low responders produce monocytic TF and 
indeed have a higher proportion intracellularly than high responders.  Potentially, the 
difference occurs either in the cell’s response to LPS or in externalising the TF onto the cell 
membrane (Egorina et al., 2005).   
 
High responders have been associated with a higher risk of myocardial infarction (Osterud 
2002).  No work has been performed so far to investigate the role of a high response in the 
development of sepsis-associated coagulopathy.  As previously discussed, there is evidence 
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that monocytic TF expression contributes to disseminated intravascular coagulation (DIC) 
(Warr et al., 1990; Taylor et al., 1991).   
 
The difference in response may potentially help elucidate what leads an individual with sepsis 
to develop coagulopathy and allow for a personalised approach to management.  As discussed 
earlier, the use of biomarkers to stratify individuals with sepsis into different endotypes can 
predict mortality.  Scicluna et al. classified individuals with sepsis into four endotypes using 
the results from 38 previous studies that measured genetic expression in such individuals.  
One endotype was associated with an increased 28-day mortality.  A combination of genetic 
and clinical criteria as well as suggested potential biomarkers for the different genetic profiles 
were identified (Scicluna et al., 2017). 
 
4.7.4 Coagulation markers following endotoxaemia 
Three of the four markers of coagulation used to identify an increase in TF activity were 
raised between four and six hours.  This coincides with the increase in monocyte cell surface 
TF expression.  Previous work by Franco et al. has demonstrated a similar increase in TAT at 
4 hours (Franco et al., 2000).  A review of the literature has not revealed any instances of 
measurement of the other complexes during human endotoxaemia, although previous work 
has associated increased levels with thrombotic conditions (Hobbelt et al., 2017; Posma et al., 
2018). Earlier work has associated an increase in levels of FIX, FX and FXI following 
endotoxaemia.  Whilst FIX and FX were shown to peak around the 4 hour timepoint, FXI 
levels were shown to peak later at 24 hours (Reitsma et al., 2003). 
 
As previously described (see introduction 1.3.2, page 8), the contact pathway can activate FXI 
and thereby promote thrombin production.  Work in this chapter has shown a decrease in 
FXIIa-C1NH at 6 hours following LPS injection.  The in vivo activator of the FXII is yet to be 
elucidated, but it can be inhibited by both AT and C1NH.  An increase in FXIIa-AT and 
corresponding drop in FXIIa-C1NH have been associated with prothrombotic states such as 
individuals with systemic lupus erythematosus and a history of previous thromboembolic 
events.  The pathology behind this is still unclear; it has been proposed that the inhibition of 
FXII may depend on the site and mechanism of initial activation.  Incubation of FXII, plasma 
and fibrin in vitro shows an increase in FXIIa-AT but no detectable level of FXIIa-C1NH 
(Bäck et al., 2013).   
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No differences between these coagulation markers were detected between the high and low 
responder groups, although this may be due to the small sample size. 
 
A limitation of this work is the lack of direct measurement of monocyte TF activity; this was 
not possible due to the small numbers of monocytes available during the timepoints 90 
minutes and 10 hours.  All measurements performed are downstream effects and therefore 
affected by the rest of the complex coagulation system.  The human endotoxaemia model is 
known to affect much more than just TF: it alters the levels of physiological anticoagulants, 
the contact pathway and fibrinolysis (Suffredini et al., 1989; van Deventer et al., 1990; 
Franco et al., 2000; Krabbe et al., 2006). 
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4.8 Summary of key findings 
This chapter confirms the previous work by Tak et al. (2017), demonstrating the differential 
return of subsets following the profound monocytopenia post-endotoxaemia.  
 
There are two peaks in TF expression: an early peak at 90 minutes, presumably due to pre-
formed TF being externalised to the cell membrane, and a later one at 6 hours that may relate 
to an increase in TF transcription.  An increase in the coagulation markers known to be 
activated by TF was demonstrated at a timepoint that coincided with this increase in cell 
surface expression. 
 
For the first time, the TF cell surface expression on each monocyte subset has been 
documented following human endotoxaemia. There is clear distinction between high and low 




5. Chapter 5.  Investigation of Monocyte Subsets during Sepsis on the 





Sepsis-associated coagulopathy is believed to occur, in part, due to dysregulated monocyte TF 
expression (Warr et al., 1990; Taylor et al., 1991).  During sepsis, multiple studies have 
shown a change in the proportion of circulating monocyte subsets with a reduction in classical 
monocytes (Herra et al., 1996; Skrzeczynska et al., 2002; Mukherjee et al., 2015).  The 
changes in TF cell surface expression and activity between these subsets remain 
uncharacterised.   
This chapter will describe blood drawn from individuals on the ICU with a diagnosis of sepsis 
and compare features with further samples taken from those that recover.  The changes in 
monocyte subsets and their TF expression will be investigated. 
 
5.2 Research aims 
- to identify changes in the proportion of circulating monocyte subsets during sepsis and 
on recovery 
- to investigate the cell surface expression of TF between monocyte subsets during 
sepsis and on recovery 
- to investigate the monocyte-endothelial interactions during sepsis using the same in 




5.3 Demographics and clinical features of participants with sepsis  
Between June 2018 and March 2019, 28 individuals were recruited from the ICUs at NUTH 
and CHSFT (see methods section 2.11, page 91).  These included 18 with a diagnosis of 
sepsis and 10 who were critically ill without sepsis.   A 20 mL blood sample was taken on 
recruitment to the study and, in 10 participants with sepsis who recovered and consented, a 
further 20 mL blood sample was taken following recovery and on discharge from intensive 
care.  Clinical details were taken at the time of the first blood sample, including cause of 
admission to ICU, evidence for infection, co-morbidities, medication history, results of 
clinically indicated blood tests and medical observations. 
 
Sepsis was diagnosed in 18 individuals with a need for organ support and evidence of 
infection.  This evidence included pathogens grown from blood cultures, bronchoalveolar 
lavage or evidence of deep-seated infection such as microbiological samples from an 
abdominal abscess or a surgical wound site.  The evidence for diagnosing sepsis, for each 
participant, is summarised in table 5.1. 
 
The remaining 10 critically ill individuals fit the same criteria for organ support but did not 
have a diagnosis of sepsis.  Most had no evidence microbiological evidence of infection.  
Participant 8 was found to have Haemophilus influenzae on sputum culture but not on 
bronchoalveolar lavage (BAL).  Participant 9 had E. coli grown in a urine culture that was 
believed to be a contaminant and was not treated.  The cause of ICU admission and the organ 
support required by this group are detailed in table 5.2. 
Both the critically ill cohort and the cohort with a diagnosis of sepsis were evenly matched.  
There was no statistically significant in age, sex, length of ICU stays prior recruitment to 
study, type or organ support required, APACHE II or SOFA score and survival to ICU 
discharge (see table 5.3). 
 
White blood cell counts, coagulation markers and platelet counts were similar between both 
cohorts (see Figure 5.1).  Twelve (67 %) individuals in the sepsis cohort and six (60 %) in the 
critically ill had a high white cell count, composed primarily of neutrophils.  Coagulopathy 
was defined as a platelet count below 150 X 109/L, prothrombin time (PT) above 15 sec 
(reference range 10-15 sec), activated partial thromboplastin time (APTT) above 35 sec 
(reference range 25-35 sec), or fibrinogen below 1.5 g/L (reference range 2.1-4.8 g/L).  
Coagulopathy was evident in 7 individuals (39 %) from the sepsis cohort and 7 (70 %) 
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individuals from the critically ill cohort (this was not statistically significant using Fisher’s 
exact test, p=0.24). 
 
Prognostic scores were calculated for both cohorts, APACHE II at the time of admission to 
ICU and SOFA at the time the first study blood sample was taken (see Figure 5.2).  The 
median APACHE II score for this cohort was 27, which has previously been associated with a 
mortality rate of 55 % in medical patients (Knaus et al., 1985).  More recent work has 
demonstrated that this mortality rate is now likely to be lower due to advances in the care of 
critically ill patients (Sadaka et al., 2017). 
The median SOFA score, measured at the time the first blood sample was taken, was 9, which 
was previously associated with an in-hospital mortality of 33 % (Vincent et al., 1996).  More 
recent work has shown the SOFA score remains a useful predictor (Innocenti et al., 2018). 
 
Most individuals with sepsis survived to leave the ICU (n=14, 78%); of these, 10 consented to 
have further blood taken following their discharge from critical care, the other 4 declined a 





    Organ support  
No. Source of sepsis Microbiological evidence Radiological evidence IV NIV IN     RRT 
1 Ischaemic bowel 
Klebsiella pneumoniae and 
Enterobacter cloacae from 
wound  
Ischaemic bowel on 
CT abdomen y   y   
2 Respiratory Influenza A PCR positive 
Right-sided 
consolidation seen on 
CXR 
y     y 
3 Intra-abdominal abscess 
Enterococcus faecium from 
blood culture 
CT abdomen showed 






Escherichia coli from 
abdominal drain fluid 
Multiple abdominal 
collections on CT 
abdomen 
y       
5 Perforated bowel 
Enterococcus faecium from 
drain fluid 
CT abdomen showed 
proximal transverse 
colon perforation 
y     y 
6 Perforated gastric conduit 
Escherichia coli from 
abdominal drain fluid none y     y 
7 Respiratory Escherichia coli from blood and bronchoalveolar lavage 
Multi-focal 
consolidation on CT 
thorax 





Proteus mirabilis from 





Gram-negative rods from 
ascitic fluid, failed to grow on 
subculture 
none y   y y 
10 Renal  Escherichia coli from blood  CT abdomen showed pyelonephritis     y   
11 Cellulitis 
Group A Streptococcus and 
Staphylococcus aureus from 
wound 
none y       
12 Ruptured oesophagus 
Lactobacillus gasseri, 
Lactobacillus fermentum, 
Streptococcus salivarius and 
Streptococcus parasanguinis 
from sputum  
Loculated pleural 
effusion seen on CT 
thorax 
y       
13 Ruptured oesophagus 
Haemophilus influenzae from 
sputum  
CT thorax showed 
consolidation and 
collection 
y   y   
14 Respiratory  Escherichia coli from bronchoalveolar lavage 
Bibasal consolidation 
on CT thorax y       
15 Respiratory Influenza A PCR positive 
CXR showed bilateral 
infiltrates and 
consolidation 
y   y y 
16 Respiratory  
Escherichia coli from blood 
and bronchoalveolar lavage, 
Candida albicans from 
bronchoalveolar lavage 
Right-sided 
consolidation on CXR       y 
17 Respiratory Influenza A PCR positive Extensive bilateral consolidation on CXR y   y   
18 Respiratory  
Serratia marcescens from 
blood and Proteus mirabilis 
from sputum  
Consolidation and 
atelectasis on CXR y       
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Table 5.1 Diagnosis of sepsis 
This table details the source and evidence of infection as well as the organ support required 
by all individuals with sepsis (n=18).  Microbiological and radiological data were gathered 
at recruitment to the study.  (CT – computerised tomography, CXR – chest radiograph, IV – 
invasive ventilation, NIV – non-invasive ventilation, IN – required inotropes or vasopressor 




    Organ support  




evidence IV NIV IN     RRT 
1 Post craniotomy for brain tumour nil nil y       
2 Head and bowel trauma nil 
CT showed 
free fluid and 
air in bowel 
wall 
y       
3 Type I respiratory failure nil 
Bilateral 
consolidation 
on chest CXR 
  y     
4 Acute hepatic failure nil nil y   y   
5 
Cardiac arrest post 
abdominal aortic 
aneurysm repair 
nil nil y   y y 
6 








on chest CXR 


















on chest CXR 




type I respiratory 
failure 
E. coli in urine 
culture 
CXR showed 
lobar collapse  y       
10 
Type I respiratory 
failure secondary 




on chest CXR 








Table 5.2 Clinical details of critically ill cohort 
This table details the source and evidence of infection as well as the organ support required 
by all individuals with critical illness who did not meet the criteria for sepsis (n=10).  
Microbiological and radiological data were gathered at recruitment to the study. 
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  Sepsis Critically ill 
Age (years) 66 (38-77) 58.5 (30-70) 
Male 12 (67 %) 7 (70 %) 
Length of stay (days) 7.5 (1-31) 5.5 (1-17) 
Invasive ventilation 15 (83 %) 8 (80 %) 
Non-invasive ventilation 1 (5 %) 1 (10 %) 
Use of inotropes or vasopressors 8 (44 %) 4 (40 %) 
Renal replacement therapy 7 (39 %) 3 (30 %) 
APACHE II score 27 (15-45) 26.5 (9-40) 
SOFA score 9 (3-16) 7 (4-14) 
Survived until ICU discharge 14 (78 %) 4 (40 %) 
 
Table 5.3 Comparison of critically ill cohort to the cohort with a diagnosis of sepsis 
This table compares the demographics, length of ICU stays (prior to recruitment into the 
study), organ support requirements, prognostic scores and survival of both cohorts.  SOFA 
scores were calculated at the time of the first blood sample; one critically ill individual and 
seven individuals with sepsis did not have a SOFA score calculated due to a lack of bilirubin 
measurement on that occasion.  There were no statistically significant differences.  Fisher’s 
exact test was used to compare male sex, invasive ventilation, non-invasive ventilation, use of 
inotropes or vasopressors, renal replacement therapy and survival.  The unpaired t-test was 








White blood cell counts (WBC), platelet count, PT, APTT and derived fibrinogen levels were 
measured in the hospital laboratories using a Sysmex XN-9000TM (Sysmex, Milton Keynes, 
UK) and ACL Top® 700 (Beckman Coulter, High Wycombe, UK) analysers.  All levels were 
taken from clinically indicated samples obtained on the day of recruitment to the study.  A 
shows the total white cell count and the individual neutrophil, monocyte and lymphocyte 
counts for the critically ill (n=10) and septic cohorts (n=18).  B shows the PT, APTT, derived 
fibrinogen and platelet count in the critically ill cohort (n=10; one participant was excluded 
from the APTT figure as they were receiving a heparin infusion at the time of sampling) and 
septic cohort (n=18; 3 values were excluded from the APTT figure because these individuals 
were receiving therapeutic level heparin at the time of sampling).  The red dashed line marks 
the upper limit of the reference range of that marker, whilst the blue dashed line marks the 
lower limit.  Error bars represent the median values and interquartile ranges.  There were no 
statistically significant differences between the cohorts for any marker.  Significance was 
calculated using the Mann-Whitney U test (WBC: p=0.91, neutrophils: p=0.91, lymphocytes: 








APACHE II score was based on information from the first 24 hours of ICU admission, SOFA 
score was calculated using information at the time of the first blood sample.  A shows the 
APACHE II scores for the individuals with sepsis (n=18) and critical illness (n=10).  The 
blue bar represents the participants that were post-operative.  Percentages denote the 
mortality rate associated with each APACHE II score (Knaus et al., 1985).  B shows the 
SOFA score for the sepsis and critically ill cohorts.  Eight participants were excluded from 
the SOFA figure as a score could not be calculated (a bilirubin level had not been measured 
on the day of the first study blood sample), seven were from the sepsis cohort and one from 
the critically ill cohort. The percentages denote the mortality rates associated with that level 
of SOFA score (Vincent et al., 1996).  There was no statistical difference between the cohorts 
(APACHE II score: p=0.98, SOFA score: p=0.81 using the unpaired t-test). 
 
Figure 5.2 Prognostic scores for the septic and the critically ill cohorts 
 177 
5.4 Monocyte subsets during sepsis, compared to those in health and those in the 
recovery after sepsis 
As described previously, 100 µL of whole blood was taken from healthy controls (n=13), 
individuals with sepsis (n=18) and the subset of individuals who recovered from sepsis and 
consented to a further blood sample (n=10).  Flow cytometry was performed using a BD 
Trucount™ tube to allow the calculation of absolute values (see methodology section 2.6.1, 
page 72). 
 
There was no statistically significant difference between the absolute monocyte count of the 
critically ill cohort, the sepsis cohort and the recovery samples of individuals with sepsis 
(Figure 5.3).   
 
Flow cytometry was used to identify the proportions of monocyte subsets during sepsis, and 
these were compared against the critically ill cohort or blood samples taken on recovery 
(figures 5.4 and 5.5).  Both the proportion of subsets and the absolute monocyte counts were 




Whole blood flow cytometry and Trucount™ absolute counting tubes were used to measure 
the absolute monocyte counts in whole blood. Error bars represent median values and 
interquartile ranges.  A compares the total number of monocytes between the critically ill 
cohort (n=10) and individuals with sepsis (n=18).  There was no statistically significant 
difference between the cohorts (p=0.65 by the Mann-Whitney U test).  B compares the 
absolute monocyte counts between blood samples taken during sepsis with a sample following 
recovery (n=10).  There was no statistically significant difference between individuals with 
sepsis and then on recovery (p=0.77 by the Wilcoxon matched-pairs signed rank test).  The 
red dashed line marks the upper limit of the reference range of that marker, whilst the blue 
dashed line marks the lower limit. The reference range is based on 13 independent healthy 
controls and defined as two standard deviations either side of the mean.   









Whole blood flow cytometry with Trucount™ absolute counting tubes were used to identify 
the counts of classical, intermediate and non-classical monocytes.  The error bars represent 
the median value and inter-quartile range.  A compares the percentage of monocyte subsets 
between the critically ill cohort (n=10) and the sepsis cohort (n=18). There were no 
statistically significant differences between the cohorts (classical: p=0.38, intermediate: 
p=0.87, non-classical: p=0.27 by the Mann-Whitney test).  B compares the absolute 
monocyte subset counts between the critically ill cohort (n=10) and the sepsis cohort (n=18).  
There were no statistically significant differences between the cohorts (classical: p=0.76, 
intermediate: p=0.87, non-classical: p=0.49 by the Mann-Whitney test).  The red dashed line 
marks the upper limit of the reference range of that marker, whilst the blue dashed line marks 
the lower limit. The reference range is based on 13 independent healthy controls and defined 
















Whole blood flow cytometry with Trucount™ absolute counting tubes were used to identify 
the absolute counts of classical, intermediate and non-classical monocytes.  The error bars 
represent the median value and inter-quartile range.  A compares the percentage of monocyte 
subsets between paired samples of individuals with sepsis and the same individuals on 
recovery and discharge from ICU (n=10).  There were no statistically significant differences 
between the cohorts (classical: p=0.56, intermediate: p=0.43, non-classical: p=0.70 by the 
Wilcoxon matched-pairs signed rank test).  B compares the absolute monocyte subset counts 
between paired samples of individuals with sepsis and the same individuals on recovery and 
discharge from ICU (n=10).  There were no statistically significant differences between the 
cohorts (classical: p=0.70, intermediate: p=0.32, non-classical: p=0.92 by the Wilcoxon 
matched-pairs signed rank test).   
  
Figure 5.5 The proportions of monocyte subsets during sepsis and following recovery 
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5.5 TF expression non-septic critical illness, sepsis and recovery from sepsis 
Whole blood flow cytometry, as previously described, was performed to identify monocytic 
TF expression.  The gating of TF-positive events is demonstrated in Figure 5.6 and used 
fluorescence minus one (FMO) controls.  
 
There was no statistically significant difference between the percentages of monocytes 
expressing TF between the critically ill and sepsis cohorts. Considering the patients who had 
sepsis, there was an increase in the proportion of TF-expressing monocytes in recovery 
samples (Figure 5.6).   
 
TF expression was also considered on monocyte subsets.  Individuals with sepsis had a higher 
percentage of TF-positive intermediate and non-classical monocytes when compared to 
critically ill individuals without sepsis.  Classical monocytes were shown to have a higher 
percentage of TF-expressing cells following recovery from sepsis.  There were no differences 
in the proportion of monocytes expressing TF in either the intermediate or non-classical 
subsets (Figure 5.7). 
 
There was no difference between total monocyte TF expression between individuals with 




Figure 5.6 Monocyte tissue factor expression increases following recovery from sepsis 
Whole blood flow cytometry was used to identify the percentage of total monocytes that 
expressed cell surface TF.  Error bars represent median values and the interquartile ranges.  
A shows a representative example of the flow gating used to identify TF-positive monocytes. 
The black gate shows positive events, whereas the red gate shows negative events, as 
demonstrated with the TF FMO.  B compares the percentage of TF-positive monocytes in the 
critically ill (n=10) and sepsis cohorts (n=18).  There was no statistical difference (p=0.09 
using Mann-Whitney test).  C compares the percentage of TF-positive monocytes between 
individuals with sepsis and the same individuals following recovery discharge from ICU 
(n=10).  The percentage of TF-positive monocytes increased following recovery from sepsis 
(p<0.01 using the Wilcoxon matched-pairs signed rank test).  
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Whole blood flow cytometry was used to identify the percentage of total monocytes that 
expressed cell surface TF.  Error bars represent median values and the interquartile ranges.  
A compares the percentage of TF-positive monocyte subsets of the critically ill (n=10) and 
sepsis cohorts (n=18).  There was no statistically significant difference between the classical 
subset, but the intermediate and non-classical subset showed higher percentages of TF in the 
sepsis cohort (classical: p=0.40, intermediate: **** – p<0.0001, non-classical: p<0.05 using 
the Mann-Whitney test).  B compares the percentage of TF-positive monocytes in individuals 
with sepsis and following their recovery (n=10).  The classical subset showed an increased 
percentage of TF-positive cells on recovery; there were no significant differences in the 
intermediate and non-classical subsets (classical: ** – p<0.01, intermediate: p=0.11, non-





Figure 5.7 Classical monocyte TF expression increases with recovery from sepsis 
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This figure shows the percentage of TF-positive monocytes in individuals with sepsis and 
evidence of coagulopathy,those with sepsis but no coagulopathy (n=8), individuals without 
sepsis and coagulopathy (n=7) and those without sepsis and no coagulopathy (n=3).  Three 
individuals with sepsis were excluded from this analysis because they received therapeutic 
levels of anticoagulation.  Coagulopathy was defined as platelet count below 150 x 109/L, PT 
above 15 sec, APTT above 35 sec or fibrinogen below 1.5 g/L.  The error bars represent the 
median value and interquartile range.   Red points show data from coagulopathic samples 
whilst black points show non-coagulopathic.  There was no significant difference between the 
cohorts (p=0.38 using the Mann-Whitney test). 
  
Figure 5.8 No change in the percentage of TF-positive monocytes between individuals 
with coagulopathy and individuals without coagulopathy 
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5.6 Monocyte-endothelial cell co-cultures 
The in vitro model of monocyte-endothelial cell interactions described in chapter 3 (see 
section 3.4, page 122) was repeated with PBMCs from healthy volunteers and individuals 
with sepsis.  Using Ficoll-Paque™ density gradient separation, PBMCs were isolated from 
whole blood samples.  Due to the smaller volume of blood received from individuals with 
sepsis compared to that available from healthy volunteers (20 mL compared to 80 mL) it was 
not possible to conduct FACS on sufficient monocytes for co-culture.  PBMCs were therefore 
used to repeat the co-culture experiments. 
 
They were cultured for 24-hours with PMVEC cells in PMVEC medium.  Some PMVECs 
were pre-treated with LPS (100 ng/mL) for one hour; the LPS was then washed off and 
PBMCs were added to the culture.  Some PBMCs were stimulated by the addition of LPS (10 
ng/mL); this LPS was not washed off (see methodology section 2.7.2, page 82). These 
conditions were set up in a 24-well plate as shown in Figure 5.9. 
 
PBMCs from healthy controls were isolated, again using Ficoll-Paque™ density gradient 
separation, on each day a co-culture was set up.  This allowed for a comparison of PBMCs 
from healthy controls and individuals with sepsis. 
 
This experiment was performed only four times due to the availability of PMVECs and 
PBMCs from a septic sample.  There were no statistically significant changes.  A trend 
towards an increase in the proportion of classical monocytes (with a corresponding decrease 
in the intermediate and nonclassical monocyte subsets) was seen in co-cultures using PBMCs 
from healthy volunteers (Figure 5.10).  This is comparable to the co-cultures described with 
healthy blood samples in Chapter 3 (see figure 3.14).   
 
When PBMCs from individuals with sepsis were used, no clear trend for the classical subset 
to increase with co-culture was seen (figure 5.10).  The intermediate subset from individuals 
with sepsis showed a statistically non-significant increase with co-culture, in contrast to the 
pattern observed using PBMC samples from healthy volunteers.  Although the non-classical 
subset appeared to change in a similar way between both healthy and sepsis samples, the 
classical and intermediate subsets appear to vary between the two groups (figure 5.10). 
However, this work would need to be extended before any conclusions could be drawn.  In 
particular the proportion of monocytes recovered from culture would need increased. 
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Although the healthy PBMCs tended towards an increase in the classical subset with co-
culture (as previously shown; see section 3.4, page 122), this was not seen when using 
PBMCs from patients with sepsis (figure 5.10).  No change in TF expression was seen when 
comparing isolated monocyte subsets from individuals with sepsis or healthy controls, after 
PBMCs had been co-cultured with PMVECs (figure 5.11).   
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 1 2 3 4 
A PBHV PBHV PBHV + L PBHV + L 
B PBHV /PM PBHV /PM PBHV /PM+L PBHV /PM+L 
C PM PM PM+L PM+L 
D PBS PBS PBS + L PBS + L 
E PBS /PM PBS /PM PBS /PM+L PBS /PM+L 
 
 
Figure 5.9 Co-culture plate set-up 
This figure depicts the set-up of a 24-well plate for a co-culture experiment of PMVECs and 
PBMCs.  LPS (100 ng/mL) was added to PMVECs and washed off after 1 hour, prior to the 
addition of PBMCs.  LPS (10 ng/mL) was added to PBMCs and not removed.  Co-culture 
were incubated at 37 ⁰C and 5 % CO2 for 24 hours.  Following this, PBMCs were harvested, 
and flow cytometry used to measure the monocyte subset proportions and the percentage of 
TF-positive monocytes.  
  
Abbreviation Meaning 
PBHV PBMC from healthy volunteer 
PBS PBMC from individual with sepsis 
PM Human pulmonary microvascular endothelial cell (PMVEC) 







PBMCs were isolated using Ficoll-Paque™ density gradient separation using samples from 
healthy volunteers and individuals with sepsis.  A proportion of PMVECs were stimulated 
with 100 ng/mL of LPS for 1 hour; the LPS was washed off prior to the addition of the 
PBMCs.  Some PBMCs were cultured alone with 10 ng/mL LPS: in contrast to the PMVEC 
stimulation, the LPS was not removed but remained there for the duration of culture.  
Following a 24-hour incubation, the proportions of monocyte subsets were measured using 
flow cytometry.  This figure shows the results of 4 independent experiments. Error bars 
represent median values and the interquartile range.  There were no statistically significant 
differences between the coculture conditions using Friedman’s test (classical healthy: 
p=0.13, intermediate healthy: p=0.13, non-classical healthy: p=0.07, classical sepsis: 
p=0.93, intermediate sepsis: p>0.99, non-classical sepsis: p=0.07).
Figure 5.10 Comparing monocyte subsets following endothelial cell co-culture using 




PBMCs were isolated using Ficoll-Paque™ density gradient separation using samples from 
healthy volunteers and individuals with sepsis.  A proportion of PMVECs were stimulated 
with 100 ng/mL of LPS for 1 hour; the LPS was washed off prior to the addition of the 
PBMCs.  Some PBMCs were cultured alone with 10 ng/mL LPS: in contrast to the PMVEC 
stimulation, the LPS was not removed but remained there for the duration of culture.  
Following a 24-hour incubation, the percentage of TF-positive monocytes were measured 
using flow cytometry.  This figure shows the results of 4 independent experiments: one sample 
was excluded from the intermediate and non-classical subset as there was too few monocytes 
to accurately gate the TF-positive events. Bars represent median values and error bars the 
upper quartile.  There were no statistically significant differences between the co-culture 
conditions using Friedman’s test (classical healthy: p=0.43, intermediate healthy: p=0.19, 
non-classical healthy: p=0.94, classical sepsis: p=0.93, intermediate sepsis: p=0.19, non-
classical sepsis: p=0.94).  
Figure 5.11 TF expression in monocyte subsets following PMVEC co-culture of 
PBMCs from healthy volunteers and patients with sepsis 
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5.7 Discussion 
5.7.1 The population of individuals with sepsis is similar to previously described cohorts. 
The cohort of individuals with sepsis were severely ill as demonstrated by a median APACHE 
II score of 27 (calculated using information from their first 24 hours in ICU) and a median 
SOFA score of 9 (on the day of the first blood sample following recruitment to the study).  
The use of these is scores is limited by the change in ICU care that has occurred since they 
were first designed.  Recent work shows that although the predicted mortality rates may not 
be as accurate, comparing APACHE II predictions and actual hospital mortality rates 
demonstrate that the score is still a good discriminator of disease severity and risk of 
mortality.  This was particularly true in regard to individuals with sepsis (Godinjak et al., 
2016; Sadaka et al., 2017).  
 
Similar work has also demonstrated that the SOFA score remains a good predictor of 
mortality following sepsis (Innocenti et al., 2018).  A limitation of this study was the 
measurement of the SOFA score on a single occasion.  A retrospective review of more than 
180,000 adults on an ICU with an infection has shown that an increase in SOFA of more than 
two points is a good predictor of mortality (Raith et al., 2017).  The SOFA score was initially 
created to be performed daily, not as a predictor of mortality but as a way of monitoring organ 
failure over time (Vincent et al., 1996).  With regard to this work, a higher score is related to 
a more severe degree of organ failure, and it remains a useful way of describing the critically 
ill and sepsis cohorts. 
 
Of this cohort, 22% did not survive to be discharged from the ICU.  This is similar to other 
larger scale studies (Fleischmann et al., 2016; Meyer et al., 2018). 
 
To ensure a diagnosis of sepsis, all patients had evidence of infection on microbiological 
culture and a need for organ support.  This is based on the most recent international definition 
of sepsis (Singer et al., 2016). 
 
Coagulopathy was present in 39% of this cohort (7 individuals).  This is in keeping with 
previous studies that have documented coagulopathy in between 30 and 75% of sepsis cases 
(Gando et al., 2016).   
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5.7.2 Change in monocyte subset during sepsis 
Multiple studies have shown an increase in either intermediate or non-classical monocytes 
associated with sepsis (Herra et al., 1996; Skrzeczynska et al., 2002; Mukherjee et al., 2015). 
The work presented here, however, showed no statistically significant difference, although 
there was perhaps a trend towards an increase in the non-classical subset.  Reasons for this 
difference seem likely to be explained, at least in part, by the heterogeneous nature of sepsis 
and the variation in flow cytometry gating between users.  Mukherjee et al., for example, 
selected only HLA-DR positive cells; previous work has shown a decrease in monocytic 
HLA-DR expression is seen in some individuals with sepsis (Drewry et al., 2018).   
 
5.7.3 TF expression during sepsis and recovery 
Previous work has demonstrated an increase in TF activity on isolated monocytes from 16 
individuals with meningococcal infection with higher levels associated with a worse 
prognosis (Osterud and Flaegstad, 1983). The samples, however, were frozen and thawed 
prior to testing.  Work performed by Maynard et al. demonstrated that the freeze-thaw cycle 
can de-crypt TF on monocytes and increase activity.  It is therefore difficult to draw any 
definite conclusions about TF activity and sepsis (Maynard et al., 1975; Osterud and 
Flaegstad, 1983).   
 
Animal models have provided some further insight, showing improved survival in a septic 
model if a monoclonal Ab to TF was given.  Monocytic TF was not investigated (Warr et al., 
1990; Taylor et al., 1991). 
 
Measurement of TF in plasma from individuals with sepsis has also been shown to be raised 
and to be particularly high in those meeting the criteria for DIC (Gando et al., 1998). 
 
Vickers et al. have previously investigated the proportion of monocytes expressing TF during 
sepsis.  They showed an increase in the TF expression of CD14 positive monocytes in 
individuals with a diagnosis of sepsis compared to those who were critically ill but did not 
have a sepsis diagnosis. Individuals on the critical care unit were screened for signs of sepsis 
according to the criteria at that time.  Participants were recruited to the study as soon as they 
reached the criteria for sepsis, and blood samples were taken within 12 hours of recruitment 
(Bone et al., 1992; Vickers et al., 1998). The work presented in this chapter supports these 
findings, with an increase in TF expression in those with sepsis when compared to critically 
ill individuals without sepsis.  These data have also shown an increase in the proportion of 
 199 
classical monocytes expressing TF following recovery from sepsis.  This has not previously 
been reported and warrants further investigation.   
 
Potentially, this prolonged change in monocytic TF expression could be an example of 
monocyte innate training (see section 1.4.8, page 36).  Previous work has demonstrated a 
change in monocyte phenotype to up to 12 months following infection (Kleinnijenhuis et al., 
2014).  Although there has been measurement of monocyte TF expression following innate 
training, there is evidence to suggest that it can promote atherosclerosis.  The Apolipoprotein 
E knockout murine model is used to study atherosclerosis.   Murine monocytes previously 
stimulated with low-dose LPS were adoptively transferred to the knockout model; using 
monocyte controls incubated with PBS, the LPS-trained monocytes were associated with an 
increase in atherosclerotic plaques (Geng et al., 2016). 
 
The percentage of monocytes expressing TF is similar to that shown following the human 
endotoxaemia model but again it is lower than that seen with in vitro work.  As discussed 
earlier, this may be related to the margination of monocytes or activation of monocytes during 
the in vitro experiments. 
 
5.7.4 Co-cultures of PMVECs and PBMCs from individuals with sepsis 
A repeat of the PMVEC co-cultures with PBMCs from healthy controls or patients with 
sepsis showed no statistically significant changes between monocyte behaviour between the 
two groups.  PBMCs isolated from healthy volunteers, however, did appear to follow the 
same trend as previously described in chapter 4, with an increase in the classical monocyte 
subset following co-culture with and without LPS (see section 3.4, page 122).  PBMCs 
isolated from individuals with sepsis did not follow this trend.  Interestingly, the intermediate 
monocyte subset appeared to increase following co-culture with PBMCs from an individual 
with sepsis and LPS-pre-treated PMVECs.   
 
With regard to monocytic TF expression following co-culture, again no statistically 
significant changes were seen.  Again, the PBMCs from healthy controls appeared to follow 
the trend seen previously, with TF expression increasing following co-culture.  No such trend 
was seen in the co-culture of PBMCs from individuals with sepsis.   
 





The percentage of monocytes expressing TF within each monocyte subset varies across 
critical illness, sepsis and recovery from sepsis.  To understand the implications this could 
have on the development of sepsis-associated coagulopathy, further work is needed to 
measure monocyte TF expression and activity sequentially from the diagnosis of sepsis and 











Sepsis-associated coagulopathy complicates a significant proportion of sepsis cases and is 
associated with worse outcomes (Gando et al., 2016; Levi and van der Poll, 2017).  To 
improve the situation, a better understanding of the pathophysiology is needed.  TF is the 
most important in vivo initiator of coagulation.  This work aimed to review the monocytic 
expression of TF and investigate its potential to contribute to the coagulopathy of sepsis. 
 
Monocyte subsets have been shown to vary with sepsis. Multiple groups have demonstrated 
an increase in either the intermediate or non-classical monocyte subsets during sepsis (Herra 
et al., 1996; Zielger-Heitbrock, 1996; Skrzeczynska et al., 2002; Mukherjee et al., 2015).  
There are a paucity of data examining monocytic TF expression during sepsis, particularly 
with regard to the monocyte subsets (Vickers et al., 1998).  Comparison of monocyte subsets 
following an IL-33 stimulus demonstrated a variable ability to express TF (Stojkovic et al., 
2017).  No work had previously been performed to investigate the TF response on monocyte 
subsets to LPS or during the model of human endotoxaemia. 
 
This project hypothesised: 
1. The classical monocyte subset predominates in the circulation during health.  This 
subset expresses a low level of cell surface TF, which shows little activity.   
 
2. Following infection, there is an increase in the cell surface expression of TF and an 
increase in its activity.   
 
3. Interaction between monocytes and the endothelium allows a local low-level 
activation of coagulation. 
 
4. During sepsis, there is a decrease in the proportion of circulating classical monocytes 
and an increase in the proportion of non-classical.  Non-classical monocytes, when 
compared to the other monocyte subsets, express higher levels of TF, leading to a 
more pro-coagulant response and predisposing to sepsis-associated coagulopathy. 
 
6.2 The cell surface expression of TF varies between monocyte subsets 
The initial results chapter examined the effect of an LPS stimulus on human monocyte subsets 
in vitro.  For the first time, the monocyte subsets have been shown to express different levels 
of TF in response to LPS.   My starting hypothesis was refuted, with classical and 
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intermediate subsets expressing the most TF and the no clear difference in TF activity 
between the subsets. 
 
The majority of monocyte TF is known to be inactive or ‘encrypted’.  How it becomes 
‘decrypted’ is yet to be elucidated.  The discrepancy between TF surface expression and 
activity of the subsets suggests that there may be different levels of encryption between the 
subsets. 
 
The mechanism by which monocytic surface expression of TF is not fully understood.  Future 
analysis of both the transcriptome and proteome following LPS stimulation is needed.  
 
To address the third part of the hypothesis, co-cultures of monocytes and PMVECs were used.  
Monocyte-endothelial interactions do appear to promote coagulation.  Monocytes were 
induced to express TF when cultured with endothelium, even without the presence of LPS.  
This effect was not dependent on cellular contact.  Further work is needed to investigate what 
could be mediating this increase in TF.  The use of monocyte-endothelial co-cultures limits 
the ability to identify fully the activation of coagulation.  Although an increase in cell surface 
TF may lead to an increase in coagulation, the creation of fibrin could not be measured in this 
model.  
 
Co-culture was shown to alter the endothelial fibrinolytic response.  Although tPA was 
unchanged, there was an increase in the expression of PAI-1, an inhibitor of fibrinolysis, 
following culture. 
 
Together this work suggests that monocytes can influence not just the initiation of coagulation 
but the fibrinolytic response.  Increasingly, the innate immune and coagulation systems have 
been shown to work cooperatively to help fight infection (Engelmann and Massberg, 2013).  
This work suggests that monocytes could be central to such cooperation. 
 
6.3 Monocytic TF expression occurs early and transiently following exposure to 
endotoxaemia 
To examine the temporal nature of monocytic TF expression, the human endotoxaemia model 
was used.  Monocytes were shown to increase expression of TF between 90 minutes and 6 
hours.  Previous studies of the endotoxaemia model have shown an increase in TF mRNA 
from 4 hours following LPS, but the earlier response seen in this project suggests that there is 
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preformed TF intracellularly capable of externalising to the cell membrane (Franco et al., 
2000). 
 
The human endotoxaemia model causes a transient increase in monocyte TF expression.  As 
mentioned previously, endotoxaemia is a model of systemic inflammation and does not 
recapitulate all the features of sepsis.  Sepsis is not caused by a single insult or virulence 
factor.  Further work is needed to examine whether monocyte TF expression is indeed 
transient during the development of sepsis. 
 
This project supports work from other groups who identified two phenotypes for monocyte 
TF expression after administration of LPS, those with a high and those with a low response.  
Very little is understood about this response or what effect it could have functionally, 
although high responders have been previously associated with an increased risk of 
myocardial infarction (Ossterud, 1995).  Previously this difference in response has been 
examined on the monocyte population as a whole.  My work has demonstrated that the change 
in response is consistent across all monocyte subsets.  Future work should investigate whether 
those with a high response are at a higher risk of thrombosis or the development of sepsis-
associated coagulopathy.   The possibility of identifying those at higher risk of sepsis-
associated coagulopathy could allow for more tailored treatments. 
 
6.4 Monocytic TF expression varies during sepsis and recovery 
To understand monocytic TF during sepsis better, blood samples were taken from individuals 
on the critical care unit with a diagnosis of sepsis and, where available, a repeat sample was 
taken when they recovered sufficiently to leave the critical care.  Finding an appropriate 
control for participants who are critically ill with a diagnosis of sepsis is challenging because 
of the heterogeneous aetiologies of sepsis.  This problem is compounded by the known 
variation between individuals, with regard to monocytic TF expression.  For this reason, the 
use of recovery samples was a useful control. 
 
Confirming previous work, monocytes were shown to express higher levels of monocyte TF 
during sepsis when compared to individuals who were critically ill and did not meet the 
criteria for sepsis (Vickers et al., 1998).  This work has demonstrated that this increase in the 
cell surface expression of TF occurs within the intermediate and non-classical subsets.  Both 
subsets have been shown to be increased during sepsis (Fingerle et al., 1993; Herra et al., 
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1996; Skrzeczynska et al., 2002; Ziegler-Heitbrock, 2007).  Potentially this could contribute 
to the coagulopathy associated with sepsis and certainly warrants further investigation.   
 
Another intriguing finding of this project was the increase in classical monocyte TF following 
recovery from sepsis which again has not previously been documented. Most sepsis studies 
have considered morbidity and mortality only for the first 30 days following diagnosis.  
Increasingly there is evidence that the risk of poor outcomes continues for much longer in 
survivors of sepsis.  A systematic review of studies investigating the long-term effects showed 
an increase in mortality for up two years following the sepsis episode (Winters et al., 2010).  
The ongoing thrombotic risk following an episode of sepsis has not been measured.  
Investigations into monocyte innate training have demonstrated an increase in the release of 
pro-inflammatory cytokines up to 12 months following infection (Kleinnijenhuis et al., 2014), 
see section 1.4.8, page 36).  Further work should investigate how long this increase in 
classical monocyte TF expression continues and its possible consequences for the individual.  
As discussed earlier (see section 1.3.4, page 16), there is a complex interplay between 
coagulation and innate immunity.  It is hypothesised that sepsis-associated coagulopathy is a 
consequence of dysregulated thromboinflammation, predisposing individuals with sepsis to 
both DIC and secondary infections (Levi et al., 1993; Levi and van der Poll, 2010; Levi and 
van der Poll, 2017).  Changes in the monocyte phenotype are able to affect not only the 
immune response but also the coagulation system.   This could explain some of the longer-
term morbidity and mortality associated with survivors of sepsis. 
 
6.5 Summary of monocytic TF expression 
This work has increased our knowledge of monocytic TF.  It has shown that TF varies 
between monocyte subsets in terms of both expression and activity.  Following systemic 
inflammation, exemplified by the human endotoxaemia model, TF expression increases in all 
monocyte subsets and does so early, supporting the idea that it is preformed intracellularly 
and moves to the membrane.  There is a change in TF expression on monocytes during sepsis, 
with the highest levels being found on the intermediate and non-classical subsets.  Monocytic 
cell surface TF expression has been shown to be higher during critical illness with sepsis than 
in critical illness without sepsis, and to increase on the classical monocyte subset upon 







This figure summarises the changes in TF expression on monocyte subsets.  The critically ill 
population, without a diagnosis of sepsis, show a relative decrease in TF expression on the 
intermediate and non-classical subsets.  During sepsis, TF expression on the intermediate 
and non-classical monocyte subsets is higher than during critical illness without sepsis.  
Following recovery from sepsis, TF on classical monocytes is raised above levels seen during 
health. The thicker red outline represents the increase in TF.  (CL – classical, IN – 
intermediate, NC – nonclassical).  
Figure 6.1 The changes in monocyte subset TF expression in different conditions 
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6.5 Strengths  
This work has led to many new insights.  Prior to this work there had been no comparison of 
monocyte subset TF expression following LPS stimulation, although there is significant 
evidence to support a change in the circulating subsets during sepsis (Herra et al., 1996; 
Skrzeczynska et al., 2002; Mukherjee et al., 2015). 
 
The use of animal models to understand the pathophysiology of sepsis has failed to translate 
into benefit for patients with sepsis (Fink, 2014).  This work has avoided the use of such 
models by using human cells, samples from individuals with a diagnosis of sepsis and the 
human endotoxaemia model (which allowed for the temporal investigation of monocyte TF 
expression).  In particular, this allowed an assessment of the high and low monocyte TF 
responder phenotype over time (Ossterud, 1995). 
 
The use of these three approaches has also allowed for a direct comparison of monocyte TF 
expression using the same flow cytometry panel run by a single investigator.  Inter-user and 
inter-panel variability were therefore controlled for, minimising problems frequently 
encountered with regard to flow cytometry studies as a whole, but particularly in measuring 
TF cell surface expression.  
 
As discussed earlier, choosing a suitable control for individuals with sepsis is challenging.  A 
strength of this work was to use not just samples from the same individuals following 




There are also some important limitations of this work.  Firstly, TF is only a small part of a 
much larger and complex process of coagulation that leads to the production of fibrin.  This 
project is focussed on only a small part of this system.  The initial response to TF is tempered 
by multiple downstream effects, especially physiological anticoagulants.   
 
TF itself is also expressed on cells other than monocytes, such as the endothelium.  Previous 
work demonstrates that even a small increase in whole TF can alter the coagulation, the effect 
of TF expressed on other cell types cannot be discounted (Butenas et al., 2005). 
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TF expression on monocytes appears to be variable between time-points, disease states, 
individuals and subsets; it is hard to control completely for such variation.  To fully 
understand monocytic TF expression, further work is needed to measure it at different time-
points.  The samples from individuals with sepsis were taken at range of time-points 
following admission to the critical care unit (a range of 1 to 31 days).  Future work would 
benefit from a stricter time limit on recruitment. 
 
Another limitation of this work is that although the TF activity was measured in different 
monocyte subsets in healthy volunteers, the activity during sepsis was not measured and not 
measured directly during endotoxaemia.  The monocyte surface expression of TF during 
sepsis has not been demonstrated to be active.  TF encryption may also vary significantly 
during different disease states and it should be examined in the future. 
 
 
6.7 Future work 
To better understand monocyte TF expression during sepsis, I would suggest a case-
controlled study performed on the critical care unit comparing critically ill individuals with 
and without a diagnosis of sepsis, as well a second group of age- and sex-matched healthy 
controls.  Similar to the study of Vickers et al, individuals on the critical care unit should be 
screened daily to look for signs of sepsis (Vickers et al., 1998).  Once a diagnosis of sepsis 
was made, they could be recruited, and the first sample taken within 12 hours.  Later samples 
could be taken within the first few days and then perhaps at 30 days and 60 days.  This would 
allow for the sequential measurement of monocytic TF expression, TF activity and other 
markers of coagulation such as prothrombin fragments 1+2 and thrombin-antithrombin 
complex. 
 
To examine the consequences of the high and low responder phenomenon further, monocytes 
from individuals who have survived sepsis could be stimulated with LPS.  Examination of 
medical records and blood samples would allow for identification of coagulopathy during 
their episode of sepsis.  A comparison could then be made between their level of response and 
their risk of sepsis-associated coagulopathy.  Samples could also be used to investigate 
possible mechanisms of high and low monocyte TF response. 
 
Further work is also needed to better understand the mechanisms by which the subsets differ 
in both TF expression and activity.  There is a possibility that the differences between 
expression and activity are related to different methods or levels of encryption between the 
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subsets.  Work to investigate the lipid profile of each subset would be an interesting way to 
start this investigation.  This project also suggests that the LPS induction of TF transcription 
may vary between the monocyte subsets.  If further work was to prove that to be the case, 




6.8 Final conclusions 
Sepsis-associated coagulopathy is associated with high mortality, and the mechanisms 
underpinning it are poorly understood.  The ability of monocytes to express TF, the main 
initiator of coagulation in vivo, and their interaction with endothelium that increases PAI-1 
means they have an important role in thromboinflammation and may contribute to sepsis-
associated coagulopathy. 
 
TF expression varies between monocyte subsets.  Classical and intermediate monocytes 
express the highest levels of TF on their cell surface.  TF activity between monocyte subsets 
does not seem to vary.  Interestingly, although LPS stimulation was shown to increase TF cell 
surface expression it did not increase the activity of the cell surface TF.  The encryption of TF 
between monocyte subsets during health and sepsis should be investigated to better 
understand the contribution of monocyte TF surface expression to sepsis-associated 
coagulopathy. 
 
The human endotoxaemia model has demonstrated that monocytes increase their cell surface 
expression of TF early following exposure to LPS.  The model also showed a variation in 
response between individuals to the LPS induction of TF expression on the monocyte surface.  
This has been demonstrated for the first time across all the monocyte subsets.  Future work 
should investigate whether this may allow for the stratification of individuals with sepsis and 
correlate with the risk of sepsis-associated coagulopathy. 
 
Different monocyte subsets have been shown to predominate in the circulation throughout 
sepsis, and this may potentially contribute to the development of sepsis-associated 
coagulopathy.  The cell surface expression of TF has been shown to increase in the 
intermediate and non-classical subsets when compared to a critically ill individuals without 
sepsis.   
 
In conclusion, monocyte subsets vary in the cell surface expression of TF and this may 
contribute to sepsis-associated coagulopathy. 
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APPENDIX A.  
 
The protocol, participant information sheet and consent form used to collect healthy 
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• Prof Matthew Wright 
 
 
SECTION B:  BACKGROUND 
 
Inflammation is implicated in a wide range of pathological processes including autoimmune 
disease, fibrosis, cancer, chronic viral infections, and cardiovascular disease. Deficient 
inflammatory processes are heavily implicated in pre-disposition to infection and in failure of 
resolution of inflammation. It has long been recognised that the initiation, maintenance, 
regulation and resolution of inflammation is a complex process, dependent on critical 
interactions. For example, during an inflammatory reaction neutrophils must interact with: 
soluble mediators in blood; vascular endothelium; interstitial cells, host-tissue epithelium; 
soluble mediators at the inflammatory site; other blood-derived cells at the site of inflammation 
(eg other neutrophils, platelets and mononuclear cells); foreign material (eg bacteria); and any 
drugs the patient may be taking. Despite recognition of this complexity, there is still a tendency 
for the human inflammation literature to focus on individual elements of the system. This 
project is based on the assumption that improved understanding of mechanisms underlying 
human inflammation can only develop through testing of the interaction between critical 
components of the system. 
 
Therefore, while the focus is predominantly on the regulation of neutrophil function (ie 
mechanisms by which bacteria and host factors impair neutrophil function and how these can 
be restored pharmacologically), the project provides the capacity to dissect interactions between 
the critical circulating cells and mediators driving inflammation, ie elements of the liquid phase 
of blood (serum/plasma) and the cellular components of blood (red cells, platelets, neutrophils, 
monocytes, eosinophils, lymphocytes, dendritic cells). 
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The investigators have a range of experience providing the optimal skill mix to ensure 
maximally efficient design of experiments studying interactions between critical components 
of human inflammation. 
 
The study focuses entirely on the study of the normal elements of human blood participating in 




SECTION C:  THE VOLUNTEER’S VISIT – CONSENT AND SAMPLING 
 
Volunteers will be identified through placement of adverts in Newcastle University notice 
boards, websites and email lists.  
 
Volunteers who express an interest will be sent a Participant Information Sheet and Consent 
Form, and asked to contact the team again if they wish to take part. The volume of blood 
requested on a given day may range from 30-240 ml. If a request for a donation of >160 ml is 
being made, the volunteer will be asked to attend for one screening visit, in order to donate a 
sample of blood (up to 5 ml) which will be sent to the local laboratory for testing haemoglobin 
concentration. Such volunteers will be excluded from further study if the haemoglobin 
concentration is below the normal range.  
 
In addition to low haemoglobin levels (in those donating >160 ml), exclusion criteria will 
consist of 
 
• blood donation (eg to the Blood Transfusion Service or to research studies) in the 
previous 90 days. 
• donation of >1 litre of blood in the previous year (this equates to around 3 donations to 
the Blood Transfusion Service in the past year). 
• a history of anaemia in the past year. 
• age under 18 years. 




If a volunteer wishes to proceed, Prof Simpson or his personal assistant will check study records 
to determine if the volunteer has donated blood in the last 3 months (see Section E below). If 
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not, he/she will be invited to come to the Clinical Research Facility, Royal Victoria Infirmary 
at a mutually convenient date and time (in almost all cases this will be a weekday morning). It 
is expected that the intended volume of blood collection will be indicated to the volunteer at 
this stage. 
 
On the study day a medically qualified member of the study team, or a registered nurse from 
the study team/Clinical Research Facility will inform the volunteer of the preferred size of 
blood donation, and will ask for witnessed, written, informed consent from the volunteer. If this 
is provided, the original consent form will be given to the volunteer to keep, and a copy will be 
made for retention by the study team (see Section E below). The volunteer should be asked for 
the name/address of his/her GP. 
 
Blood sampling will be performed in the Clinical Research Facility, Royal Victoria Infirmary. 
The position most comfortable for the volunteer should be decided, but wherever possible 
phlebotomy should be performed in a semi-recumbent position, on a couch that has a self-
reclining function. Upon completion of phlebotomy, pressure should be applied to the site until 
haemostasis is secured. If the volunteer has no known allergy to sticking plaster, one should be 
offered. The volunteer should be offered a carton of fruit juice and/or a drink of water. If the 
volunteer feels well he/she should be allowed to leave. A book token should be offered to the 
participant (for the time and inconvenience incurred by the study). 
 
Vasovagal symptoms occasionally accompany phlebotomy. If the participant feels unwell 
during or after the procedure, phlebotomy should be discontinued, and the couch should be 
positioned so that the volunteer is supine. Management should proceed on an individual basis, 
but in the majority of instances the vasovagal symptoms are expected to be self-limiting. 
 
After the volunteer has left, and assuming the appropriate consent has been given regarding 
‘information for the GP’, a letter must be sent to the GP informing him/her of the volunteer’s 
participation. If the procedure has had to be abandoned because of a vasovagal episode or other 
reason, the GP should be informed of this in the letter. 
SECTION D:  SAMPLE PROCESSING 
 
Blood samples will be processed in the Institute of Cellular Medicine. Samples will be separated 
into fluid phase and cellular components. Standard techniques will be involved – typically 
dextran sedimentation and density gradient centrifugation of anticoagulated whole blood will 
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be used for this process, yielding red cells, plasma, granulocytes and mononuclear cell fractions. 
Variations and extra steps will be used as indicated, for example: to prepare serum (eg adding 
CaCl2 to plasma); to prepare platelets (eg centrifugation of platelet rich plasma); or to isolate 
specific populations of leukocytes (eg by positive or negative selection using antibody-loaded 
columns, or by flow sorting). DNA or RNA will be prepared from aliquots using standard DNA 
or RNA isolation kits. 
 
DNA/RNA will not be used to test for any genes known to provide diagnostic information. 
 
Cells will be used fresh. Liquid phase samples will be stored frozen. Cytospins may be prepared 
yielding glass slides with cells. 
 
 
SECTION E: RECORDING AND STORAGE OF DATA AND SAMPLES 
 
A logbook of participants will be kept in a locked drawer and will be accessible only to Prof 
Simpson (chief investigator), his personal assistant, and regulatory authorities with access to 
study documents. 
 
The logbook will keep a record of all volunteers expressing an interest in donating blood for 
the study. The logbook will record any donation made by that individual, along with  
• the volunteer’s contact details and date of birth 
• the name and address of the volunteer’s GP (if known and if the volunteer agrees for 
information to be sent to the GP) 
• the date of donation,  
• the volume of donation and  
• any comments relating to whether the procedure was well tolerated or not.  
 
The logbook will also record the unique study number for each individual’s donation. The first 
6 letters indicate the study, the next 3 digits the individual’s unique number, the last letter will 
indicate whether it is the individual’s first donation or not. 
eg  ICM-BLD-001.A would be volunteer number 1’s first donation 
 ICM-BLD-001.B would be volunteer number 1’s second donation 
 ICM-BLD-074.D would be volunteer number 74’s fourth donation etc. 
 
The unique number will be used to label all samples arising. 
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Samples will be stored in freezers in the Institute of Cellular Medicine. 
 
Any data held on University computers may only use the unique identifier number, ie no 
personal data may be used to label samples. 
 
The only information linking the volunteer’s identity to his/her samples will be held in the 
logbook. As described above, this will be held in a locked drawer, geographically distinct from 
the location of the freezers or university computers on which results are held. 
 
Team investigators will be notified in advance of dates when donations are to be made. They 
will be invited to contact the researcher performing the blood prep, who will prepare aliquots 





Version 2, 2.6.12 






Institute of Cellular Medicine 
4th Floor William Leech Building 
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PARTICIPANT INFORMATION SHEET  





The role of inflammation in human immunity 
 
You are being invited to take part in a research study.  Before you decide it is important for you 
to understand why the research is being done and what it will involve.  Please take time to read 
the following information carefully. Talk to others about the study if you wish.  
• Part 1 tells you the purpose of this study and what will happen to you if you take part. 
• Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information.  Take time 
to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Inflammation is the body’s way of protecting organs from damage from insults such as 
infections. However under-active inflammation leaves patients prone to developing infection 
and over-active inflammation may actually damage the host’s organs. Inflammation is now 
recognised to be a key factor in diseases as diverse as arthritis, cancer, fibrosis (scarring), 
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strokes, as well as infection. We require a far greater understanding of the processes controlling 
initiation, regulation and resolution of inflammation if new effective treatments are to be 
discovered. This project seeks to study the processes of initiation, regulation and resolution of 
inflammation. 
 
Why have you been chosen? 
You have been identified as a healthy individual who may be willing to take part.  
 
Do you have to take part? 
No. It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to withdraw at 
any time and without giving a reason.  A decision to withdraw at any time, or a decision not to 
take part, will not affect the standard of care you receive in the NHS at any time. 
 
How long can you take to decide? 
You should take as much time as you wish.  
 
 
What will happen to you if you take part? 
You will visit the Clinical Research Facility at the Royal Victoria Infirmary, where a single 
blood sample will be taken by a doctor or nurse. Afterwards you will rest for a few minutes, 
and pressure will be applied to the vein. You will be given water or a carton of juice to drink. 
This is very similar to advice issued by the Blood Transfusion Service 
(www.blood.co.uk/giving-blood/what-happens/) which states “Once you have given blood, you 
should have a short rest before being given some refreshments usually a drink and biscuits.” 
This ends your participation on the day. Your sample will be processed in the lab, dividing it 
into its constituent parts (various blood cells and the liquid part of blood). These will be used 
to study the behaviour and function of blood cells. 
 
Are there situations in which you should not take part? 
In healthy individuals the bone marrow rapidly replaces blood cells if any bleeding takes place. 
However we impose limits on when you can provide blood for us. These are any from 
• if you have donated blood (eg to the Blood Transfusion Service or to research studies) 
in the previous 90 days. 
• if you have donated >1 litre of blood in the previous year (this equates to around 3 
donations to the Blood Transfusion Service in the past year). 
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• if you have been told by a doctor that you have anaemia in the past year. 
• if you are under 18 years of age. 
• if you are on any regular, prescribed medication (the oral contraceptive pill is 
permissible in female participants). 
 
How much blood is taken as part of this study? 
You must be aware that the amount of blood we request is more than the usual small samples 
of blood that you might have previously given at your GP surgery, but less than the size of a 
donation to the Blood Transfusion Service. Depending on the precise population of blood cells 
to be studied that day we may take between 30 and 160ml of blood. To place these figures in 
context, a tablespoon holds approximately 15ml, a typical clinical sample at the GP surgery is 




What are the possible disadvantages and risks of taking part? 
As with all blood samples, the blood test may leave a small bruise. There is a low risk (<5%) 
of fainting when blood is taken. The risk is higher if you have a history of fainting in the past 
and we ask you to let us know in advance of taking blood if this is the case. We have taken 
steps to minimise any problems associated with the unlikely event of fainting, in that you will 
be on a reclining chair/bed in a medically supported environment. 
 
What are the potential benefits of taking part? 
There is no direct benefit to you.  
 
Is there any reimbursement for taking part? 
You will be offered a £5 book token, which is intended to take account of the time and 
inconvenience of the trip to hospital. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 




Will your taking part in this study be kept confidential? 
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Yes. All the information about your participation in this study will be kept confidential. The 
details are included in Part 2. 
 
Contact details 
Should you wish further information please contact 
John Simpson,  
Professor of Respiratory Medicine,  
Newcastle University 
E-mail: j.simpson@ncl.ac.uk   
Phone: 0191 222 7770 
 
 
This completes Part 1 of the Information Sheet. If the information in Part 1 has interested you 
and you are considering participation, please continue to read the additional information in Part 













What will happen if you do not wish to carry on with the study? 
You may withdraw from the study at any time. If you choose not to participate in the study 
now, or at any stage, this will not in any way influence the care you receive from the NHS at 
any stage in the future. 
 
What if there is a problem? 
If you have a concern about your treatment by members of staff during the study, you should 
ask to speak with the researchers who will do their best to answer your concerns (a contact 
number for Prof Simpson is at the end of Part 1 of the Information Sheet). If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from your hospital. In addition, the local Patient and Liaison 
Service (PALS) can provide very useful information if you have any concerns. The PALS 
website www.pals.nhs.uk/ will provide you with up to date details, but at the time of writing 
the local contact is  
Ms Angie Brown 
Patient Advice and Liaison Service 
Newcastle Hospitals NHS Foundation Trust 
New Victoria Wing 
Royal Victoria Infirmary 
Queen Victoria Road 
Newcastle upon Tyne NE1 4LP 
northoftynepals@nhct.nhs.uk 
0800 032 0202 
 
In the unlikely event that something goes wrong and you are harmed during the study there are 
no special compensation arrangements. If you are harmed and this is due to someone’s 
negligence then you may have grounds for a legal action for compensation against the 
NHS/Newcastle University but you may have to pay for your legal costs. The normal NHS 






Will your taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept 
strictly confidential.  
 
Involvement of the GP 
With your permission, we shall inform your GP by letter that you have taken part in our 
study.  
 
Will any genetic tests be done? 
We shall retain a sample from which DNA can be prepared. Our study protocol specifically 
states that we must not test for genes known to provide diagnostic information (eg the cystic 
fibrosis gene, muscular dystrophy genes, or certain cancer genes). Instead we are limited solely 
to studying the make up of genes that are involved in inflammation or in the way that the body 
handles certain drugs that interfere with inflammation. None of these genes are used 
diagnostically. 
 
Will any information and material be stored? 
Yes, but only with your permission. Your personal information (your name, date of birth, 
contact details and your consent form) will be kept in a locked drawer. A unique identifier 
number allocated to you will be kept with this information in the locked drawer. In this way, 
your blood samples and any research information held on computers ONLY carry the unique 
identifier number and not your details. As such, the only people who could potentially identify 
you from blood samples etc are Professor Simpson or his personal assistant. 
 
Using this system we shall keep information about your health and your medicines on a 
password protected computer, ie the data will only be linked to your unique identifier number. 
We propose to store a sample of your blood but this will only be labelled with a study number. 
In line with Trust policy we propose to keep your information and samples for up to 15 years 
after completion of the study, at which point we propose to destroy the samples. As medicine 
advances and new information becomes available, we occasionally find good reasons to 
perform additional tests on stored samples in the future. Should this situation arise we may use 
your samples again, but this would be on the strict condition that you could not be identified 
from the sample except by our research team, and that we obtain fresh and separate permission 
from an ethics committee. 
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Can you take part in this study more than once? 
Yes, but only under strict condition that you do not breach any of the ‘exclusion’ criteria (see 
bullet points in Part A). For example, if we take a blood sample of 80mls or less we may contact 
you again after 30 days to ask if you would give a further sample. If the volume of blood taken 
is between 81mls and 160mls we would contact you after 3 months (90 days). This is the most 
often we would ask you to give samples and may be much longer depending on volunteers and 
your availability. If we took the maximum allowed at each visit this is still less than 1 litre of 
blood over a year (equivalent to less than 3 blood donations).  
 
What will happen to the results of the research study? 
We intend for the results to be published in medical/scientific journals and presented at 
medical/scientific meetings. All information in the public domain will be anonymous, ie you 
cannot be identified from these publications/presentations.  
 
Who is funding and organising the research? 
The research is funded by Newcastle University.  
 
 
Who has reviewed the study? 
The study has also been reviewed and approved by a local Research Ethics Committee and the 
regional Research and Development Office. 
 
Is there an independent doctor you can approach for further information? 
If you would like to discuss any aspect of this research with an experienced researcher who is 
not linked in any way to this study, please feel free to contact 
Dr Ian Forrest 
Consultant Respiratory Physician 
Royal Victoria Infirmary 
Queen Victoria Road 
Newcastle upon Tyne NE1 4LP 
 
You will be given a copy of this Information Sheet and a signed consent form to keep. 
Thank you for taking time to read this sheet and for considering taking part. 
 
Version 3, 05.06.13 
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CONSENT FORM  
(for volunteers providing ≤160 ml blood) 
Title of Project: The role of inflammation in human immunity 
Lead Investigator: Prof J Simpson, Institute of Cellular Medicine 
              Please initial box 
 
1.  I confirm that I have read and understood the information sheet dated ....5/6/13..................   
     (version ....3........) for the above study. I have had the opportunity to consider the               
      information, ask questions and have had these questions answered satisfactorily. 
 
2. I have informed the study team of any blood donations I have provided (eg to the  
    Blood Transfusion Service) in the last year and of any previous history of anaemia.                                           
 
3.  I understand that my participation is voluntary and that I am free to withdraw at any  
     time, without giving any reason, without my medical care or legal rights being affected.               
 
4.   I agree that samples prepared from my blood may be stored for up to 15 years after  
      completion of the study.                                                                                                                       
 
5.   I agree that my samples may be used in future studies on condition that I cannot be  
      identified from those samples and that ethical approval is granted for such studies.                                                                                                                         
 
6. I agree that the research team may send a letter informing my general practitioner of my  
      participation in this study.                                                                                 
 
7. I understand that relevant sections of my records collected during the  
     study may be looked at by individuals from regulatory authorities or from the NHS Trust,  
     where this is relevant to my taking part in this research.                                                  
          
 
____________________________                  _______________        _____________________ 
Name of Participant                                           Date                               Signature                      
 
____________________________                 _______________         _____________________ 
Name of Person Taking Consent                      Date                              Signature 
 
____________________________                 _______________         _____________________ 
Name of Phlebotomist                                      Date                              Signature 
1 copy of this form to be given to participant; 1 for researcher (to be filed in central file)  






APPENDIX B.  
 
The protocol, participant information sheet and consent form used to obtain blood 
samples from the human endotoxaemia model. 
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Study Protocol 
Does mitochondrial haplogroup predict the inflammatory response in a model of human 
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Although sepsis is one of the oldest syndromes recognised within medicine, understanding of 
its biology remains incomplete. The healthcare burden from infection remains substantial. 
Severe sepsis is found in approximately 2% of hospital admissions in the USA, half of which 
require treatment in the intensive care unit (ICU)(1). As many as 30% of patients have sepsis 
on admission or during their ICU stay. The mortality associated with sepsis seems to be 
substantially higher than that of other syndromes leading to ICU admission (2) and it is the 
most common cause of death in non-surgical ICUs (3).  
 
Risk factors for the development of severe sepsis are premorbid health status and 
physiological reserve of the host, causative organism, timeliness of intervention and host 
genetic characteristics. Gram-negative infections account for a greater proportion of severe 
sepsis than Gram-positive infections (4) and they are also associated with a worse outcome 
(5). Studies exploring genetic factors have concentrated on polymorphisms in nuclear genes 
involved in the innate inflammatory response (6), coagulation and fibrinolysis (1).  
 
Impaired cellular respiration is important in the development of multi-organ dysfunction in 
severe sepsis (7). Natural variation in mitochondrial DNA (mtDNA) is an understudied area 
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likely to yield insights into how the host genome may influence outcome in severe sepsis. 
Human mtDNA is maternally inherited and codes for 13 essential protein components of the 
mitochondrial respiratory chain. Individuals can be divided into mtDNA haplogroups on the 
basis of specific single nucleotide polymorphisms (SNPs) in their mitochondrial genome. The 
most common subdivision of mtDNA in Europe, haplogroup H, is associated with enhanced 
oxidative phosphorylation and is a strong independent predictor of survival after admission to 
the ICU with severe infection (8). The frequency of haplogroup H is approximately 40% in 
North East England (9).  
 
Human survival from infection requires an appropriate inflammatory response: an 
unbalanced, hyperinflammatory response predisposes patients to overwhelming inflammation, 
while protracted immunosuppression is associated with organ dysfunction and heightened risk 
of nosocomial and opportunistic infections (10). An observational study performed in 
Newcastle suggested that patients with haplogroup H had a survival advantage, and higher 
fevers, when compared with non- H haplogroups (8). Recent data from our laboratory 
(manuscript in preparation) suggest that mitochondrial genes regulate the expression of TLR-
4 and triggering receptor expressed on myeloid cells type 1 (TREM1) on human monocytes 
through interferon gamma-dependent pathways, which in turn influences the early 
inflammatory response to lipopolysaccharide (LPS).  
 
 
Previous research on sepsis has focused on isolated mediators using a reductionist approach 
often derived from animal models (11). A genome wide study has questioned the validity of 
using murine models (12) whilst experimental human endotoxaemia shows much greater 
correlation with transcriptomic changes due to inflammatory stresses in human disease (13). 
Injection of LPS, a non-infectious Gram-negative bacterial cell-wall product, is a well-
recognised, safe, investigational technique that has been used experimentally for over 50 
years(14). The dose used is adjusted to body weight to ensure a standardised reaction in all 
participants. While we recognise that administration of low dose endotoxin is not a clinical 
model of sepsis, it does represent a significant improvement in experimental modeling over 
animal studies. Human endotoxaemia reproduces the earliest features of the pathogenesis of 
sepsis (which are almost impossible to study in the clinical setting), paving the way to define 
mechanisms of pathogenesis, and “drugable” targets.  
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The prevailing frequency of haplogroup H in the general population and the human 
endotoxaemia model together provide a unique opportunity to begin to explore the 
contribution of mitochondrial function to the early inflammatory response in sepsis. The aim 
of this seed application is therefore to test the hypothesis that mitochondrial haplogroup H 
leads to a more pronounced pro- inflammatory response to intravenous lipopolysaccharide 
in a model of human endotoxaemia.  
 
Experimental Plan using the Human Endotoxaemia Model 
 
The human intravenous endotoxaemia model has been used for more than 50 years as a model 
of acute systemic inflammation, encountered in conditions such as sepsis and trauma. Low 
dose purified lipopolysaccharide (LPS, also referred to as endotoxin) from the cell membrane 
of Escherichia coli (E.coli) is administered to healthy volunteers resulting in transient, flu-like 
symptoms, and an acute systemic inflammatory response, which, at least partially, mimics the 
inflammatory response of early sepsis. The doses needed in humans to mimic the clinical 
entity of severe sepsis are ethically unacceptable.  
 
The effects of Good Manufacturing Practice (GMP) grade LPS from E.coli are highly 
reproducible (15).  Within an hour of the intravenous administration of LPS, volunteers 
experience varying degrees of flu-like symptoms e.g. chills, headache, myalgia , nausea, 
photophobia and sleepiness. In general the response is dose-dependent. Most subjects only 
experience symptoms for about two to six hours. The core temperature increases within one 
hour of administration and peaks at three to five hours and meets in the SIRS criterion for 
fever in most participants. Any drop in blood pressure is prevented by the administration of 
intravenous fluid, but an increase in heart rate of 20bpm within the first four hours is 
consistently seen. No severe cardiovascular complications resulting from endotoxin 
administration have been reported (15). Whilst, in some subjects the respiratory rate and 
minute ventilation increases with administration of high doses of endotoxin (4ng/kg), this is 
less often seen using lower doses (14). The change in white blood cell count is a little more 
delayed, but in most participants the peak is seen by nine hours and fulfilling the SIRS 
leukocytosis criterion. 
 
Our group has considerable previous (16) and on-going experience with LPS challenge 
studies. Our close liaison with van der Poll’s group in Amsterdam and Gilroy’s group in 
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London give us confidence that we can safely extend our investigations to an intravenous 
model of human endotoxaemia using GMP grade endotoxin from the NIH endotoxin 
repository.  
 
Following ethical approval, we shall recruit 30 healthy, non-smoking, volunteers aged 18 - 
40. The sample size is pragmatic (given the novelty of this experimental design), informed by 
a previous observational, cohort study and by the distribution of haplogroups within the 
population (8). We shall dichotomise the study cohort into H and non-H haplogroups for 
analysis. We will attempt to recruit as many volunteers as possible up to a maximum of 30, 
but believe that analysis of data from 12 volunteers will be informative. 
 
We will advertise the study at Newcastle University using mechanisms that have served us 
well in current and previous inhaled LPS studies. Participants providing informed, written 
consent will undergo an initial health screen and will be required to have no significant 
medical history or recent febrile illness, as well as normal physical examination, 
electrocardiography, oxygen saturation, full blood count, urea and electrolytes, and liver 
function tests. Blood will be drawn for determination of mitochondrial haplogroup, but we 
will be blinded to the results until study completion.  
 
Volunteers will be asked to refrain from caffeine or alcohol for 24 hours before the study and 
will spend a full day (10 hours) in the Intensive Care Unit at City Hospitals Sunderland. Vital 
signs (pulse rate, blood pressure, temperature, respiratory rate and oxygen level) will be 
monitored at baseline and every 30 minutes throughout the day. A venous line will be inserted 
into each arm. Systemic inflammation will be induced by intravenous injection of a bolus of 
2ng/kg of U.S reference E. coli endotoxin made available by the National Institute of Health 
(Bethesda, USA). Doses of up to 4ng/kg have been used but the inflammatory response 
appears to be similar whether 2ng/kg or 4ng/kg is used (15), Therefore in an attempt to reduce 
any unpleasant symptoms for volunteers the lower dose will be used. Participants can eat and 
drink at any point following injection of endotoxin. 20ml of blood will be drawn at baseline 
and at 90 minutes, 4, 6 and 10 hours. Volunteers will attend for blood sampling and follow-up 









The primary objective is to test the hypothesis that mitochondrial haplogroup predicts the 
inflammatory response in a model of human endotoxaemia, the primary outcome measure 





(i) To determine the expression of HLA-DR, TLR4 and TREM-1 by monocyte 
subsets in different haplogroups. 
(ii) To determine the release of reactive oxygen species in blood in different 
haplogroups. 
(iii) To determine the profile of additional proinflammatory and anti-inflammatory 
mediators in plasma in different haplogroups. 
(iv) To determine mitochondrial DNA (mtDNA) copy number in plasma in different 
haplogroups. 
(v) To determine the changes in leukocyte dynamics and function in response to 
intravenous LPS. 
(vi) To measure the clinical response (temperature, pulse rate, blood pressure, 




Participant Enrolment and Selection 
 
An advert will be placed on Newcastle University email lists and notice boards. Potential 
participants will be asked to make contact with the research team only if they consider 
themselves to be healthy. Interested individuals will be invited to contact the research team 
who will send out information on the study (participant information sheets and screening 
consent form). Participants sent such information will be invited to contact the research team 
to arrange a screening visit (see below) or to decline participation. If no reply is received after 





Healthy volunteers will be recruited from within Newcastle University. The screening visit 
will take the form of: 
 
• a short history 
• vital signs measurement (temperature, pulse rate, blood pressure)  
• measurement of oxygen saturation breathing room air 
• cardiorespiratory examination  
• electrocardiogram 
• blood sample for full blood count 
• blood sample for urea & electrolytes assay, liver function tests and C-reactive protein 
• urinary pregnancy test in women 
 
 
Eligibility will be based on the results of this and inclusion and exclusion criteria (see 




All volunteers will be recruited through advertisement within Newcastle University. 
Volunteers will be screened at the preassessment clinic at City Hospitals Sunderland 
Foundation Trust. If found eligible for the study, they will be given time to consider if they 
wish to continue to study entry (minimum 24 hours) and invited to re-attend on a set day. 
Participants will be asked to attend the integrated critical care unit (ICCU, City Hospitals 
Sunderland Foundation Trust) for LPS administration. Downstream preparation and analysis 
of samples generated by the study will be performed in the Simpson lab, in the flow 
cytometry facilities (Centre for Life and Institute of Cellular Medicine), in the Wellcome 
Trust Centre for Mitochondrial Research (Centre for Life, eg for assessment of mitochondrial 
DNA), all Newcastle University. Processing of screening blood tests and routine clinical tests 










• Healthy adult volunteers aged between 18 and 40 years of age 




A volunteer will not be eligible for inclusion in the study if any of the following criteria apply 
at entry: 
 
1. Age <18 or >40 years. 
2. Needle phobia. 
3. Current participation in a clinical trial. 
4. Known history of mitochondrial disease. 
5. Past history of chronic respiratory disease. 
6. Past or current history of conditions known to affect immunity or cardiac function (e.g. 
diabetes, ischaemic heart disease, congenital heart disease, valvular heart disease, cirrhosis, 
chronic renal impairment, recurrent urinary tract infection). 
7. Known history of immunodeficiency. 
8. Known history of hepatitis B/C or HIV. 
9. History of an acute intercurrent cardiorespiratory illness. 
10. Pregnant or breastfeeding. 
11. Any current medication (except oral contraceptive pill). 
12. Current history of smoking. 
13. Reported alcohol intake >21 units per week. 
14. Abnormal physical signs detected at cardiorespiratory examination. 
15. Temperature >37.3 degrees celsius. 
16. Oxygen saturation <95% breathing room air. 
17. Haemoglobin outside the laboratory reference range. 
18. Platelet count less than 100 x 10∧9/l or greater than 650 x 10∧9/l. 
19. Total white cell count outside the laboratory reference range. 
20. Any deviation of greater than 20% from normal in the differential white cell count. 
21. Serum sodium, potassium, creatinine outside the laboratory reference range. 
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22. Blood urea greater than 10mg/dl. 
23. Bilirubin greater than 30micromol/l. 
24. Alanine transferase greater than twice the upper limit of the laboratory reference range. 
25. Allergy to the any of the constituents of Hartmann's solution. 
26. Currently participating in a clinical trial that the chief investigator feels would interfere 





All eligible volunteers will be given written and verbal information regarding study 
participation. All will be asked to give written consent with a minimum 24 hours to consider 
entering the study. Consent will be taken by Dr Rostron or Dr Roy. Pseudoanonymised data 
(linked by a unique study code) will be entered on an excel database. 
 
 
Ineligible and non-recruited participants 
 
For volunteers found to be ineligible at screening, or eligible but not subsequently entered 
into the study, the reason for ineligibility or non-recruitment will be entered on the excel 
database.  Only anonymised data will be entered on to the database and this will include 
gender, age, “ineligible” or “non-recruitment” and the associated reason. If found ineligible, 
permission will be sought from participants to contact their GP with the results of screening 
tests and any further action required.  
 
Study visit 1 (day 0) 
 
Volunteers satisfying study criteria, wishing to proceed with the study, and providing written 
informed consent will attend the integrated critical care unit (ICCU), City Hospitals 
Sunderland on an agreed day. Volunteers will be asked to refrain from caffeine or alcohol for 
24 hours before the study and during study visit 1. Volunteers will spend a full day (10 hours) 
in the Intensive Care Unit at City Hospitals Sunderland. A brief history (regarding symptoms 
of any acute illness) will be sought. In female participants, a repeat urinary pregnancy test 
will be performed and will be reviewed by a medical practitioner who will offer appropriate 
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advice. Only those participants who have a negative test will be allowed to proceed with the 
study. Vital signs (pulse rate, blood pressure, temperature, respiratory rate and oxygen level) 
will be monitored at baseline and every 30 minutes throughout the day. A venous cannula will 
be inserted into each arm. Intravenous fluid (Hartmann’s solution, a solution with 
concentration of salts similar to that of blood) will be administered via one of the intravenous 
cannulae. Systemic inflammation will be induced by intravenous injection of a bolus of 
2ng/kg of U.S reference E. coli endotoxin into the other intravenous cannula. Participants can 
eat and drink at any point following injection of endotoxin, but will be asked to refrain from 
caffeine and alcohol during the day of study visit 1. 80ml will be drawn at baseline, 90 
minutes, 6 and 10 hours. 20ml of blood will be drawn at 4 hours following injection of 
endotoxin. Volunteers are advised to use a suitable method of contraception for 48 hours 
following injection of LPS. 
 
Study visit 2 (day 1) 
 
Volunteers will be asked to attend the ICCU at City Hospitals Sunderland. All will undergo a 
brief history, examination and blood sampling (20mls). 
 
Study visit 3 (day 7) 
 
Volunteers will be asked to attend the ICCU at City Hospitals Sunderland. All will undergo a 
brief history, examination and blood sampling (20mls). 
 
Study Assessments: processing and analysis of blood samples 
 
Screening visit blood samples will be sent to the hospital laboratories at City Hospitals 
Sunderland for assessment of full blood count, urea and electrolytes, liver function tests and 
C-reactive protein (CRP) (8mls). A sample will also be taken for mitochondrial haplogroup 
typing (2mls) which will be performed at the Centre for Life, Newcastle University 
 
Blood samples will be taken at baseline, 90 minutes, 4, 6 and 10 hours after administration of 
intravenous LPS.  Blood sample volume that will be drawn will be approximately 80mls will 
be drawn at baseline, 90 minutes, 6 and 10 hours.  
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20mls at 4 hours. Full blood count analysis and measurement of serum CRP and procalcitonin 
(PCT) will be done in the hospital laboratories at City Hospitals Sunderland NHS Foundation 
Trust. All other sampling will be performed at Newcastle University. Assessment of free 
mitochondrial DNA (mtDNA) will performed at the Centre for Life, all other scientific 
processing and analysis will be undertaken in the Medical School, Newcastle University. 
 
Sampling at baseline, 90 minutes, 6 and 10 hours: 
 
• Full blood count (2mls) 
• Serum (9 mls) for CRP, PCT, cytokines and free mtDNA 
• Flow cytometry (4 mls) 
• Prothrombotic markers (5mls) 
• Transcriptome (RNA sequencing), epigenome (ATAC sequencing) and proteome 




Sampling at 4 hour, 24 hour and 7 day time points: 
 
• Full blood count (2mls) 
• Serum (9 mls) for CRP, PCT, cytokines and free mtDNA 
• Flow cytometry (4 mls) 
• Prothrombotic markers (5mls) 
 
 
The total volume of blood sampled over the study period (390ml) will be similar to the 
volume of blood drawn for the donation of blood. Scientific samples will be stored in a locked 
freezer, in swipe-card protected premises in the Institute of Cellular Medicine.  Freezers are 
accessible to the research team, and to individuals who maintain university research freezers 
and their governance. Samples will be destroyed after five years, unless we believe there is 





Data from analysis of blood samples will be compared between haplogroup H and non-H 







Blood sampling can be accompanied by discomfort or by vasovagal symptoms. Risks are 
minimised through all samples being taken in a fully supported medical facility. Blood will be 
drawn whilst the volunteer is positioned on a bed or in a self-reclining chair. Volunteers 
feeling syncopal will be positioned supine and venepuncture will be discontinued. The total 
volume of blood to be sampled over the entire study is less than the volume required for a 
standard blood donation. 
 
Intravenous administration of LPS 
 
LPS will be administered to volunteers whilst they are monitored in the integrated critical care 
unit (ICCU) at City Hospitals Sunderland. Participants will be observed for 10 hours 
following LPS administration. 
 
Expected symptoms include chills, headache, photophobia (aversion to bright lights), myalgia 
(muscle aches), arthralgia (joint pains), nausea (feeling sick), and rarely, vomiting. Peak 
symptom intensity occurs around 1 - 2 hr post-injection, abating afterwards to baseline by 6 - 
8 hr. No severe or sustained adverse 
effects secondary to endotoxin at this dose have been reported. Less than 5% of volunteers 
feel the need to treat these symptoms with medicines such as paracetamol/acetaminophen or 
non-steroidal agents by mouth or IV (e.g., aspirin, ibuprofen). Such agents may alter the 
inflammatory response and their use should be recorded. Other adverse signs include fever, 
increase or decrease in heart rate and decrease in blood pressure (hypotension), medications 
required to treat adverse effects will be readily available (e.g. intravenous fluid in the event of 
a significant episode of hypotension or paracetamol in the event of significant symptoms of 
fever). Significant hypotension only occurs rarely (less than 1 in 1000 volunteers) and is 
rapidly treated by the administration of an intravenous fluid bolus. 
 
Vital signs will be measured at baseline, then every 30 minutes until six hours following LPS 
administration and then hourly thereafter until participants are allowed home. Symptoms 
scores for nausea, muscle aches, headache and chills will be recorded. 
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3. Burden of time 
 
Volunteers wil be required to attend for a screening visit, a ten hour study day for induction of 
inflammation, observation and sampling, followed by two further study visits for follow-up 
and sampling. Volunteers will required to attend the Integrated Critical Care Unit of City 
Hospitals Sunderland for study visits. The host institution and follow-up study visits will 
facilitate safety monitoring for volunteers. In recognition of the burden on the volunteer in 




Our research group has experience with the LPS challenge models. We have 
successfully administered 60µg of inhaled LPS to young, healthy participants with no 
significant adverse events recorded (16).  
 
Intravenous LPS has been administered to healthy volunteers for over 40 years. There is a 
substantial body of evidence to support the safe administration of higher doses (4ng/kg) of 
intravenous LPS than we intend to use in this study. 
Nevertheless, we feel that we must remain vigilant in detecting and recording any adverse 
events as a result of exposure to LPS or other procedures undertaken. Whilst recognising that 
this current work is not a clinical trial, our groups' previous work (which included a clinical 
trial) benefited from classifying and monitoring adverse events in the manner described 
below, and we have elected to continue using this terminology in this research. 
 
Definitions 
An adverse event (AE) is any untoward medical occurrence in a study participant. 
A serious adverse event (SAE) is any untoward medical occurrence in a study participant or 
effect that: 
• results in death 
• is life threatening (i.e. the subject was at risk of death at the time of the event; it does not 
refer to an event which hypothetically might have caused death if it were more severe) 
• requires admission to hospital as an in-patient beyond one calendar day or requires the 
volunteer to stay longer than 12 hours following injection of lipopolysaccharide 
• results in persistent or significant disability or incapacity 
• is a congenital anomaly or birth defect 
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If an adverse event is detected, a member of the research team will make an assessment of 
seriousness as defined by the above definitions. If the event is deemed to be serious (SAEs) a 
member of the research team will then consider if the event was: 
• Related – that is it resulted from administration of research procedures and/or 
• Unexpected – that is a type of event that is not identified as an expected occurrence 
 
Detecting and reporting AE and SAEs 
 
All AEs and SAEs will be recorded from the time a participant consents to join the study until 
24 hours after completing the final study assessments. A medically qualified member of the 
research team will ask about the occurrence of AEs/SAEs during the study. Information to be 
collected includes type of event, onset date, researcher assessment of implications, if any, for 
safety of participants and how these will be addressed, date of resolution as well as treatment 
required, investigations needed and outcome. All information will be recorded in the 
participants study file. 
An AE/SAE may necessitate discontinuation of a given part of the study (but progression 
through the remainder of the study) or complete and immediate discontinuation of any further 
participation. All participants will maintain the right to discontinue or completely withdraw 
from the study at any time for any reason, or without stating a reason. The reason and 
circumstances for premature discontinuation (where known) will be documented in the 
participant’s study file. 
 
If a SAE has occurred, the research team must report the information to Newcastle upon Tyne 
Hospitals R&D within 24 hours.  The SAE form must be completed as thoroughly as possible 
with all available details of the event, signed by the Investigator or designee.  The SAE form 
should be transmitted by fax or by hand to the office.  
NUTH R&D is responsible for reporting SAEs that are considered to be related and 
unexpected as described above to the Research Ethics Committee (REC) that approved the 
study (main REC) within 15 days of becoming aware of the event using the NRES Reporting 
of SAE Form. The Co-ordinator of the main REC should acknowledge receipt of related, 








The attending clinician will ensure that the participant's symptoms have settled and that their 
observations are trending to normal (all altered parameters, e.g., elevated heart rate and 
temperature, demonstrating consistent reduction toward baseline values) prior to sanctioning 
the end of observation and subsequent discharge. After bolus injection of 2ng/kg LPS 
symptoms normally fully abate by 6 - 8 hr. Individual observations follow overlapping but 
discrete time-courses. These have normally returned to baseline by 10hr. All monitoring and 
venous cannulae will be removed and haemostasis will be ensured. It will be confirmed that 
the participant is happy to be discharged home and has the contact details of the research team 
in case of any concern. 
 
 
End of study 
 
The study will be completed on day 7 of the final volunteer. Scientific analysis of samples in 
accordance with the experimental plan may be performed after this. 
 
Process if new information is available 
 
If any further information becomes available that leads to further studies then consent will be 
obtained from volunteers and ethic approval will be sought. 
 
Criteria for terminating the project 
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Does the DNA of our cell’s batteries influence our response 
to bacteria? 
 
PARTICIPANT INFORMATION SHEET 
 







You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully. Talk to others about the study if you wish.  
• Part 1 tells you the purpose of this study, outlines what will happen to you if you take 
part, and informs you about the conduct of the study. 
 




Please ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part. 
 
PART 1 
What is the purpose of the study? 
Sepsis (previously known as septicaemia or blood poisoning) is a common medical 
emergency. It is severe, life-threatening infection. Internationally, it claims the lives of eight 
million people every year, 44000 of which are in the United Kingdom. Sepsis arises when the 
body’s response to an infection, the inflammatory response, injures its own tissues and 
organs. It can lead to shock, failure of the body’s organ and death especially if not recognized 
early and treated promptly. The proportion of people who die when they have sepsis is greater 
than that of other causes of admission to critical care. One of the major difficulties is that we 
have limited understanding of the body’s early response to infection. 
In order to function, the body’s organs are dependent on cellular energy production. A major 
source of energy is the cell’s mitochondria, they are the batteries for the body’s organs. The 
efficiency of these batteries is determined by the DNA (mitochondrial DNA) that codes for 
the mitochondrial proteins that make up the energy producing apparatus.  
This study seeks to determine if an individual’s mitochondrial DNA also has an effect on the 
inflammatory response to a purified bacterial cell wall component that stimulates a mild, 
transient inflammatory response. 
All studies will take place in the Integrated Critical Care Unit at City Hospitals Sunderland, 
using established methods. 
 
Why have you been chosen? 
You have been chosen because you are a healthy individual who has responded to the e-mail 
we sent out to Newcastle University mailing lists or to adverts placed on university notice 
boards. 
 
What will happen to you if you take part? 
You will attend for a screening visit. If the screening visit is satisfactory and you want to 
proceed to the study you will then be asked to return for 3 separate study visits, over a week. 
The procedures we would like you to have are: 
• Blood samples. Some of the samples will be used to measure the numbers of cells in the 
blood and the levels of markers of inflammation. They will be analysed in the clinical 
laboratories in City Hospitals Sunderland. The remainder and the majority of the blood 
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samples will be transferred by the research team to Newcastle University. They will be 
used to assess mitochondrial DNA in the blood (this will occur at the Centre for Life, 
Newcastle University) and which populations of the cells of the immune system change 
and how they change in response to LPS (this will occur at the Medical School, 
Newcastle University)  
• Intravenous injection of lipopolysaccharide (LPS). LPS is a product made by certain 
bacteria and is just one small component of the bacterium – i.e. you would not be 
injected with actual bacteria that may cause an infection but a small, non-infectious 
component of the bacterium. The aim is to cause a mild, transient inflammatory 
response in the blood, which will result in temporary flu-like symptoms (typically 
lasting up to six hours).  
Greater detail about each of these is found in Part 2. 
Do you have to take part? 
No. It is up to you to decide whether or not to take part.   
You are free to withdraw from the study at any time and without giving a reason.  A decision 
not to take part, or withdraw at any time, will not affect the health care you receive at any 
stage, now or in the future. 
 
How long can you take to decide? 
You should take as much time as you wish. 
 
Do you have to complete all of the tests described? 
While we obviously prefer to obtain all of the samples described, you are under no obligation 
to have any of the tests. You can complete all of the tests, or you can decline as many of the 
tests as you wish.  
 
Involvement of your GP 
With your permission, we shall inform your GP by letter that you are taking part in our study. 
With your permission, should any abnormal clinical results emerge during your tests, we 
would inform you and your GP. 
 
Will any genetic tests be done? 
Yes. Part of our research aims to determine how ‘mitochondrial DNA’ behaves in response to 
inflammation. Mitochondria are the ‘batteries of cells', providing the cell with energy. Some 
research studies have suggested that mitochondrial DNA in white blood cells may respond 
differently during inflammation. We seek to test this in more detail in the current study. We 
shall not, at any point, be testing DNA for genes associated with specific medical conditions. 
 
 252 
What are the potential benefits of taking part? 
There is no direct benefit to you.  
 
Is there any reimbursement for taking part? 
Yes. We shall reimburse any travel costs. There is no reimbursement for attending the 
screening visit, but we will offer a payment of £250 for completing the subsequent study 
days. You are not obliged to take this if you do not wish to. 
 
Can you access the results of the research? 
Yes. We will be happy to send you a summary of the overall results of the study after its 
completion, should you so wish. If you would like us to do this, please contact Professor 




What will happen to the results of the research study? 
We intend for the results to be published in medical/scientific journals and presented at 
medical/scientific meetings. All information in the public domain will be anonymous (i.e. you 
cannot be identified from these publications/presentations). We intend that the results of the 
study will inform the design of future studies and treatments for people with sepsis.  
 
What if there is a problem? 
If you have a concern about your treatment by members of staff during the study, you should 
ask to speak with the researchers who will do their best to answer your concerns (see contact 
details below for Professor Simpson). If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. Details can be obtained from your 
hospital. 
In the unlikely event that something goes wrong and you are harmed during the study there 
are no special compensation arrangements. If you are harmed and this is due to someone’s 
negligence then you may have grounds for a legal action for compensation against the 
NHS/Newcastle University but you may have to pay for your legal costs. The normal NHS 
complaints mechanisms will still be available to you.  
 
Will any material be stored? 
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Yes, but only with your permission. We propose to store the liquid portion from blood 
samples (plasma/serum), some of the cells and their products and the mitochondrial DNA. 
These will be kept in an anonymised form (i.e. you cannot be identified from the samples). 
We propose to keep your samples for up to 5 years after completion of the study.  
At 5 years we propose to destroy the samples and images. However, as medicine advances 
and new information becomes available, we occasionally find good reasons to perform 
additional tests on stored samples in the future. Should this situation arise we may ask to use 
your samples again, but this would be on the strict condition that we explain the nature of any 
further research we intend to carry out, the type of tests we wish to perform and that you give 
permission for this, that the information would be anonymous (i.e. you could not be identified 
from them) and that we obtain new and separate permission from an ethics committee. 
 
Will your taking part in this study be kept confidential? 
Yes. Your information and samples will be given a study identity number, and all the 
information would remain strictly confidential.   
All information that is collected about you during the course of the research will be kept 
strictly confidential. We will keep a record that you have taken part in the study (name, date 
of birth, email address) but will not keep any other personal information about you save that 
required in the medical screening. All documents, samples and information about you will be 
pseudo‐anonymized with a study code known only to the research team. Professional 
standards of confidentiality will be adhered to and the handling, processing, storage and 
destruction of data will be conducted in accordance with the Data Protection Act (1998). 
Ultimately the information we acquire may be published in journals or presented at 
conferences but it will not be possible to identify you or any other participant from these 
publications. 
 
Who is organising and funding the research? 
The research team is made up of clinicians and staff from Newcastle University, City 
Hospitals Sunderland NHS Foundation Trust and Newcastle Upon Tyne Teaching Hospitals 
NHS Trust. The research is funded by Newcastle University. 
 
Who has reviewed the study? 
The scientific basis of the study was independently reviewed by doctors/scientists at 
Newcastle University. The study has also been independently reviewed and approved by a 




Is there an independent doctor you can approach for further information? 
If you would like to discuss any aspect of this research with an experienced researcher who is 
not linked in any way to this study, please feel free to contact: 
Dr Stephen Wright 









This completes Part 1 of the Participant Information 
 
If the information in Part 1 has interested you and you are considering participation, please 
continue to read the additional information in Part 2 before making your decision. 
 
THANK YOU FOR TAKING THE TIME TO READ THIS 





Does the DNA of our cell’s batteries influence our response 
to bacteria? 





What will happen to you if you take part? 
You will attend for a screening visit to see if you satisfy all the necessary conditions for the 




On a day suitable to you, you would come to the Pre-assessment clinic at City Hospitals 
Sunderland. The purpose of this visit is to check that you do not have any features which 
might exclude you from our study, and to answer any questions you may have. Please also 
note that you should not be taking part in any other medical research studies at the time. 
A doctor from the research team will take a short medical history and examine your heart and 
lungs. 
You would also have:  
• Simple measurements of heart rate, blood pressure and temperature 
• Measurement of the oxygen level in the blood (this involves placing a probe on your 
finger and does not involve needles) 
• A blood sample taken to check your ‘full blood count’ (which tells us about your white 
blood cells) and blood biochemistry. The volume of blood needed is equivalent to two 
teaspoons. 
• For female participants a urine test to exclude pregnancy. The result will be reviewed 
by a medical practitioner and appropriate advice will be given. 
 
 
The information obtained will be kept confidential by the research team. We shall inform you 
if we find any unexpected abnormalities and, with your permission, inform your general 
practitioner. If we are satisfied that there are no reasons to prevent you taking part, and if you 




Study visits in Summary 
 
Study Visit 1:  
Venue: Integrated Critical Care Unit (ICCU) City Hospitals Sunderland 
Time: 11 hours 
You will be asked to refrain from alcohol and caffeine for 24 hours before this visit. You will 
also be asked to fast from midnight before injection.  
• Confirmation of consent 
• Pregnancy test if female to confirm that the volunteer is not pregnant. The test will be 
reviewed by a medical practitioner and appropriate advice will be given. 
• Brief medical history and examination of heart and lungs 
• Insertion of intravenous cannulae, one in each arm 
• Baseline blood tests 
• Administration of intravenous fluid 
• Administration of lipopolysaccharide into a vein through a cannula 
• You will be allowed to eat and drink following lipopolysaccharide injection but asked 
to refrain from caffeine and alcohol during study visit 1. You will be allowed to bring 
your own food with you, alternatively sandwiches will be provided at meal times. 
• Observation over the following 10 hours, within ICCU, City Hospitals Sunderland 
(including measurement of blood pressure, heart rate, temperature and oxygen level) 
• Blood tests taken at 90 minutes, 4 hours, 6 hours and 10 hours after administration of 
LPS (blood tests will be taken from a cannula placed in your vein at the baseline blood 
test, so such that we can take blood more than once from a single use of a needle). 
 
Study visit 2: the day after visit 1 
Venue: Integrated Critical Care Unit (ICCU) City Hospitals Sunderland 
Time: Approximately 30 minutes 
• Brief medical history and examination of heart and lungs 
• Blood test 
 
Study visit 3: 7 days after visit 1 
Venue: Integrated Critical Care Unit (ICCU) City Hospitals Sunderland 
Time: Approximately 30 minutes 
• Brief medical history and examination of heart and lungs 
• Blood test 
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At the end of this visit, your involvement in the study will be complete.  
A more detailed explanation and potential symptoms associated with each procedure are 
described in the next section. 
 
Blood sampling  
 
At the screening visit we shall take a single blood sample using a needle. The amount of 
blood on the screening day will be approximately 10mls. 
 
On Study visit 1, you will have a cannula placed in each arm. One will be for administration 
of intravenous LPS, the other will be for administration of intravenous fluid and multiple 
blood samples.  Blood will be taken at baseline, then at 90 minutes, 4 hours, 6 hours and 10 
hours after the administration of intravenous LPS. The volume of blood we require at 
baseline, 90 minutes, 6 hours and 10 hours will be 80mls (about one third of a cup full) and 
the volume we require at 4 hours will be 20ml (about a tablespoon full) The total volume that 
we require during study visit 1 will be approximately 340ml 
 
On study visit 2, we shall take a single blood sample using a needle. The amount of blood on 
the screening day will be approximately 20mls (about a tablespoon full).  
 
On study visit 3, we shall take a single blood sample using a needle. The amount of blood on 
the screening day will be approximately 20mls (about a tablespoon full).  
  
Therefore, the maximum amount of blood that a volunteer can be asked to provide over the 
course of this entire study (including screening visit) is approximately 390mls. To place this 
in context, this is similar to a standard blood donation to the Blood Transfusion Service..  
 
 
Intravenous injection of LPS 
LPS is a product made by certain bacteria and is just one small component of the bacterium – 
i.e., you would not be injected with actual bacteria that may cause an infection but a small, 
non-infectious component of the bacterium. The dose of LPS we use is 2 nanograms per kg 
bodyweight. (A nanogram is 1 x 10 -9g and is the mass of an average human cell, and the 
human body is made up of trillions of human cells).  This dose has proved to be extremely 
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informative and safe in previous studies. We would be pleased to supply you with further 
literature from such studies if you wish. Your pulse, blood pressure, temperature and oxygen 
levels will be recorded after the injection of LPS..  
 
The LPS is used to cause a mild inflammatory response in the blood for a few hours only. 
Volunteers may feel slightly tired or have a warm, flushed or ’flu-like’ feeling a few hours 
afterwards. They may also feel like their heart rate has increased or decreased. Some but not 
all of volunteers may feel sick or have a headache, but this only lasts for a few hours. About 1 
in 20 volunteers may feel the need to take medicines such as paracetamol  or ibuprofen for 
symptom relief.  
 
Rarely (less than 1 in 1000) volunteers may experience a drop in blood pressure, this will be 
corrected by intravenous fluid. 
 
After the intravenous LPS you will rest in the integrated critical care unit for approximately 
10 hours. During this period you will have blood samples (as described above) and 
intermittent recording of your pulse, blood pressure, temperature and oxygen levels. 
 
You will be provided with a 24-hour telephone number to contact in the unlikely event that 






Should you wish any further information, please contact: 
 
Professor John Simpson 
Professor of Respiratory Medicine 
Institute of Cellular Medicine 
3rd Floor, William Leech Building 















Does the DNA of our cell’s batteries influence our response 
to bacteria? 
 
 CONSENT FORM 
 
PARTICIPANT NUMBER  
 
TO BE COMPLETED BY THE PARTICIPANT (please initial each box): 
 
1. I Confirm that I have read and understood the Participant information sheet, 
dated  …………………. version ………. for the above study.  I have had the 
opportunity to consider information, ask questions and have had those questions 
answered fully. 
 
[      ] 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, and without my medical care or legal 
rights being affected.      
 
[      ] 
3. I understand that information gathered for the purpose of the study will be 
kept in a secure confidential file. I agree that this file may be looked at by 
researchers involved in this study or, where relevant, by regulatory authorities 
overseeing the research. I understand that my personal data will be processed 
and stored in compliance with the 1998 Data Protection Act.  
 
[      ] 
 
4. I agree to a clinical history and examination at each study visit and if 
clinically indicated 
[      ] 
 
5. I agree to the injection of  lipopolysaccharide (LPS) into a vein through a 
cannula 
[      ] 
 
6. I agree to have blood tests, as outlined in the participant information sheet, 
and I am aware that while this includes some DNA analysis none of that DNA 
testing is about specific medical conditions  
 
[      ] 
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7. I agree that my blood may be stored for up to 5 years after completion of the 
study and that these will be stored in a secured, confidential way 
 
 
[      ] 
8. I agree that my samples may be used in future studies, on condition that I 
understand the nature of any further research and the types of tests that will be 
done, that I cannot be identified from my samples, and that new ethical 
approval is granted for those studies 
 
[      ] 
9. I agree that the research team may inform my general practitioner of any 
abnormal screening results or any adverse events during the study 
[      ] 
10.  I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from the research team, from 
regulatory authorities or from City Hospitals Sunderland NHS Foundation 
Trust, where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records. 
 
11. I agree that the research team may inform my general practitioner of my 
participation in the study  




[      ] 
 
12. I agree to take part in this study [      ] 
 
13. 7. I can confirm that I have retained a copy of the consent form and another 
copy has been retained by the research team and will be filed in the investigator 
site file 
[      ] 
_______________________   _______________________  
 ________________ 
Participant’s Name    Signature    
 Date 
_______________________   _______________________  
 ________________ 






APPENDIX C.  
 
The protocol, participant information sheets, consent forms and data collection sheet 
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Infections acquired during a stay within an intensive care unit (ICU) are common, affecting 
approximately 20% of patients (Vincent et al., 1995). Large-scale international studies have 
demonstrated that the risk of developing a hospital-acquired infection increases with the 
duration of ICU stay.  Those individuals who develop an infection have twice the ICU mortality 
rate (25% vs .11%, p<0.001) and an overall longer duration of stay when compared to 
individuals who do not develop an infection (Vincent et al., 2009; Lambert et al., 2011). 
 
There are two reasons for this susceptibility to infection.  Firstly, the use of necessary 
interventions such as mechanical ventilation and central venous lines increases the risk.  
Secondly, however there is mounting evidence that these patients have a dysfunction of their 
innate immune response.  Dysfunction in several types of white blood cell within the ICU has 
previously been demonstrated and associated with an increased risk of developing an infection 
with the ICU. Complement mediated neutrophil dysfunction, a deactivation of monocytes (loss 
of HLA DR expression) and an increase in regulatory T cells that act to counter the 
inflammatory response have all be demonstrated in critically ill patients on the ICU.  All were 
associated with an increased risk of developing a hospital-acquired infection (Conway Morris 
et al., 2013). 
 
Empirical antibiotics are often used in ICUs to ensure adequate coverage of critically ill patients 
and are often continued even after a specific pathogen is identified (Garnacho-Montero et al., 
2014).  Understandably critical care clinicians will often prioritise the health of their patient over 
the need to limit antibiotic use because of the rise of bacterial strains resistant to antibiotics 
(Martin-Loeches et al., 2017).  There is an urgent need to identify alternative treatments that 
are not antibiotics, but to do this the basic mechanisms underpinning the susceptibility of 
critically ill patients to infection need to be further understood. 
 
Monocytes, one of the white blood cells involved in the innate immune response, are now 
divided into at least three subclasses that have different functional properties: classical, 
intermediate and non-classical.  Classical are the most involved in bacterial killing, they display 
the most phagocytic activity, release the widest range of reactive oxygen species and the most 
cytokines. Intermediate monocytes have been shown to express the most HLA class II 
molecules whilst non-classical monocytes have been shown to ‘patrol’ the endothelium and 
may have a role in tissue repair (Ziegler-Heitbrock, 1996a; Auffray, 2007; Ziegler-Heitbrock et 
al., 2010a; Wong, 2011).  
 
Although classical monocytes are best suited to bacterial killing, previous work demonstrates 
that critically ill patients have a reduction in this subclass and instead have an expansion in 
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the proportion of non-classical monocytes (Fingerle, 1993; Fingerle-Rowson, 1998).  The 
cause of this change in monocyte subclass is not currently understood. 
 
Human studies show that recombinant macrophage-colony stimulating factor (MCSF) can 
increase the proportion of non-classical monocytes in vivo.  MCSF is present at high levels 
during sepsis and may explain the increase in the non-classical (Saleh, 1995).  
 
This study will investigate the mechanisms that lead to an increased susceptibility to 
infection in critically ill patients; with the aim of identifying therapeutic targets for 
improving their innate immune response and reducing the frequency of infections.  
ORIGINAL HYPOTHESIS 
We hypothesize that individuals who are critically ill have an increased susceptibility to 
infection due to a defect in their innate immunity.   In particular the reduction in classical 
monocytes and concurrent predominance of circulating non-classical monocyte contributes to 
the impaired immune response.  We believe that the increase in MCSF is the cause of the 
switch in monocyte subset and could potentially offer a novel therapeutic target. 
STUDY DESIGN 
 
Participant Enrolment and Selection 
Individuals who have been admitted to the intensive care unit (ICU) and would be suitable for 
the study will be identified by their clinical care team or research nurse.  The individual, or their 
next of kin, will be given a copy of the study’s participant information sheet and consent form.  
If they wish to be included in the study they will be recruited following written informed consent.  
 
Setting 
The intensive care units (ICU) at City Hospitals Sunderland NHS Trust (CHSFT) and The 
Newcastle upon Tyne Hospitals NHS Foundation Trust (NUTH). 
 
Inclusion criteria 
• Expected to remain in the ICU for longer than 24 hours 
• Expected to survive in the ICU for longer than 24 hours 
• Provision of written informed consent (either from the participant or next of kin) 
• Requires organ support (either inotropes, ventilator, non-invasive ventilator, 
haemofiltration) 
• They or their relatives/legal representative will be provided written, informed consent 
 
Exclusion criteria 
• <16 years of age 
• Pregnancy 
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• Known infection with human immunodeficiency virus 
• Haematological malignancy 
• Concurrent use of immunosuppressant medication other than corticosteroids (allowed 
up to prednisolone 10mg/kg or equivalent) 
 
Consent 
Individuals eligible for the study will be identified by the clinical care team or research nurses 
and will be given verbal and written information regarding the study.  All individuals who are 
approached will be given time to consider the information received prior to consent.  All study 
subjects will be enrolled after giving signed informed consent.  In those individuals where it is 
not possible to for them to give consent, the next of kin or appropriate legal representative will 
be approached.  Wherever possible retrospective consent will be sought when an individual 




Management of ineligible participants 
For individuals found to be ineligible for the trial the reason for ineligibility or non-recruitment 
will be recorded.  Only anonymised data will be entered on to the database and this will 
include gender, age, “ineligible” or “non-recruitment” and the associated reason.  
 
Sampling 
Study participation will involve two visits, each of less than 1 hour. 
 
Study visit 1  
This will occur following recruitment and include:  
1. Data collection & preparation  
a. Details will be obtained from the subject through a medical interview and/or 
review of the medical notes; which will include but will not necessarily be limited 
to: age, sex, ethnicity, cause for the ICU admission, co-morbidities and 
concurrent medications.   
2. Blood sampling 
a. Blood will be sampled following initial recruitment.  20 mL of blood will be 
collected. The most likely risk is that blood sampling may contribute to the 
development of anaemia in the participant.  This risk has been minimised by 
limiting the amount of blood taken to 20 mL.  This is similar to what is taken in 
a routine clinical blood test.  
b. Blood sampling can be accompanied by discomfort or by vasovagal symptoms. 
To minimise these risks samples will be taken wherever possible from an 
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indwelling line (an arterial line will be used preferentially if present, if not then a 
venous line). For the majority of this population the participant will be semi-
recumbent in a hospital bed and sedated.  In those few individuals who are not, 
samples will be taken with them in a bed or self-reclining chair.  Participants 
who feel syncopal will be positioned supine and venepuncture will be 
discontinued. 
c. Plasma will be removed and frozen (at -80oC) for future testing 
d. The cell fraction will used to isolate white blood cells for future testing. 
e. Stored blood samples will be labelled with a unique anonymous identifier 
3. Post procedure 
a. Subjects will be monitored by an ICU nurse 
Study visit 2: 
Where applicable this visit will occur within the next working day of discharge from the ICU 
between usual working hours.  It will include: 
1. Blood sampling – 20 ml of blood will be taken and processed as detailed above. 




Our research group has experience with taken blood samples from patients on the intensive 
care unit.  Nevertheless, we feel that we must remain vigilant in detecting and recording any 
adverse events as a result of any procedures undertaken.  
 
Whilst recognising that this current work is not a clinical trial, our groups' previous work (which 
included a clinical trial) benefited from classifying and monitoring adverse events in the manner 
described below, and we have elected to continue using this terminology in this research. 
 
Definitions 
An adverse event (AE) is any untoward medical occurrence in a study participant. 
A serious adverse event (SAE) is any untoward medical occurrence in a study participant or 
effect that: 
• results in death 
• is life threatening (i.e. the subject was at risk of death at the time of the event; it does 
not refer to an event which hypothetically might have caused death if it were more 
severe) 
• results in persistent or significant disability or incapacity 
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If an adverse event is detected, a member of the research team will make an assessment of 
seriousness as defined by the above definitions. If the event is deemed to be serious (SAEs) 
a member of the research team will then consider if the event was: 
• Related – that is it resulted from research procedures and/or 
• Unexpected – that is a type of event that is not identified as an expected occurrence 
 
Detecting and reporting AE and SAEs 
All AEs and SAEs will be recorded from the time a participant consents to join the study and 
for up to an hour following venepuncture. Research nurses or members of clinical care team 
will inform the research team of any concerns that may constitute an AE or SAE. Information 
to be collected includes type of event, onset date, researcher assessment of implications, if 
any, for safety of participants and how these will be addressed, date of resolution as well as 
treatment required, investigations needed and outcome. All information will be recorded in the 
participants study file. 
 
An AE/SAE may necessitate discontinuation of a given part of the study (but progression 
through the remainder of the study) or complete and immediate discontinuation of any further 
participation. Such an event may include, but not be limited to, a vasovagal response to 
venepuncture.  All participants will maintain the right to discontinue or completely withdraw 
from the study at any time for any reason, or without stating a reason. The reason and 
circumstances for premature discontinuation (where known) will be documented in the 
participant’s study file. 
 
If a SAE has occurred, the research team must report the information to Newcastle upon Tyne 
Hospitals R&D within 24 hours.  The SAE form must be completed as thoroughly as possible 
with all available details of the event, signed by the Investigator or designee.  The SAE form 
should be transmitted by fax or by hand to the office.  
 
NUTH R&D is responsible for reporting SAEs that are considered to be related and unexpected 
as described above to the Research Ethics Committee (REC) that approved the study (main 
REC) within 15 days of becoming aware of the event using the NRES Reporting of SAE Form. 
The Co-ordinator of the main REC should acknowledge receipt of related, unexpected safety 
report within 30 days. 
 
Each AE should be clinically assessed for causality based on the information available, i.e. the 
relationship of the AE to the study should be established. All adverse events judged as having 
a reasonable suspected causal relationship to the study (i.e. definitely, probably or possibly 
related) are considered to be adverse reactions. If any doubt about the causality exists, the 
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local Principal Investigator should consult the Chief Investigator. In the case of discrepant 
views on causality between the Principal Investigator and others, the main REC and other 





Measurements of biomarker blood levels and proportions of monocyte subclass will be 
expressed within 95% confidence limits. Comparisons will be made between the two 
dependent timepoints using a paired t test and statistical significance identified by a nominal p 
value of <0.05. Statistical analysis will be performed using standard University software.  We 
intend to write a prospective statistical analysis plan ahead of embarking on experiments with 








The primary outcome variable will be the measurement of monocyte subclasses during critical 
illness and on recovery.  As well as the measurement of MCSF at both timepoints.  Secondary 
outcomes will include the effects of critical illness on the function of immune cells and their 
interactions with the coagulation system and the endothelium (blood vessel lining). 
 
Research team and project management 
The proposed project will be conducted by Professor John Simpson, Dr Anthony Rostron, Dr 
Marie-Hélène Ruchaud-Sparagano, Mr Jonathan Scott and Dr Kathryn Musgrave.  Statistical 
work will be assisted by statisticians from the University.   
EXPECTED VALUE OF RESULTS 
To increase our understanding of the basic mechanisms under-pinning the susceptibility of 
critically ill individuals to infection. 
 
To identify novel therapeutic targets to improve the innate immune response in the critically ill. 
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PARTICIPANT INFORMATION SHEET: The Effects of Critical Illness on the Innate Immune System 
 
Researchers: Dr Kathryn Musgrave, Dr Anthony Rostron and Prof John Simpson 
 
You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully.  Ask us if there is anything that is not clear or if you would like more 
information. 
Thank you for reading. 
PART ONE 
 
What is the background and purpose of the study? 
Patients in an intensive care unit are more likely to develop an infection compared to other patients in a hospital.  
We believe that this is, in part, because of a problem with how their body fights infection. To treat infection we 
give antibiotic medicines but some bacteria are becoming resistant to these medicines.  It is therefore important 
that we find alternative treatments. 
 
White blood cells are essential to detect and fight infection.  Monocytes are a type white blood cells, they help to 
fight infection but it is not yet fully understood how monocytes interact with other cells in the body to trigger the 
body’s defence mechanisms.  We will take samples of blood to allow us to analyse the ways in which monocytes 
- and other types of white cells - react to infection. 
 
This study aims to better understand why patients staying in an intensive care unit are more likely to develop 
infections. We hope that this will allow us to identify ways in which the system could be helped to stop the 
increased number of infections in these patients. 
 
Why have you been invited to take part? 
You have been asked to take part because you are currently a patient on an intensive care unit and have been 
identified by the doctors and nurses looking after you.  
Do you have to take part? 
It is up to you to decide whether to take part.  If you do, you will be given this information sheet to keep and be 
asked to sign a consent form. You are still free to withdraw at any time and without giving a reason.  A decision 
to withdraw at any time, or a decision not to take part, will not affect the standard of care received by you now or 
at any stage in the future.  
 
How long can you take to decide? 
You should take as much time as you wish. 
 
What will happen to you if you take part? 
If you decide to take part in the study, you will be asked to provide written consent.  
What do I have to do? 
The study will involve two visits from a researcher.  At the first visit there will be discussion about your medical 
history and a blood sample will be taken.  At the second and final visit a further blood sample will be taken. 
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What are the possible disadvantages and risks of taking part? 
The taking of blood samples and may cause mild discomfort and bruising but wherever possible a tube already 
present in a blood vessel will be used. 
 
What are the possible benefits of taking part? 
There will be no direct benefits to you. 
 
Is there any reimbursement for taking part? 
No.  
 
What will happen when the study ends? 
You will continue with your usual care at the hospital. 
 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed.  
 
Will your taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential.  
 
Contact details 
Should you wish further information Dr Kathryn Musgrave (Haematology Registrar and 
Clinical Research Associate) or Prof John Simpson (Professor of Respiratory Medicine) will 
be happy to answer your questions. The best contact number is 0191 222 7770. 
 
This completes Part 1 of the Information Sheet. If the information in Part 1 has interested you 
and you are considering participation, please continue to read the additional information in 










What will happen if I wish to take part in the study? 
There will be two visits from the researcher. 
 
First visit (occurs once consent is given) 
During this visit there will be: 
4. Medical interview and review of medical records 
a. Discussion with a doctor where details are collected relating to but limited by: age; sex; 
ethnicity; cause for the ICU admission; other health problems; concurrent medications.  
5. Blood test 
a. A blood sample of 20ml (about a tablespoon) with be taken, this is a small amount that 
is similar to the amount of blood taken during a routine blood test.  
b. Wherever possible blood will be taken from a tube that is already in place in a blood 
vessel 
c. We will process the blood sample to isolate the white blood cells from other parts of the 
blood, the other part will be stored for subsequent analysis.  
d. Stored blood samples will be labelled with a unique anonymous identifier 
e. The blood will be taken by a medically qualified professional (either a nurse or a doctor). 
 
Second visit (occurs the next working day following discharge from the intensive care unit) 
During this visit there will be: 
1. Blood test 
a. A further blood sample of 20ml will be taken. 
b. This second sample allows us to compare how the white blood cells behave once an 
individual has recovered from illness 
 
What will happen if I don’t want to carry on with the study? 
Participation in this study is completely voluntary and you can decide to withdraw from the study at any time. 
Withdrawing from the study will not affect the care that you get from the NHS at any stage in the future. 
What if there is a problem? 
If you have a concern about your treatment by members of staff during the study, you should ask to speak with the 
researchers who will do their best to answer your concerns (a contact number is at the end of Part 1 of the 
Information Sheet). If you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure. Details can be obtained from your hospital. 
In the unlikely event that something goes wrong and you are harmed during the study there are no special 
compensation arrangements.  If you are harmed and this is due to someone’s negligence then you may have 
grounds for a legal action for compensation against the NHS/Newcastle University but you may have to pay for 
your legal costs.  The normal NHS complaints mechanisms will still be available to you.  
Will your taking part in the study be kept confidential? 
All information that is collected about you during the research will be kept strictly confidential. 





Will any genetic tests be done? 
Yes. The genetic tests will help us understand how blood cells respond to illness. We shall not, at any point, be 
testing for genes associated with specific medical conditions.   
 
Will any information and material be stored? 
Yes, but only with your permission.  Information about you will be collected and entered onto a secure database.  
Access to this database will be password protected and only available to your doctors and the research staff.  All 
data stored on computers will not use your name – you will be given a unique study number under which all data 
and test results will be entered.   
Any blood that we obtain as part of the research will be processed in Professor Simpson’s research laboratory at 
Newcastle University.  We shall store the liquid component of blood (called serum or plasma) in freezers.  The 
samples will only be labelled with your unique study number (i.e. your name will not appear).   
It is possible that in the future new tests will become available that will help to predict the development of blood 
clots or infection.  Should this situation arise we may use your samples again, but this would be on condition that 
you agree to this, that you could not be identified from the sample except by our research team, and that we obtain 
fresh and separate permission from a Research Ethics Committee.  The Ethics Committee is completely 
independent from this study. 
We may share samples with other investigators or commercial organisations in the UK or internationally, to help 
further understanding of severe infection. If this is happens, the samples shared would be anonymous and external 
investigators or organisations would not be able to identify you. The anonymised data collected as part of the study 
may also be used to understand the sample analyses.  
This study is being overseen by Newcastle upon Tyne Hospitals NHS Foundation Trust.   
Authorised persons from the Trust or from other legally authorised regulatory bodies may 
look at some parts of your medical records and the data collected for the study.   This is to 
ensure the quality of the work being carried out. All will have a duty of confidentiality to you 
as a research participant and nothing that could reveal your identity will be disclosed outside 
the research site.   
What will happen to the results of the research study? 
We intend for the results of this study to be published in medical/scientific journals and presented at 
medical/scientific meetings. All information in the public domain will be anonymous and it will not be possible to 
identify you from these publications/presentations.  
Who is organising and funding the research?   
This study has been funded by Professor Simpson’s research group through an educational grant and will be 
overseen by the Newcastle Upon Tyne Hospitals NHS Foundation Trust and Newcastle University.  
 
Who has reviewed the study?  




What if something goes wrong?  
 
If you have any concerns about any aspect of this study, you should contact the local Principal 
Investigator (Prof John Simpson, telephone number 0191 222 7770), who will do their best to 
answer your questions. If you remain unhappy and wish to complain formally, you can do this 
through the normal NHS Complaints Procedure.  
 
If something does go wrong and you are harmed due to someone’s negligence, then they you 
may have grounds for a legal action against their NHS Trust, but you may have to pay legal 
costs.  
 
Is there an independent doctor you can approach for further information? 
If you would like to discuss any aspect of this research with an experienced researcher who is not linked in any 
way to this study, please feel free to contact Dr Ian Forrest, Consultant Respiratory Physician, Newcastle upon 
Tyne Hospitals NHS Foundation Trust. 
Alternatively, you may prefer to raise your concerns through the Patient Advise and Liaison Service 
(PALS).  This service is confidential and can be contacted on Freephone: 0800 032 0202 
  
Alternatively, if you wish to make a formal complaint you can contact the Patient Relations Department through 
any of the details below: 
 
Telephone:          0191 223 1382 or 0191 223 1454 
Email:                   patient.relations@nuth.nhs.uk 
Address:              Patient Relations Department 
The Newcastle upon Tyne Hospitals NHS Foundation Trust 
The Freeman Hospital 




Thank you for taking the time to read this information.  
If you agree to take part in the study you will be given a copy of this information to keep, along with a copy of 







                            
 










  confirm that I have read and understood the information sheet dated 30/11//2017  
(version 1.0) for the above study.  I have had the opportunity to consider the 
nformation, ask questions, and have had these answered satisfactorily. 
 
 
  understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.  
 
 
  understand that relevant sections of any of my medical notes and data collected during 
the study may be looked at by responsible individuals from regulatory authorities or 
from the NHS Trust.  I give permission for these individuals to have access to my 
records and understand that all information will be treated as confidential and in a way 
compliant with the Data Protection Act. 
 
 
  agree to a 20ml blood sample being taken on two occasions 
 
 
  agree to storage, in an anonymised fashion, of my blood samples for 5 years  
 
 
  agree to storage of information about my medical condition for 5 years 
 
 
  agree that my samples may be used in future studies, on condition that I understand 
the nature of any further research and the types of tests that will be done, that I cannot 
be identified from my samples, and that new ethical approval is granted for those 
studies. 
 
 f I become more unwell and I am no longer able to understand that the study is 
continuing, I agree that all the information and samples already collected can still be 







   




    
Name of Person taking consent Signature Date 
  
1 for participant; 1 for researcher; 1 for case notes 
 
 




                  
 
PERSONAL CONSULTEE DECLARATION FORM:  






Researchers: Dr Kathryn Musgrave, Dr Anthony Rostron and Prof John Simpson 
 
 
1. I (__________________) have been consulted about (_________________ )’s  
participation in this research project. I confirm that I have read and understand the 
information sheet dated 30/11/17 (Version 1.0) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
questions answered satisfactorily.    
 
 
2. I understand that his/her participation is voluntary and that I am free to withdraw 
them at any time, without giving any reason, without their medical care or legal 
rights being affected. 
 
 
3. I understand that relevant sections of any of his/her medical notes and data 
collected during the study may be looked at by responsible individuals from 
regulatory authorities or from the NHS Trust.  I give permission for these 
individuals to have access to their records and understand that all information will 
be treated as confidential and in a way compliant with the Data Protection Act. 
 
 
4. I agree to a 20ml blood sample being taken on two occasions 
 
 
       5. I agree to storage, in an anonymised fashion, of his/her blood samples for 5 years  
 
 
        6. I agree to storage of information about his/her medical condition for 5 years 
 
 
7. I agree that these samples may be used in future studies, on condition that 
he/she understand the nature of any further research and the types of tests that 
will be done, that his/her cannot be identified from the samples, and that new 





   
Name of Consultee Signature Date  
 
 





   
Name of Person taking consent Signature Date 
  
1 for consultee; 1 for researcher; 1 for case notes 
 
Please initial in the box 
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PROFESSIONAL CONSULTEE DECLARATION FORM:  






Researchers: Dr Kathryn Musgrave, Dr Anthony Rostron and Prof John Simpson 
 
 
1. I (__________________) have been consulted about (_________________ )’s  
participation in this research project. I confirm that I have read and understand the 
information sheet dated 30/11/17 (Version 1.0) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
questions answered satisfactorily. I am independent of this study.    
 
 
2. I understand that his/her participation is voluntary and that I am free to withdraw 
them at any time, without giving any reason, without their medical care or legal 
rights being affected. 
 
 
3. I understand that relevant sections of any of his/her medical notes and data 
collected during the study may be looked at by responsible individuals from 
regulatory authorities or from the NHS Trust.  I give permission for these 
individuals to have access to their records and understand that all information will 
be treated as confidential and in a way compliant with the Data Protection Act. 
 
 
4. I agree to a 20ml blood sample being taken on two occasions 
 
 
       5. I agree to storage, in an anonymised fashion, of his/her blood samples for 5 years  
 
 
        6. I agree to storage of information about his/her medical condition for 5 years 
 
 
7. I agree that these samples may be used in future studies, on condition that 
he/she understand the nature of any further research and the types of tests that 
will be done, that his/her cannot be identified from the samples, and that new 





   
Name of Consultee Signature Date  
 
 





   
Name of Person taking consent Signature Date 
  
1 for consultee; 1 for researcher; 1 for case notes 
 
Please initial in the box 
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RECOVERED CAPACITY CONSENT FORM:  









  confirm that I have read and understood the information sheet dated 30/11//2017  
version 1.0) for the above study.  I have had the opportunity to consider the 
nformation, ask questions, and have had these answered satisfactorily. 
 
 
  understand that my participation is voluntary and that I am free to withdraw at any 
ime, without giving any reason, without my medical care or legal rights being affected.  
 
 
  understand that relevant sections of any of my medical notes and data collected during 
he study may be looked at by responsible individuals from regulatory authorities or 
from the NHS Trust.  I give permission for these individuals to have access to my 
records and understand that all information will be treated as confidential and in a way 
compliant with the Data Protection Act. 
 
 
  agree to a 20ml blood sample being taken on two occasions 
 
 
  agree to storage, in an anonymised fashion, of my blood samples for 5 years  
 
 
  agree to storage of information about my medical condition for 5 years 
 
 
  agree that my samples may be used in future studies, on condition that I understand 
he nature of any further research and the types of tests that will be done, that I cannot 
be identified from my samples, and that new ethical approval is granted for those 
studies. 
 
 f I become more unwell and I am no longer able to understand that the study is 
continuing, I agree that all the information and samples already collected can still be 







   




    
Name of Person taking consent Signature Date 
  
1 for participant; 1 for researcher; 1 for case notes 
 
 
Please initial in the box 
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DATA COLLECTION SHEET                         Participant 
Number:____________________ 
Age (years): ___________ 
 
Sex (delete as appropriate):    MALE/FEMALE 
 
Ethnicity (tick as appropriate): 
 
White     _______________  
 
Black or Black British   _______________ 
 
Asian or Asian British    _______________ 
 
Mixed     _______________ 
 
Other (please specify)   _______________ 
  
Does not wish to disclose  _______________ 







Are they currently requiring: (tick all that apply) 
 




Inotropic support     Haemofiltration/dialysis 
 
Do they have a diagnosis of sepsis?  (delete as appropriate):    YES/NO 
 
If yes, please complete the below section: 
 
Presumed focus of infection________________________________________________ 
 











DIAGNOSIS OF SEPSIS 
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Complete the following table using data recorded now and during the first 24 hours of 
admission (choose the worst recorded levels). 
 
  
Worst recorded in 
first 24hrs of ICU 
admission 
At first study visit 
Clinical condition 
  
Age     
Severe organ dysfunction or 
immunocompromise prior to admission 
(see below)*     
Acute renal failure?     
Post elective surgery?     
Post emergency surgery?     
 
    
Observations     
Glasgow Coma Score (GCS)     
Temperature     
Mean arterial pressure (MAP)     
PROGNOSTIC SCORE  
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Heart rate     
Respiratory rate     
FiO2     
PaO2     
PaCO2     
Urine output (mL per day)     
 
    
Blood tests     
arterial pH     
Haematocrit     
white blood count     
Platelets     
Serum sodium     
Serum potassium     
Creatine     
Bilirubin     
 
    
Inotropes (tick all that apply):     
Dobutamine     
Dopamine (≤5μg/kg/min)     
Dopamine (>5μg/kg/min)     
Epinephrine (≤0.1μg/kg/min)     
Ephinephrine (>0.1μg/kg/min)     
Norepinephrine (≤0.1μg/kg/min)     
Norephinephrine (>0.1μg/kg/min)     
* Definitions of immunocompromise and organ dysfunction (tick all that apply): 
 






Tick all that 
apply 
Cardiovascular dysfunction 
NYHA class IV (Severe limitations. Experiences symptoms even 
while at rest.)   
    
Renal dysfunction 
need for chronic dialysis   
    
Liver dysfunction 
biopsy proven cirrhosis   
portal hypertension   
previous upper GI bleed secondary to portal hypertension   
previous coma secondary to hepatic failure   
    
Respiratory dysfunction 
severe exercise restriction due to chronic restrictive, obstructive 
or vascular disease   
chronic hypoxia or hypercapnia   
secondary polycythaemia   
severe pulmonary hypertension   
respirator dependent   
    
Immunocompromise 
received radiation therapy   
long-term steroid use   
disease that affects the immune system    
Please note:  high dose steroid therapy (>equivalent prednisolone 10mg/kg), 
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